U.S. patent application number 15/187209 was filed with the patent office on 2016-12-22 for anti b7-h3 antibody.
This patent application is currently assigned to Daiichi Sankyo Company, Limited. The applicant listed for this patent is Daiichi Sankyo Company, Limited. Invention is credited to Keisuke Fukuchi, Kenji Hirotani, Tatsuji Matsuoka, Kenji Murakami, Shu Takahashi, Takeshi Takizawa, Atsushi Urano, Mitsuhiro Yazawa.
Application Number | 20160368990 15/187209 |
Document ID | / |
Family ID | 47072232 |
Filed Date | 2016-12-22 |
United States Patent
Application |
20160368990 |
Kind Code |
A1 |
Takahashi; Shu ; et
al. |
December 22, 2016 |
ANTI B7-H3 ANTIBODY
Abstract
The present invention relates to an antibody having a
therapeutic effect on a tumor. That is, the invention relates to an
antibody which binds to B7-H3 to exhibit an antitumor activity. An
object of the invention is to provide a pharmaceutical having a
therapeutic effect on a tumor. By obtaining an anti-B7-H3 antibody
which binds to B7-H3 to exhibit an antitumor activity, a
pharmaceutical composition for treating a tumor comprising the
antibody and the like are obtained.
Inventors: |
Takahashi; Shu; (Chiba,
JP) ; Matsuoka; Tatsuji; (Tokyo, JP) ;
Murakami; Kenji; (Chiba, JP) ; Takizawa; Takeshi;
(Tokyo, JP) ; Hirotani; Kenji; (Tokyo, JP)
; Urano; Atsushi; (Tokyo, JP) ; Fukuchi;
Keisuke; (Tokyo, JP) ; Yazawa; Mitsuhiro;
(Tokyo, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Daiichi Sankyo Company, Limited |
Tokyo |
|
JP |
|
|
Assignee: |
Daiichi Sankyo Company,
Limited
Tokyo
JP
|
Family ID: |
47072232 |
Appl. No.: |
15/187209 |
Filed: |
June 20, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13455021 |
Apr 24, 2012 |
9371395 |
|
|
15187209 |
|
|
|
|
PCT/JP2012/060904 |
Apr 24, 2012 |
|
|
|
13455021 |
|
|
|
|
61478878 |
Apr 25, 2011 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/92 20130101;
C07K 2317/40 20130101; A61K 45/06 20130101; C07K 16/30 20130101;
C07K 2317/73 20130101; C07K 2317/24 20130101; C07K 16/2827
20130101; C07K 2317/732 20130101; C07K 16/42 20130101; A61K
39/39558 20130101; A61K 2039/505 20130101; C07K 2317/734 20130101;
A61P 35/00 20180101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; A61K 39/395 20060101 A61K039/395; A61K 45/06 20060101
A61K045/06; C07K 16/30 20060101 C07K016/30 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 25, 2011 |
JP |
2011-097645 |
Claims
1. An antibody characterized by having the following properties:
(a) having a competitive inhibitory activity against M30 antibody
consisting of heavy chain comprising an amino acid sequence
consisting of amino acid residues 20 to 471 of SEQ ID NO:51 and
light chain comprising an amino acid sequence consisting of amino
acid residues 23 to 235 of SEQ ID NO:53 for the binding to an IgC1
and/or IgC2 domain of B7-H3 comprising SEQ ID NO:6 or SEQ ID NO:10;
(b) having an antibody-dependent cell-mediated phagocytosis (ADCP)
activity; and (c) having an in vivo antitumor activity against
tumors expressing B7-H3 comprising SEQ ID NO:6 or SEQ ID NO:10.
2. The antibody according to claim 1, which has an
antibody-dependent cellular cytotoxicity (ADCC) activity and/or a
complement-dependent cytotoxicity (CDC) activity.
3. The antibody according to claim 1, wherein the tumor is
cancer.
4. The antibody according to claim 3, wherein the cancer is lung
cancer, breast cancer, prostate cancer, pancreatic cancer,
colorectal cancer, a melanoma, liver cancer, ovarian cancer,
bladder cancer, stomach cancer, esophageal cancer, or kidney
cancer.
5. The antibody according to claim 1, wherein a constant region is
a human constant region.
6. The antibody according to claim 1, which is humanized.
7. The antibody according to claim 6, which comprises a heavy chain
variable region consisting of (a) an amino acid sequence comprising
amino acid numbers 20 to 141 in SEQ ID NO:85, (b) an amino acid
sequence comprising amino acid numbers 20 to 141 in SEQ ID NO:87,
(c) an amino acid sequence comprising amino acid numbers 20 to 141
in SEQ ID NO:89, (d) an amino acid sequence comprising amino acid
numbers 20 to 141 in SEQ ID NO:91, (e) an amino acid sequence
having a homology of at least 95% or more with any of the framework
amino acid residues of the sequences (a) to (d), or (f) an amino
acid sequence wherein one or several amino acids are deleted,
substituted or added within any of the framework region sequences
of (a) to (d); and a light chain variable region consisting of (g)
an amino acid sequence comprising amino acid numbers 21 to 128 in
SEQ ID NO:71, (h) an amino acid sequence comprising amino acid
numbers 21 to 128 in SEQ ID NO:73, (i) an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:75, (j) an
amino acid sequence comprising amino acid numbers 21 to 128 in SEQ
ID NO:77, (k) an amino acid sequence comprising amino acid numbers
21 to 128 in SEQ ID NO:79, (1) an amino acid sequence comprising
amino acid numbers 21 to 128 in SEQ ID NO:81, (m) an amino acid
sequence comprising amino acid numbers 21 to 128 in SEQ ID NO:83,
(n) an amino acid sequence having a homology of at least 95% or
more with any of the framework amino acids of the sequences (g) to
(m), or (o) an amino acid sequence wherein one or several amino
acids are deleted, substituted or added within any of the framework
region sequences of (g) to (m).
8. The antibody according to claim 7, which comprises a heavy chain
variable region and a light chain variable region consisting of a
heavy chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:71; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:73; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:75; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:77; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:79; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:81; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:85 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:83; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:91 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:71; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:91 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:73; a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:91 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:75; or a heavy
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 20 to 141 in SEQ ID NO:91 and a light
chain variable region consisting of an amino acid sequence
comprising amino acid numbers 21 to 128 in SEQ ID NO:77.
9. The antibody according to claim 8, which comprises a heavy chain
and a light chain consisting of a heavy chain consisting of an
amino acid sequence comprising amino acid numbers 20 to 471 in SEQ
ID NO:85 and a light chain consisting of an amino acid sequence
comprising amino acid numbers 21 to 233 in SEQ ID NO:71; a heavy
chain consisting of an amino acid sequence comprising amino acid
numbers 20 to 471 in SEQ ID NO:85 and a light chain consisting of
an amino acid sequence comprising amino acid numbers 21 to 233 in
SEQ ID NO:73; a heavy chain consisting of an amino acid sequence
comprising amino acid numbers 20 to 471 in SEQ ID NO: 85 and a
light chain consisting of an amino acid sequence comprising amino
acid numbers 21 to 233 in SEQ ID NO:75; a heavy chain consisting of
an amino acid sequence comprising amino acid numbers 20 to 471 in
SEQ ID NO:85 and a light chain consisting of an amino acid sequence
comprising amino acid numbers 21 to 233 in SEQ ID NO:77; a heavy
chain consisting of an amino acid sequence comprising amino acid
numbers 20 to 471 in SEQ ID NO:85 and a light chain consisting of
an amino acid sequence comprising amino acid numbers 21 to 233 in
SEQ ID NO:79; a heavy chain consisting of an amino acid sequence
comprising amino acid numbers 20 to 471 in SEQ ID NO:85 and a light
chain consisting of an amino acid sequence comprising amino acid
numbers 21 to 233 in SEQ ID NO:81; a heavy chain consisting of an
amino acid sequence comprising amino acid numbers 20 to 471 in SEQ
ID NO:85 and a light chain consisting of an amino acid sequence
comprising amino acid numbers 21 to 233 in SEQ ID NO:83; a heavy
chain consisting of an amino acid sequence comprising amino acid
numbers 20 to 471 in SEQ ID NO:91 and a light chain consisting of
an amino acid sequence comprising amino acid numbers 21 to 233 in
SEQ ID NO:71; a heavy chain consisting of an amino acid sequence
comprising amino acid numbers 20 to 471 in SEQ ID NO: 91 and a
light chain consisting of an amino acid sequence comprising amino
acid numbers 21 to 233 in SEQ ID NO:73; a heavy chain consisting of
an amino acid sequence comprising amino acid numbers 20 to 471 in
SEQ ID NO:91 and a light chain consisting of an amino acid sequence
comprising amino acid numbers 21 to 233 in SEQ ID NO:75; or a heavy
chain consisting of an amino acid sequence comprising amino acid
numbers 20 to 471 in SEQ ID NO:91 and a light chain consisting of
an amino acid sequence comprising amino acid numbers 21 to 233 in
SEQ ID NO:77.
10. The antibody according to claim 7, which comprises a heavy
chain and a light chain consisting of a heavy chain consisting of
an amino acid sequence comprising SEQ ID NO:85 and a light chain
consisting of an amino acid sequence comprising SEQ ID NO:71; a
heavy chain consisting of an amino acid sequence comprising SEQ ID
NO:85 and a light chain consisting of an amino acid sequence
comprising SEQ ID NO:73; a heavy chain consisting of an amino acid
sequence comprising SEQ ID NO:85 and a light chain consisting of an
amino acid sequence comprising SEQ ID NO:75; a heavy chain
consisting of an amino acid sequence comprising SEQ ID NO: 85 and a
light chain consisting of an amino acid sequence comprising SEQ ID
NO:77; a heavy chain consisting of an amino acid sequence
comprising SEQ ID NO:85 and a light chain consisting of an amino
acid sequence comprising SEQ ID NO:79; a heavy chain consisting of
an amino acid sequence comprising SEQ ID NO:85 and a light chain
consisting of an amino acid sequence comprising SEQ ID NO:81; a
heavy chain consisting of an amino acid sequence comprising SEQ ID
NO:85 and a light chain consisting of an amino acid sequence SEQ ID
NO:83; a heavy chain consisting of an amino acid sequence
comprising SEQ ID NO:91 and a light chain consisting of an amino
acid sequence comprising SEQ ID NO:71; a heavy chain consisting of
an amino acid sequence comprising SEQ ID NO:91 and a light chain
consisting of an amino acid sequence comprising SEQ ID NO:73; a
heavy chain consisting of an amino acid sequence comprising SEQ ID
NO:91 and a light chain consisting of an amino acid sequence
comprising SEQ ID NO:75; or a heavy chain consisting of an amino
acid sequence comprising SEQ ID NO:91 and a light chain consisting
of an amino acid sequence comprising SEQ ID NO:77.
11. The antibody according to claim 1, wherein the modification of
a glycan, when present, is regulated to enhance an
antibody-dependent cellular cytotoxic activity as compared with an
unmodified antibody.
12. A polynucleotide encoding the antibody according to claim
1.
13. The polynucleotide according to claim 12, which comprises a
nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ
ID NO:50 and a nucleotide sequence comprising nucleotide numbers 67
to 390 in SEQ ID NO:52.
14. The polynucleotide according to claim 12, which comprises a
nucleotide sequence comprising SEQ ID NO:62 and a nucleotide
sequence comprising SEQ ID NO:58.
15. The polynucleotide according to claim 12, which comprises a
nucleotide sequence consisting of (a) a nucleotide sequence
comprising nucleotide numbers 58 to 423 in SEQ ID NO:84, (b) a
nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ
ID NO:86, (c) a nucleotide sequence comprising nucleotide numbers
58 to 423 in SEQ ID NO:88, (d) a nucleotide sequence comprising
nucleotide numbers 58 to 423 in SEQ ID NO:90, and (e) a nucleotide
sequence comprising a polynucleotide which hybridizes to a
polynucleotide consisting of a nucleotide sequence complementary to
any of the nucleotide sequences (a) to (d) under stringent
conditions; and a nucleotide sequence selected (f) a nucleotide
sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO:70,
(g) a nucleotide sequence comprising nucleotide numbers 61 to 384
in SEQ ID NO:72, (h) a nucleotide sequence comprising nucleotide
numbers 61 to 384 in SEQ ID NO:74, (i) a nucleotide sequence
comprising nucleotide numbers 61 to 384 in SEQ ID NO:76, (j) a
nucleotide sequence comprising nucleotide numbers 61 to 384 in SEQ
ID NO:78, (k) a nucleotide sequence comprising nucleotide numbers
61 to 384 in SEQ ID NO:80, (l) a nucleotide sequence comprising
nucleotide numbers 61 to 384 in SEQ ID NO:82, or (m) a nucleotide
sequence comprising a polynucleotide which hybridizes to a
polynucleotide consisting of a nucleotide sequence complementary to
any of the nucleotide sequences (f) to (l) under stringent
conditions.
16. The polynucleotide according to claim 15, which comprises
nucleotide sequences consisting of a nucleotide sequence comprising
nucleotide numbers 58 to 423 in SEQ ID NO:84 and a nucleotide
sequence comprising nucleotide numbers 61 to 384 in SEQ ID NO:70; a
nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ
ID NO:84 and a nucleotide sequence comprising nucleotide numbers 61
to 384 in SEQ ID NO:72; a nucleotide sequence comprising nucleotide
numbers 58 to 423 in SEQ ID NO:84 and a nucleotide sequence
comprising nucleotide numbers 61 to 384 in SEQ ID NO:74; a
nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ
ID NO:84 and a nucleotide sequence comprising nucleotide numbers 61
to 384 in SEQ ID NO:76; a nucleotide sequence comprising nucleotide
numbers 58 to 423 in SEQ ID NO:84 and a nucleotide sequence
comprising nucleotide numbers 61 to 384 in SEQ ID NO:78; a
nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ
ID NO:84 and a nucleotide sequence comprising nucleotide numbers 61
to 384 in SEQ ID NO:80; a nucleotide sequence comprising nucleotide
numbers 58 to 423 in SEQ ID NO:84 and a nucleotide sequence
comprising nucleotide numbers 61 to 384 in SEQ ID NO:82; a
nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ
ID NO:90 and a nucleotide sequence comprising nucleotide numbers 61
to 384 in SEQ ID NO:70; a nucleotide sequence comprising nucleotide
numbers 58 to 423 in SEQ ID NO:90 and a nucleotide sequence
comprising nucleotide numbers 61 to 384 in SEQ ID NO:72; a
nucleotide sequence comprising nucleotide numbers 58 to 423 in SEQ
ID NO:90 and a nucleotide sequence comprising nucleotide numbers 61
to 384 in SEQ ID NO:74; or a nucleotide sequence comprising
nucleotide numbers 58 to 423 in SEQ ID NO:90 and a nucleotide
sequence comprising nucleotide numbers 61 to 384 in SEQ ID
NO:76.
17. The polynucleotide according to claim 15, which comprises
nucleotide sequences consisting of a nucleotide sequence comprising
nucleotide numbers 58 to 1413 in SEQ ID NO:84 and a nucleotide
sequence comprising nucleotide numbers 61 to 699 in SEQ ID NO:70; a
nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ
ID NO:84 and a nucleotide sequence comprising nucleotide numbers 61
to 699 in SEQ ID NO:72; a nucleotide sequence comprising nucleotide
numbers 58 to 1413 in SEQ ID NO:84 and a nucleotide sequence
comprising nucleotide numbers 61 to 699 in SEQ ID NO:74; a
nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ
ID NO:84 and a nucleotide sequence comprising nucleotide numbers 61
to 699 in SEQ ID NO:76; a nucleotide sequence comprising nucleotide
numbers 58 to 1413 in SEQ ID NO:84 and a nucleotide sequence
comprising nucleotide numbers 61 to 699 in SEQ ID NO:78; a
nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ
ID NO:84 and a nucleotide sequence comprising nucleotide numbers 61
to 699 in SEQ ID NO:80; a nucleotide sequence comprising nucleotide
numbers 58 to 1413 in SEQ ID NO:84 and a nucleotide sequence
comprising nucleotide numbers 61 to 699 in SEQ ID NO:82; a
nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ
ID NO:90 and a nucleotide sequence comprising nucleotide numbers 61
to 699 in SEQ ID NO:70; a nucleotide sequence comprising nucleotide
numbers 58 to 1413 in SEQ ID NO:90 and a nucleotide sequence
comprising nucleotide numbers 61 to 699 in SEQ ID NO:72; a
nucleotide sequence comprising nucleotide numbers 58 to 1413 in SEQ
ID NO:90 and a nucleotide sequence comprising nucleotide numbers 61
to 699 in SEQ ID NO:74; or a nucleotide sequence comprising
nucleotide numbers 58 to 1413 in SEQ ID NO:90 and a nucleotide
sequence comprising nucleotide numbers 61 to 699 in SEQ ID
NO:76.
18. The polynucleotide according to claim 12, which comprises
nucleotide sequences consisting of a nucleotide sequence comprising
SEQ ID NO:84 and a nucleotide sequence comprising SEQ ID NO:70; a
nucleotide sequence comprising SEQ ID NO:84 and a nucleotide
sequence comprising SEQ ID NO:72; a nucleotide sequence comprising
SEQ ID NO:84 and a nucleotide sequence comprising SEQ ID NO:74; a
nucleotide sequence comprising SEQ ID NO:84 and a nucleotide
sequence comprising SEQ ID NO:76; a nucleotide sequence comprising
SEQ ID NO:84 and a nucleotide sequence comprising SEQ ID NO:78; a
nucleotide sequence comprising SEQ ID NO:84 and a nucleotide
sequence comprising SEQ ID NO:80; a nucleotide sequence comprising
SEQ ID NO:84 and a nucleotide sequence comprising SEQ ID NO:82; a
nucleotide sequence comprising SEQ ID NO:90 and a nucleotide
sequence comprising SEQ ID NO:70; a nucleotide sequence comprising
SEQ ID NO:90 and a nucleotide sequence comprising SEQ ID NO:72; a
nucleotide sequence comprising SEQ ID NO:90 and a nucleotide
sequence comprising SEQ ID NO:74; or a nucleotide sequence
comprising SEQ ID NO:90 and a nucleotide sequence comprising SEQ ID
NO:76.
19. An expression vector comprising a polynucleotide according to
claim 12.
20. A host cell which is transformed in vitro with the expression
vector according to claim 19.
21. The host cell according to claim 20, wherein the host cell is a
eukaryotic cell.
22. A method of producing an antibody, comprising a step of
culturing a host cell according to claim 20 and a step of
collecting the antibody from a cultured product obtained in the
culturing step.
23. An antibody obtained by a production method according to claim
22.
24. The antibody according to claim 23, wherein the modification of
a glycan, when present, is regulated to enhance an
antibody-dependent cellular cytotoxic activity as compared with an
unmodified antibody.
25. A pharmaceutical composition comprising at least one of the
antibodies according to claim 1.
26. A pharmaceutical composition, comprising at least one of the
antibodies according to claim 1 and at least one therapeutic agent
for cancer.
27. The pharmaceutical composition according to claim 25, wherein
the tumor is cancer.
28. The pharmaceutical composition according to claim 27, wherein
the cancer is lung cancer, breast cancer, prostate cancer,
pancreatic cancer, colorectal cancer, a melanoma, liver cancer,
ovarian cancer, bladder cancer, stomach cancer, esophageal cancer,
or kidney cancer.
29. A pharmaceutical composition, comprising at least one of the
antibodies according to claim 23.
30. A pharmaceutical composition, comprising at least one of the
antibodies according to claim 23 and at least one therapeutic agent
for cancer.
31. The pharmaceutical composition according to claim 29, wherein
the tumor is cancer.
32. The pharmaceutical composition according to claim 31, wherein
the cancer is lung cancer, breast cancer, prostate cancer,
pancreatic cancer, colorectal cancer, a melanoma, liver cancer,
ovarian cancer, bladder cancer, stomach cancer, esophageal cancer,
or kidney cancer.
33. A method of treating a tumor expressing B7-H3, comprising
administering at least one of the antibodies according to claim 1
to an individual.
34. A method of treating a tumor expressing B7-H3, comprising
administering (1) at least one of the antibodies according to claim
1 and (2) at least one therapeutic agent for cancer simultaneously,
separately, or sequentially to an individual.
35. The method according to claim 33, wherein the tumor is
cancer.
36. The method according to claim 35, wherein the cancer is lung
cancer, breast cancer, prostate cancer, pancreatic cancer,
colorectal cancer, a melanoma, liver cancer, ovarian cancer,
bladder cancer, stomach cancer, esophageal cancer, or kidney
cancer.
37. A method of treating a tumor expressing B7-H3, comprising
administering at least one of the antibodies according to claim 23
to an individual.
38. A method of treating a tumor expressing B7-H3, comprising
administering (1) at least one of the antibodies according to claim
23 and (2) at least one therapeutic agent for cancer
simultaneously, separately, or sequentially to an individual.
39. The method according to claim 37, wherein the tumor is
cancer.
40. The method according to claim 39, wherein the cancer is lung
cancer, breast cancer, prostate cancer, pancreatic cancer,
colorectal cancer, a melanoma, liver cancer, ovarian cancer,
bladder cancer, stomach cancer, esophageal cancer, or kidney
cancer.
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a division of U.S. patent application
Ser. No. 13/455,021, filed Apr. 24, 2012, which is a continuation
of International Application No. PCT/JP2012/060904, filed Apr. 24,
2012, which claims the benefit of U.S. Provisional Application No.
61/478,878, filed Apr. 25, 2011, the disclosures of which are
incorporated by reference herein.
STATEMENT REGARDING SEQUENCE LISTING
[0002] The sequence listing associated with this application is
provided in text format in lieu of a paper copy and is hereby
incorporated by reference into the specification. The name of the
text file containing the sequence listing is 56388 Sequence Final
2016-06-17.txt. The text file is 129 KB; was created on Jun. 17,
2016; and is being submitted via EFS-Web with the filing of the
specification.
TECHNICAL FIELD
[0003] The present invention relates to an antibody which binds to
B7-H3 and is useful as a therapeutic and/or preventive agent for a
tumor, and also relates to a method of treating and/or preventing a
tumor using the antibody.
BACKGROUND ART
[0004] B7-H3 is a protein having a single-pass transmembrane
structure (Non-patent document 1). The N-terminal extracellular
domain of B7-H3 contains two variants. Variant 1 contains a V-like
or C-like Ig domain at two sites, respectively, and Variant 2
contains a V-like or C-like Ig domain at one site, respectively.
The C-terminal intracellular domain of B7-H3 contains 45 amino
acids.
[0005] As a receptor for B7-H3, TLT-2 having a single-pass
transmembrane structure has been reported (Non-patent document 2).
However, there is also a report insisting that TLT-2 is not a
receptor for B7-H3 (Non-patent document 3). According to the former
report, the activation of CD8-positive T cells is enhanced when the
receptor is bound to B7-H3.
[0006] It has been clinically reported that B7-H3 is overexpressed
in many cancer types, particularly in non-small-cell lung cancer,
kidney cancer, urothelial carcinoma, colorectal cancer, prostate
cancer, glioblastoma multiforme, ovarian cancer, and pancreatic
cancer (Non-patent documents 4 to 11). Further, it has been
reported that in prostate cancer, the intensity of expression of
B7-H3 positively correlates with clinicopathological malignancy
such as tumor volume, extraprostatic invasion, or Gleason score,
and also correlates with cancer progression (Non-patent document
8). Similarly, in glioblastoma multiforme, the expression of B7-H3
negatively correlates with event-free survival (Non-patent document
9), and in pancreatic cancer, the expression of B7-H3 correlates
with lymph node metastasis and pathological progression (Non-patent
document 11). In ovarian cancer, the expression of B7-H3 correlates
with lymph node metastasis and pathological progression.
[0007] Further, it has been reported that by introducing siRNA
against B7-H3 gene into a B7-H3-positive cancer cell line,
adhesiveness to fibronectin is reduced to reduce cell migration and
matrigel invasion (Non-patent document 12). Further, it has been
reported that in glioblastoma multiforme, the expression of B7-H3
allows escape from NK cell-mediated cell death (Non-patent document
13).
[0008] On the other hand, B7-H3 has been reported to be expressed
not only in cancer cells, but also in tumors or surrounding vessels
(Non-patent documents 5 and 14). It has been reported that when
B7-H3 is expressed in ovarian cancer blood vessels, the survival
rate is decreased.
[0009] B7 family molecules have been suggested to be related to the
immune system. B7-H3 has been reported to be expressed in
monocytes, dendritic cells, and activated T cells (Non-patent
document 15). It has been reported that as cytotoxic T cells are
activated, B7-H3 co-stimulates the proliferation of CD4-positive or
CD8-positive T cells. However, there is also a report that B7-H3
does not play a co-stimulatory role (Non-patent document 1).
[0010] B7-H3 molecules have been reported to be related to
autoimmune diseases. It has been reported that in rheumatism and
other autoimmune diseases, B7-H3 plays an important role in the
interaction between fibroblast-like synoviocytes and activated
T-cells (Non-patent document 16) and that B7-H3 functions as a
co-stimulatory factor when cytokines are released from activated
macrophages and therefore is related to the occurrence of sepsis
(Non-patent document 17). Further, it has been reported that by
administering an anti-B7-H3 antibody to a mouse model of asthma
during the induction phase, asthma is improved due to the
suppression of Th2 cell-mediated cytokine production in regional
lymph nodes through the administration of an anti-mouse B7-H3
antibody (Non-patent document 18).
[0011] With respect to B7-H3, it has been reported that an antibody
against mouse B7-H3 enhances intratumoral infiltrating CD8-positive
T cells and suppresses tumor growth (Non-patent document 14).
Further, there is a patent which discloses that an antibody which
recognizes B7-H3 variant 1 exhibits an in vivo antitumor effect on
adenocarcinoma (Patent document 1).
[0012] In spite of these studies, an epitope for an anti-B7-H3
antibody which exhibits an in vivo antitumor effect has not been
clarified so far, and there has been no report that a specific
amino acid sequence of the extracellular domain of B7-H3 is useful
as an epitope for a monoclonal antibody for treating cancer.
[0013] Even if antibodies are specific for the same antigen, the
properties of the antibodies vary due to a difference of epitopes
or sequences of the antibodies. Due to the difference in properties
of the antibodies, when being clinically administrated to humans,
the antibodies exhibit different reactions in terms of the
effectiveness of the medicinal agent, the frequency of therapeutic
response, the incidence of side effects or drug resistance,
etc.
[0014] Also for the antibody against B7-H3, the creation of an
antibody having unprecedented properties has been strongly
demanded.
RELATED ART DOCUMENTS
Patent Document
[0015] Patent Document 1: WO 2008/066691
Non-Patent Documents
[0015] [0016] Non-patent Document 1: The Journal of Immunology,
2004, vol. 172, pp. 2352-2359 [0017] Non-patent Document 2:
Proceedings of the National Academy of Sciences of the United
States of America, 2008, vol. 105, pp. 10495-10500 [0018]
Non-patent Document 3: European Journal of Immunology, 2009, vol.
39 pp. 1754-1764 [0019] Non-patent Document 4: Lung Cancer, 2009,
vol. 66, pp. 245-249 [0020] Non-patent Document 5: Clinical Cancer
Research, 2008, vol. 14, pp. 5150-5157 [0021] Non-patent Document
6: Clinical Cancer Research 2008, vol. 14, pp. 4800-4808 [0022]
Non-patent Document 7: Cancer Immunology, Immunotherapy, 2010, vol.
59, pp. 1163-1171 [0023] Non-patent Document 8: Cancer Research,
2007, vol. 67, pp. 7893-7900 [0024] Non-patent Document 9:
Histopathology, 2008, vol. 53, pp. 73-80 [0025] Non-patent Document
10: Modern Pathology, 2010, vol. 23, pp. 1104-1112 [0026]
Non-patent Document 11: British Journal of Cancer, 2009, vol. 101,
pp. 1709-1716 [0027] Non-patent Document 12: Current Cancer Drug
Targets, 2008, vol. 8, pp. 404-413 [0028] Non-patent Document 13:
Proceedings of the National Academy of Sciences of the United
States of America, 2004, vol. 101, pp. 12640-12645 [0029]
Non-patent Document 14: Modern Pathology, 2010, vol. 23, pp.
1104-1112 [0030] Non-patent Document 15: Nature Immunology, 2001,
vol. 2, pp. 269-274 [0031] Non-patent Document 16: The Journal of
Immunology, 2008, vol. 180, pp. 2989-2998 [0032] Non-patent
Document 17: The Journal of Immunology, 2010, vol. 185, pp.
3677-3684 [0033] Non-patent Document 18: The Journal of Immunology,
2008, vol. 181, pp. 4062-4071
SUMMARY OF THE INVENTION
Problems to be Solved by the Invention
[0034] An object of the invention is to provide an antibody and a
functional fragment of the antibody to be used in a pharmaceutical
having a therapeutic effect on a tumor, a method of treating a
tumor using the antibody or a functional fragment of the antibody,
and the like.
Means for Solving the Problems
[0035] The present inventors made intensive studies in order to
achieve the above object, and as a result, they discovered an
antibody which specifically binds to B7-H3 to exhibit an antitumor
activity, and thus completed the invention. That is, the invention
includes the following inventions.
[0036] (1) An antibody characterized by having the following
properties: [0037] (a) specific binding to B7-H3; [0038] (b) having
an antibody-dependent cell-mediated phagocytosis (ADCP) activity;
and [0039] (c) having an in vivo antitumor activity, [0040] or a
functional fragment of the antibody.
[0041] (2) The antibody or a functional fragment of the antibody
according to the above (1), wherein B7-H3 is a molecule including
an amino acid sequence represented by SEQ ID NO:6 or 10.
[0042] (3) The antibody or a functional fragment of the antibody
according to the above (1) or (2), which binds to IgC1 and/or IgC2
each of which is a domain of B7-H3.
[0043] (4) The antibody or a functional fragment of the antibody
according to the above (3), wherein IgC1 is a domain including an
amino acid sequence represented by amino acid numbers 140 to 244 in
SEQ ID NO:6, and IgC2 is a domain including an amino acid sequence
represented by amino acid numbers 358 to 456 in SEQ ID NO:6.
[0044] (5) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (4), which has a
competitive inhibitory activity against M30 antibody for the
binding to B7-H3.
[0045] (6) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (5), which has an
antibody-dependent cellular cytotoxicity (ADCC) activity and/or a
complement-dependent cytotoxicity (CDC) activity.
[0046] (7) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (6), wherein the tumor is
cancer.
[0047] (8) The antibody or a functional fragment of the antibody
according to the above (7), wherein the cancer is lung cancer,
breast cancer, prostate cancer, pancreatic cancer, colorectal
cancer, a melanoma, liver cancer, ovarian cancer, bladder cancer,
stomach cancer, esophageal cancer, or kidney cancer.
[0048] (9) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (8), which comprises CDRH1
consisting of an amino acid sequence represented by SEQ ID NO:92,
CDRH2 consisting of an amino acid sequence represented by SEQ ID
NO:93, and CDRH3 consisting of an amino acid sequence represented
by SEQ ID NO:94 as complementarity determining regions of the heavy
chain and comprises CDRL1 consisting of an amino acid sequence
represented by SEQ ID NO:95, CDRL2 consisting of an amino acid
sequence represented by SEQ ID NO:96, and CDRL3 consisting of an
amino acid sequence represented by SEQ ID NO:97 as complementarity
determining regions of the light chain.
[0049] (10) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (9), which comprises a
heavy chain variable region consisting of an amino acid sequence
represented by amino acid numbers 20 to 141 in SEQ ID NO:51 and a
light chain variable region consisting of an amino acid sequence
represented by amino acid numbers 23 to 130 in SEQ ID NO:53.
[0050] (11) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (10), wherein a constant
region is a human-derived constant region.
[0051] (12) The antibody or a functional fragment of the antibody
according to the above (11), which comprises a heavy chain
consisting of an amino acid sequence represented by SEQ ID NO:63
and a light chain consisting of an amino acid sequence represented
by SEQ ID NO:59.
[0052] (13) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (12), which is
humanized.
[0053] (14) The antibody or a functional fragment of the antibody
according to the above (13), which comprises: a heavy chain
variable region consisting of an amino acid sequence selected from
the group consisting of (a) an amino acid sequence represented by
amino acid numbers 20 to 141 in SEQ ID NO:85, (b) an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:87, (c) an amino acid sequence represented by amino acid numbers
20 to 141 in SEQ ID NO:89, (d) an amino acid sequence represented
by amino acid numbers 20 to 141 in SEQ ID NO:91, (e) an amino acid
sequence having a homology of at least 95% or more with any of the
sequences (a) to (d), and (f) an amino acid sequence wherein one or
several amino acids are deleted, substituted or added in any of the
sequences (a) to (d); and a light chain variable region consisting
of an amino acid sequence selected from the group consisting of (g)
an amino acid sequence represented by amino acid numbers 21 to 128
in SEQ ID NO:71, (h) an amino acid sequence represented by amino
acid numbers 21 to 128 in SEQ ID NO:73, (i) an amino acid sequence
represented by amino acid numbers 21 to 128 in SEQ ID NO:75, (j) an
amino acid sequence represented by amino acid numbers 21 to 128 in
SEQ ID NO:77, (k) an amino acid sequence represented by amino acid
numbers 21 to 128 in SEQ ID NO:79, (1) an amino acid sequence
represented by amino acid numbers 21 to 128 in SEQ ID NO:81, (m) an
amino acid sequence represented by amino acid numbers 21 to 128 in
SEQ ID NO:83, (n) an amino acid sequence having a homology of at
least 95% or more with any of the sequences (g) to (m), and (o) an
amino acid sequence wherein one or several amino acids are deleted,
substituted or added in any of the sequences (g) to (m).
[0054] (15) The antibody or a functional fragment of the antibody
according to the above (14), which comprises a heavy chain variable
region and a light chain variable region selected from the group
consisting of: a heavy chain variable region consisting of an amino
acid sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:85 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:71; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:85 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:73; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:85 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:75; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:85 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:77; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:85 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:79; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:85 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:81; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:85 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:83; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:91 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:71; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:91 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:73; a heavy chain variable region consisting of an amino acid
sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:91 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:75; and a heavy chain variable region consisting of an amino
acid sequence represented by amino acid numbers 20 to 141 in SEQ ID
NO:91 and a light chain variable region consisting of an amino acid
sequence represented by amino acid numbers 21 to 128 in SEQ ID
NO:77.
[0055] (16) The antibody or a functional fragment of the antibody
according to the above (14) or (15), which comprises a heavy chain
and a light chain selected from the group consisting of: a heavy
chain consisting of an amino acid sequence represented by amino
acid numbers 20 to 471 in SEQ ID NO:85 and a light chain consisting
of an amino acid sequence represented by amino acid numbers 21 to
233 in SEQ ID NO:71; a heavy chain consisting of an amino acid
sequence represented by amino acid numbers 20 to 471 in SEQ ID
NO:85 and a light chain consisting of an amino acid sequence
represented by amino acid numbers 21 to 233 in SEQ ID NO:73; a
heavy chain consisting of an amino acid sequence represented by
amino acid numbers 20 to 471 in SEQ ID NO:85 and a light chain
consisting of an amino acid sequence represented by amino acid
numbers 21 to 233 in SEQ ID NO:75; a heavy chain consisting of an
amino acid sequence represented by amino acid numbers 20 to 471 in
SEQ ID NO:85 and a light chain consisting of an amino acid sequence
represented by amino acid numbers 21 to 233 in SEQ ID NO:77; a
heavy chain consisting of an amino acid sequence represented by
amino acid numbers 20 to 471 in SEQ ID NO:85 and a light chain
consisting of an amino acid sequence represented by amino acid
numbers 21 to 233 in SEQ ID NO:79; a heavy chain consisting of an
amino acid sequence represented by amino acid numbers 20 to 471 in
SEQ ID NO:85 and a light chain consisting of an amino acid sequence
represented by amino acid numbers 21 to 233 in SEQ ID NO:81; a
heavy chain consisting of an amino acid sequence represented by
amino acid numbers 20 to 471 in SEQ ID NO:85 and a light chain
consisting of an amino acid sequence represented by amino acid
numbers 21 to 233 in SEQ ID NO:83; a heavy chain consisting of an
amino acid sequence represented by amino acid numbers 20 to 471 in
SEQ ID NO:91 and a light chain consisting of an amino acid sequence
represented by amino acid numbers 21 to 233 in SEQ ID NO:71; a
heavy chain consisting of an amino acid sequence represented by
amino acid numbers 20 to 471 in SEQ ID NO:91 and a light chain
consisting of an amino acid sequence represented by amino acid
numbers 21 to 233 in SEQ ID NO:73; a heavy chain consisting of an
amino acid sequence represented by amino acid numbers 20 to 471 in
SEQ ID NO:91 and a light chain consisting of an amino acid sequence
represented by amino acid numbers 21 to 233 in SEQ ID NO:75; and a
heavy chain consisting of an amino acid sequence represented by
amino acid numbers 20 to 471 in SEQ ID NO:91 and a light chain
consisting of an amino acid sequence represented by amino acid
numbers 21 to 233 in SEQ ID NO:77.
[0056] (17) The antibody or a functional fragment of the antibody
according to any one of the above (14) to (16), which comprises a
heavy chain and a light chain selected from the group consisting
of: a heavy chain consisting of an amino acid sequence represented
by SEQ ID NO:85 and a light chain consisting of an amino acid
sequence represented by SEQ ID NO:71; a heavy chain consisting of
an amino acid sequence represented by SEQ ID NO:85 and a light
chain consisting of an amino acid sequence represented by SEQ ID
NO:73; a heavy chain consisting of an amino acid sequence
represented by SEQ ID NO:85 and a light chain consisting of an
amino acid sequence represented by SEQ ID NO:75; a heavy chain
consisting of an amino acid sequence represented by SEQ ID NO:85
and a light chain consisting of an amino acid sequence represented
by SEQ ID NO:77; a heavy chain consisting of an amino acid sequence
represented by SEQ ID NO:85 and a light chain consisting of an
amino acid sequence represented by SEQ ID NO:79; a heavy chain
consisting of an amino acid sequence represented by SEQ ID NO:85
and a light chain consisting of an amino acid sequence represented
by SEQ ID NO:81; a heavy chain consisting of an amino acid sequence
represented by SEQ ID NO:85 and a light chain consisting of g an
amino acid sequence represented by SEQ ID NO:83; a heavy chain
consisting of an amino acid sequence represented by SEQ ID NO:91
and a light chain consisting of an amino acid sequence represented
by SEQ ID NO:71; a heavy chain consisting of an amino acid sequence
represented by SEQ ID NO:91 and a light chain consisting of an
amino acid sequence represented by SEQ ID NO:73; a heavy chain
consisting of an amino acid sequence represented by SEQ ID NO:91
and a light chain consisting of an amino acid sequence represented
by SEQ ID NO:75; and a heavy chain consisting of an amino acid
sequence represented by SEQ ID NO:91 and a light chain consisting
of an amino acid sequence represented by SEQ ID NO:77.
[0057] (18) The functional fragment of the antibody according to
any one of the above (1) to (17), wherein the functional fragment
is selected from the group consisting of Fab, F(ab).sub.2, Fab' and
Fv.
[0058] (19) A polynucleotide encoding the antibody or a functional
fragment of the antibody according to any one of the above (1) to
(18).
[0059] (20) The polynucleotide according to the above (19), which
comprises a nucleotide sequence represented by nucleotide numbers
58 to 423 in SEQ ID NO:50 and a nucleotide sequence represented by
nucleotide numbers 67 to 390 in SEQ ID NO:52.
[0060] (21) The polynucleotide according to the above (19) or (20),
which includes a nucleotide sequence represented by SEQ ID NO:62
and a nucleotide sequence represented by SEQ ID NO:58.
[0061] (22) The polynucleotide according to the above (19) or (20),
which comprises: a nucleotide sequence selected from the group
consisting of (a) a nucleotide sequence represented by nucleotide
numbers 58 to 423 in SEQ ID NO:84, (b) a nucleotide sequence
represented by nucleotide numbers 58 to 423 in SEQ ID NO:86, (c) a
nucleotide sequence represented by nucleotide numbers 58 to 423 in
SEQ ID NO:88, (d) a nucleotide sequence represented by nucleotide
numbers 58 to 423 in SEQ ID NO:90, and (e) a nucleotide sequence
comprising a polynucleotide which hybridizes to a polynucleotide
consisting of a nucleotide sequence complementary to any of the
nucleotide sequences (a) to (d) under stringent conditions; and a
nucleotide sequence selected from the group consisting of (f) a
nucleotide sequence represented by nucleotide numbers 61 to 384 in
SEQ ID NO:70, (g) a nucleotide sequence represented by nucleotide
numbers 61 to 384 in SEQ ID NO:72, (h) a nucleotide sequence
represented by nucleotide numbers 61 to 384 in SEQ ID NO:74, (i) a
nucleotide sequence represented by nucleotide numbers 61 to 384 in
SEQ ID NO:76, (j) a nucleotide sequence represented by nucleotide
numbers 61 to 384 in SEQ ID NO:78, (k) a nucleotide sequence
represented by nucleotide numbers 61 to 384 in SEQ ID NO:80, (1) a
nucleotide sequence represented by nucleotide numbers 61 to 384 in
SEQ ID NO:82, and (m) a nucleotide sequence comprising a
polynucleotide which hybridizes to a polynucleotide consisting of a
nucleotide sequence complementary to any of the nucleotide
sequences (f) to (1) under stringent conditions.
[0062] (23) The polynucleotide according to the above (22), which
comprises nucleotide sequences selected from the group consisting
of: a nucleotide sequence represented by nucleotide numbers 58 to
423 in SEQ ID NO:84 and a nucleotide sequence represented by
nucleotide numbers 61 to 384 in SEQ ID NO:70; a nucleotide sequence
represented by nucleotide numbers 58 to 423 in SEQ ID NO:84 and a
nucleotide sequence represented by nucleotide numbers 61 to 384 in
SEQ ID NO:72; a nucleotide sequence represented by nucleotide
numbers 58 to 423 in SEQ ID NO:84 and a nucleotide sequence
represented by nucleotide numbers 61 to 384 in SEQ ID NO:74; a
nucleotide sequence represented by nucleotide numbers 58 to 423 in
SEQ ID NO:84 and a nucleotide sequence represented by nucleotide
numbers 61 to 384 in SEQ ID NO:76; a nucleotide sequence
represented by nucleotide numbers 58 to 423 in SEQ ID NO:84 and a
nucleotide sequence represented by nucleotide numbers 61 to 384 in
SEQ ID NO:78; a nucleotide sequence represented by nucleotide
numbers 58 to 423 in SEQ ID NO:84 and a nucleotide sequence
represented by nucleotide numbers 61 to 384 in SEQ ID NO:80; a
nucleotide sequence represented by nucleotide numbers 58 to 423 in
SEQ ID NO:84 and a nucleotide sequence represented by nucleotide
numbers 61 to 384 in SEQ ID NO:82; a nucleotide sequence
represented by nucleotide numbers 58 to 423 in SEQ ID NO:90 and a
nucleotide sequence represented by nucleotide numbers 61 to 384 in
SEQ ID NO:70; a nucleotide sequence represented by nucleotide
numbers 58 to 423 in SEQ ID NO:90 and a nucleotide sequence
represented by nucleotide numbers 61 to 384 in SEQ ID NO:72; a
nucleotide sequence represented by nucleotide numbers 58 to 423 in
SEQ ID NO:90 and a nucleotide sequence represented by nucleotide
numbers 61 to 384 in SEQ ID NO:74; and a nucleotide sequence
represented by nucleotide numbers 58 to 423 in SEQ ID NO:90 and a
nucleotide sequence represented by nucleotide numbers 61 to 384 in
SEQ ID NO:76.
[0063] (24) The polynucleotide according to the above (22) or (23),
which comprises nucleotide sequences selected from the group
consisting of: a nucleotide sequence represented by nucleotide
numbers 58 to 1413 in SEQ ID NO:84 and a nucleotide sequence
represented by nucleotide numbers 61 to 699 in SEQ ID NO:70; a
nucleotide sequence represented by nucleotide numbers 58 to 1413 in
SEQ ID NO:84 and a nucleotide sequence represented by nucleotide
numbers 61 to 699 in SEQ ID NO:72; a nucleotide sequence
represented by nucleotide numbers 58 to 1413 in SEQ ID NO:84 and a
nucleotide sequence represented by nucleotide numbers 61 to 699 in
SEQ ID NO:74; a nucleotide sequence represented by nucleotide
numbers 58 to 1413 in SEQ ID NO:84 and a nucleotide sequence
represented by nucleotide numbers 61 to 699 in SEQ ID NO:76; a
nucleotide sequence represented by nucleotide numbers 58 to 1413 in
SEQ ID NO:84 and a nucleotide sequence represented by nucleotide
numbers 61 to 699 in SEQ ID NO:78; a nucleotide sequence
represented by nucleotide numbers 58 to 1413 in SEQ ID NO:84 and a
nucleotide sequence represented by nucleotide numbers 61 to 699 in
SEQ ID NO:80; a nucleotide sequence represented by nucleotide
numbers 58 to 1413 in SEQ ID NO:84 and a nucleotide sequence
represented by nucleotide numbers 61 to 699 in SEQ ID NO:82; a
nucleotide sequence represented by nucleotide numbers 58 to 1413 in
SEQ ID NO:90 and a nucleotide sequence represented by nucleotide
numbers 61 to 699 in SEQ ID NO:70; a nucleotide sequence
represented by nucleotide numbers 58 to 1413 in SEQ ID NO:90 and a
nucleotide sequence represented by nucleotide numbers 61 to 699 in
SEQ ID NO:72; a nucleotide sequence represented by nucleotide
numbers 58 to 1413 in SEQ ID NO:90 and a nucleotide sequence
represented by nucleotide numbers 61 to 699 in SEQ ID NO:74; and a
nucleotide sequence represented by nucleotide numbers 58 to 1413 in
SEQ ID NO:90 and a nucleotide sequence represented by nucleotide
numbers 61 to 699 in SEQ ID NO:76.
[0064] (25) The polynucleotide according to any one of the above
(22) to (24), which comprises nucleotide sequences selected from
the group consisting of: a nucleotide sequence represented by SEQ
ID NO:84 and a nucleotide sequence represented by SEQ ID NO:70; a
nucleotide sequence represented by SEQ ID NO:84 and a nucleotide
sequence represented by SEQ ID NO:72; a nucleotide sequence
represented by SEQ ID NO:84 and a nucleotide sequence represented
by SEQ ID NO:74; a nucleotide sequence represented by SEQ ID NO:84
and a nucleotide sequence represented by SEQ ID NO:76; a nucleotide
sequence represented by SEQ ID NO:84 and a nucleotide sequence
represented by SEQ ID NO:78; a nucleotide sequence represented by
SEQ ID NO:84 and a nucleotide sequence represented by SEQ ID NO:80;
a nucleotide sequence represented by SEQ ID NO:84 and a nucleotide
sequence represented by SEQ ID NO:82; a nucleotide sequence
represented by SEQ ID NO:90 and a nucleotide sequence represented
by SEQ ID NO:70; a nucleotide sequence represented by SEQ ID NO:90
and a nucleotide sequence represented by SEQ ID NO:72; a nucleotide
sequence represented by SEQ ID NO:90 and a nucleotide sequence
represented by SEQ ID NO:74; and a nucleotide sequence represented
by SEQ ID NO:90 and a nucleotide sequence represented by SEQ ID
NO:76.
[0065] (26) An expression vector including a polynucleotide
according to any one of the above (19) to (25).
[0066] (27) A host cell, which is transformed with the expression
vector according to the above (26).
[0067] (28) The host cell according to the above (27), wherein the
host cell is a eukaryotic cell.
[0068] (29) A method of producing an antibody or a functional
fragment of the antibody, characterized by including a step of
culturing the host cell according to the above (27) or (28) and a
step of collecting a desired antibody or a functional fragment of
the antibody from a cultured product obtained in the culturing
step.
[0069] (30) An antibody or a functional fragment of the antibody,
characterized by being obtained by the production method according
to the above (29).
[0070] (31) The functional fragment of the antibody according to
the above (30), wherein the functional fragment is selected from
the group consisting of Fab, F(ab).sub.2, Fab' and Fv.
[0071] (32) The antibody or a functional fragment of the antibody
according to any one of the above (1) to (18), (30), and (31),
wherein the modification of a glycan is regulated to enhance an
antibody-dependent cellular cytotoxic activity.
[0072] (33) A pharmaceutical composition characterized by including
at least one of the antibodies or functional fragments of the
antibodies according to the above (1) to (18), and (30) to
(32).
[0073] (34) The pharmaceutical composition according to the above
(33), which is for treating a tumor.
[0074] (35) A pharmaceutical composition for treating a tumor
characterized by including at least one of the antibodies or
functional fragments of the antibodies according to the above (1)
to (18), and (30) to (32) and at least one therapeutic agent for
cancer.
[0075] (36) The pharmaceutical composition according to the above
(34) or (35), wherein the tumor is cancer.
[0076] (37) The pharmaceutical composition according to the above
(36), wherein the cancer is lung cancer, breast cancer, prostate
cancer, pancreatic cancer, colorectal cancer, a melanoma, liver
cancer, ovarian cancer, bladder cancer, stomach cancer, esophageal
cancer, or kidney cancer.
[0077] (38) A method of treating a tumor, characterized by
administering at least one of the antibodies or functional
fragments of the antibodies according to the above (1) to (18), and
(30) to (32) to an individual.
[0078] (39) A method of treating a tumor, characterized by
administering at least one of the antibodies or functional
fragments of the antibodies according to the above (1) to (18), and
(30) to (32) and at least one therapeutic agent for cancer
simultaneously, separately, or sequentially to an individual.
[0079] (40) The treatment method according to the above (38) or
(39), wherein the tumor is cancer.
[0080] (41) The treatment method according to the above (40),
wherein the cancer is lung cancer, breast cancer, prostate cancer,
pancreatic cancer, colorectal cancer, a melanoma, liver cancer,
ovarian cancer, bladder cancer, stomach cancer, esophageal cancer,
or kidney cancer.
Advantage of the Invention
[0081] According to the invention, a therapeutic agent or the like
for cancer comprising an antibody which binds to B7-H3 and has an
antitumor activity against cancer cells can be obtained.
BRIEF DESCRIPTION OF THE DRAWINGS
[0082] FIG. 1 is a graph showing the presence or absence of an ADCP
activity of an anti-B7-H3 antibody against NCI-H322 cells. The
error bars in the graph represent standard errors (n=3).
[0083] FIG. 2 is a graph showing the presence or absence of an ADCP
activity of a commercially available anti-B7-H3 antibody against
NCI-H322 cells.
[0084] FIG. 3 is a graph showing the presence or absence of an ADCC
activity of M30 antibody against empty vector-transfected 293 cells
and B7-H3-expressing 293 cells. The error bars in the graph
represent standard errors (n=3). In the drawing, the "mock" denotes
the ADCC activity of M30 against empty vector-transfected 293
cells, and the "B7H3" denotes the ADCC activity of M30 against
B7-H3-expressing 293 cells.
[0085] FIG. 4 is a graph showing the presence or absence of a CDC
activity of an anti-B7-H3 antibody against NCI-H322 cells. The
error bars in the graph represent standard errors (n=3).
[0086] FIG. 5-1 is a graph showing the reactivity of M30 antibody
against a B7-H3 deficient mutant (B7-H3 IgV1). The dotted line
indicates the binding property of a control antibody, and the solid
line indicates the binding property of an M30 antibody.
[0087] FIG. 5-2 is a graph showing the reactivity of M30 antibody
against a B7-H3 deficient mutant (B7-H3 IgC1). The dotted line
indicates the binding property of a control antibody, and the solid
line indicates the binding property of an M30 antibody.
[0088] FIG. 5-3 is a graph showing the reactivity of M30 antibody
against a B7-H3 deficient mutant (B7-H3 IgV2). The dotted line
indicates the binding property of a control antibody, and the solid
line indicates the binding property of an M30 antibody.
[0089] FIG. 5-4 is a graph showing the reactivity of M30 antibody
against a B7-H3 deficient mutant (B7-H3 IgC2). The dotted line
indicates the binding property of a control antibody, and the solid
line indicates the binding property of an M30 antibody.
[0090] FIG. 5-5 is a graph showing the reactivity of M30 antibody
against a B7-H3 deficient mutant (B7-H3 IgC1-V2-C2). The dotted
line indicates the binding property of a control antibody, and the
solid line indicates the binding property of an M30 antibody.
[0091] FIG. 5-6 is a graph showing the reactivity of M30 antibody
against a B7-H3 deficient mutant (B7-H3 IgV2-C2). The dotted line
indicates the binding property of a control antibody, and the solid
line indicates the binding property of an M30 antibody.
[0092] FIG. 6 is a graph showing the antitumor activities of
anti-B7-H3 antibodies against mice implanted with NCI-H322 cells.
The error bars in the graph represent standard errors (n=10).
[0093] FIG. 7 is a graph showing the antitumor activity of M30
antibody when macrophages were depleted in vivo. The error bars in
the graph represent standard errors (n=8). Further, the "mm 3"
denotes "mm.sup.3".
[0094] FIG. 8 is a graph showing the ADCP activities of M30
antibody and cM30 antibody against NCI-H322 cells. The error bars
in the graph represent standard errors (n=4).
[0095] FIG. 9 is a graph showing the antitumor activities of M30
antibody and cM30 antibody against mice implanted with MDA-MB-231
cells. The error bars in the graph represent standard errors
(n=9).
[0096] FIG. 10-1 is a graph showing the competitive inhibitory
activities of cM30 antibody and M30-H1-L4 antibody against M30 for
the binding to an extracellular domain polypeptide antigen of a
B7-H3 variant 1 antigen. The error bars in the graph represent
standard errors (n=3).
[0097] FIG. 10-2 is a graph showing the competitive inhibitory
activities of cM30 antibody and M30-H1-L4 antibody against M30 for
the binding to an extracellular domain polypeptide antigen of a
B7-H3 variant 2 antigen. The error bars in the graph represent
standard errors (n=3).
[0098] FIG. 11 is a graph showing the ADCP activities of M30
antibody, cM30 antibody, and M30-H1-L4 antibody against NCI-H322
cells. The error bars in the graph represent standard errors
(n=4).
[0099] FIG. 12 is a graph showing the ADCC activities of cM30
antibody and M30-H1-L4 antibody against NCI-H322 cells. The error
bars in the graph represent standard errors (n=3).
[0100] FIG. 13-1 shows a nucleotide sequence of B7-H3 variant 1
(SEQ ID NO:5).
[0101] FIG. 13-2 shows an amino acid sequence of the B7-H3 variant
1 (SEQ ID NO:6).
[0102] FIG. 14-1 shows a nucleotide sequence of B7-H3 variant 2
(SEQ ID NO:9).
[0103] FIG. 14-2 shows an amino acid sequence of the B7-H3 variant
2 (SEQ ID NO:10).
[0104] FIG. 15-1 shows a nucleotide sequence of B7-H3 IgV1 (SEQ ID
NO:20).
[0105] FIG. 15-2 shows an amino acid sequence of the B7-H3 IgV1
(SEQ ID NO:21).
[0106] FIG. 16-1 shows a nucleotide sequence of B7-H3 IgC1 (SEQ ID
NO:22).
[0107] FIG. 16-2 shows an amino acid sequence of the B7-H3 IgC1
(SEQ ID NO:23).
[0108] FIG. 17-1 shows a nucleotide sequence of B7-H3 IgV2 (SEQ ID
NO:24).
[0109] FIG. 17-2 shows an amino acid sequence of the B7-H3 IgV2
(SEQ ID NO:25).
[0110] FIG. 18-1 shows a nucleotide sequence of B7-H3 IgC2 (SEQ ID
NO:26).
[0111] FIG. 18-2 shows an amino acid sequence of the B7-H3 IgC2
(SEQ ID NO:27).
[0112] FIG. 19-1 shows a nucleotide sequence of B7-H3 IgC1-V2-C2
(SEQ ID NO:28).
[0113] FIG. 19-2 shows an amino acid sequence of the B7-H3
IgC1-V2-C2 (SEQ ID NO:29).
[0114] FIG. 20-1 shows a nucleotide sequence of B7-H3 IgV2-C2 (SEQ
ID NO:30).
[0115] FIG. 20-2 shows an amino acid sequence of B7-H3 IgV2-C2 (SEQ
ID NO:31).
[0116] FIG. 21-1 shows a nucleotide sequence of an M30 antibody
heavy chain (SEQ ID NO:50).
[0117] FIG. 21-2 shows an amino acid sequence of the M30 antibody
heavy chain (SEQ ID NO:51).
[0118] FIG. 22-1 shows a nucleotide sequence of an M30 antibody
light chain (SEQ ID NO:52).
[0119] FIG. 22-2 shows an amino acid sequence of the M30 antibody
light chain (SEQ ID NO:53).
[0120] FIG. 23 shows a nucleotide sequence of a human .kappa. chain
secretory signal, a human .kappa. chain constant region, and a
human poly-A additional signal (SEQ ID NO:56).
[0121] FIG. 24 shows a nucleotide sequence of a signal sequence and
a constant region of human IgG1 (SEQ ID NO:57).
[0122] FIG. 25-1 shows a nucleotide sequence of an M30 antibody
chimera-type light chain (SEQ ID NO:58).
[0123] FIG. 25-2 shows an amino acid sequence of the M30 antibody
chimera-type light chain (SEQ ID NO:59).
[0124] FIG. 26-1 shows a nucleotide sequence of an M30 antibody
chimera-type heavy chain (SEQ ID NO:62).
[0125] FIG. 26-2 shows an amino acid sequence of the M30 antibody
chimera-type heavy chain (SEQ ID NO:63).
[0126] FIG. 27-1 shows a nucleotide sequence of an M30-L1-type
light chain (SEQ ID NO:70).
[0127] FIG. 27-2 shows an amino acid sequence of the M30-L1-type
light chain (SEQ ID NO: 71).
[0128] FIG. 28-1 shows a nucleotide sequence of an M30-L2-type
light chain (SEQ ID NO:72).
[0129] FIG. 28-2 shows an amino acid sequence of the M30-L2-type
light chain (SEQ ID NO:73).
[0130] FIG. 29-1 shows a nucleotide sequence of an M30-L3-type
light chain (SEQ ID NO:74).
[0131] FIG. 29-2 shows an amino acid sequence of the M30-L3-type
light chain (SEQ ID NO:75).
[0132] FIG. 30-1 shows a nucleotide sequence of an M30-L4-type
light chain (SEQ ID NO:76).
[0133] FIG. 30-2 shows an amino acid sequence of the M30-L4-type
light chain (SEQ ID NO:77).
[0134] FIG. 31-1 shows a nucleotide sequence of an M30-L5-type
light chain (SEQ ID NO: 78).
[0135] FIG. 31-2 shows an amino acid sequence of the M30-L5-type
light chain (SEQ ID NO:79).
[0136] FIG. 32-1 shows a nucleotide sequence of an M30-L6-type
light chain (SEQ ID NO:80).
[0137] FIG. 32-2 shows an amino acid sequence of the M30-L6-type
light chain (SEQ ID NO:81).
[0138] FIG. 33-1 shows a nucleotide sequence of an M30-L7-type
light chain (SEQ ID NO: 82).
[0139] FIG. 33-2 shows an amino acid sequence of the M30-L7-type
light chain (SEQ ID NO:83).
[0140] FIG. 34-1 shows a nucleotide sequence of an M30-H1-type
heavy chain (SEQ ID NO:84).
[0141] FIG. 34-2 shows an amino acid sequence of the M30-H1-type
heavy chain (SEQ ID NO:85).
[0142] FIG. 35-1 shows a nucleotide sequence of an M30-H2-type
heavy chain (SEQ ID NO:86).
[0143] FIG. 35-2 shows an amino acid sequence of the M30-H2-type
heavy chain (SEQ ID NO:87).
[0144] FIG. 36-1 shows a nucleotide sequence of an M30-H3-type
heavy chain (SEQ ID NO:88).
[0145] FIG. 36-2 shows an amino acid sequence of the M30-H3-type
heavy chain (SEQ ID NO:89).
[0146] FIG. 37-1 shows a nucleotide sequence of an M30-H4-type
heavy chain (SEQ ID NO:90).
[0147] FIG. 37-2 shows an amino acid sequence of the M30-H4-type
heavy chain (SEQ ID NO:91).
[0148] FIG. 38 is a graph showing the antitumor activity of a
humanized M30 (M30-H1-L4) antibody against mice implanted with
MDA-MB-231 cells. The error bars in the graph represent standard
errors (n=6).
MODE FOR CARRYING OUT THE INVENTION
[0149] The terms "cancer" and "tumor" as used herein are used with
the same meaning.
[0150] The term "gene" as used herein includes not only DNA, but
also mRNA thereof, cDNA thereof and cRNA thereof.
[0151] The term "polynucleotide" as used herein is used with the
same meaning as a nucleic acid and also includes DNA, RNA, probes,
oligonucleotides, and primers.
[0152] The terms "polypeptide" and "protein" as used herein are
used without distinction.
[0153] The term "cell" as used herein also includes cells in an
animal individual and cultured cells.
[0154] The term "B7-H3" as used herein is used in the same meaning
as B7-H3 protein, and also refers to B7-H3 variant 1 and/or B7-H3
variant 2.
[0155] The term "cell injury" as used herein refers to a state in
which a pathological change is caused in cells in a form of some
kind, and the cell injury is not limited to direct injury and
includes all sorts of damages to the structure and function of
cells such as DNA cleavage, base-dimer formation, chromosomal
cleavage, damage to cell division machinery, and a decrease in
various enzymatic activities.
[0156] The term "cytotoxic activity" as used herein refers to an
activity of causing the above-described cell injury.
[0157] The term "antibody-dependent cell-mediated phagocytosis
activity" as used herein refers to "antibody-dependent cell
phagocytosis (ADCP) activity" and means an activity of
phagocytosing target cells such as tumor cells by monocytes or
macrophages mediated by an antibody. The term also called
"antibody-dependent phagocytosis activity".
[0158] The term "antibody-dependent cellular cytotoxicity activity"
as used herein refers to "antibody-dependent cellular cytotoxicity
(ADCC) activity" and means an activity of damaging target cells
such as tumor cells by NK cells mediated by an antibody.
[0159] The term "complement-dependent cytotoxicity activity" as
used herein refers to "complement-dependent cytotoxicity (CDC)
activity" and means an activity of damaging target cells such as
tumor cells by a complement mediated by an antibody.
[0160] The term "functional fragment of an antibody" as used herein
refers to a partial fragment of an antibody having an
antigen-binding activity, wherein the fragment has a full or
partial function of the antibody, including Fab, F(ab').sub.2,
scFv, and the like. The term also includes Fab' which is a
monovalent fragment in a variable region of an antibody obtained by
treating, F(ab').sub.2 under reducing conditions. However, the term
is not limited to these molecules as long as the fragment has a
binding affinity for an antigen. Further, these functional
fragments include not only a fragment obtained by treating a
full-length molecule of an antibody protein with an appropriate
enzyme, but also a protein produced in an appropriate host cell
using a genetically modified antibody gene.
[0161] The term "Fab" as used herein refers to a monovalent
fragment in a variable region of an antibody obtained by treating
F(ab').sub.2 under reducing conditions as described above. However,
Fab' produced using a genetically modified antibody gene is also
included in the Fab' in the invention.
[0162] The term "epitope" as used herein refers to a partial
peptide or a partial tertiary structure of B7-H3 to which a
specific anti-B7-H3 antibody binds. The epitope which is a partial
peptide of the above-described B7-H3 can be determined by a method
well known to those skilled in the art such as an immunoassay, and
for example, the following method can be employed. First, various
partial structures of an antigen are produced. In the production of
the partial structures, a known oligopeptide synthesis technique
can be used. For example, a series of polypeptides having
appropriately reduced lengths obtained by sequentially shortening
B7-H3 from the C terminus or N terminus are produced using a
genetic recombination technique known to those skilled in the art.
Thereafter, the reactivity of an antibody against these
polypeptides is examined and a recognition site is roughly
determined. Then, peptides having shorter lengths are synthesized
and the reactivity of the antibody with these peptides is examined,
whereby the epitope can be determined. Further, the epitope which
is a partial tertiary structure of an antigen to which a specific
antibody binds can be determined by specifying the amino acid
residues of the antigen which lie adjacent to the antibody by an
X-ray structural analysis.
[0163] The phrase "antibodies which bind to the same epitope" as
used herein refers to different antibodies which bind to a common
epitope. If a second antibody binds to a partial peptide or a
partial tertiary structure to which a first antibody binds, it can
be determined that the first antibody and the second antibody bind
to the same epitope. Further, by confirming that a second antibody
competes with a first antibody for the binding to an antigen (that
is, the second antibody inhibits the binding between the first
antibody and the antigen), it can be determined that the first
antibody and the second antibody bind to the same epitope even if
the specific epitope sequence or structure has not been determined.
Further, when the first antibody and the second antibody bind to
the same epitope and also the first antibody has a special activity
such as an antitumor activity, it can be expected that also the
second antibody has the same activity. Accordingly, when a second
anti-B7-H3 antibody binds to a partial peptide to which a first
anti-B7-H3 antibody binds, it can be determined that the first
antibody and the second antibody bind to the same epitope of B7-H3.
Further, by confirming that a second anti-B7-H3 antibody competes
with a first anti-B7-H3 antibody for the binding to B7-H3, it can
be determined that the first antibody and the second antibody are
antibodies which bind to the same epitope of B7-H3.
[0164] The term "CDR" as used herein refers to a complementarity
determining region (CDR), and it is known that each heavy and light
chain of an antibody molecule has three complementarity determining
regions (CDRs). The CDR is also called the hypervariable region,
and is present in a variable region of each heavy and light chain
of an antibody. It is a site which has unusually high variability
in its primary structure, and there are three separate CDRs in the
primary structure of each heavy and light polypeptide chain. In
this specification, as for the CDRs of an antibody, the CDRs of the
heavy chain are represented by CDRH1, CDRH2, and CDRH3 from the
amino-terminal side of the amino acid sequence of the heavy chain,
and the CDRs of the light chain are represented by CDRL1, CDRL2,
and CDRL3 from the amino-terminal side of the amino acid sequence
of the light chain. These sites are proximate to one another in the
tertiary structure and determine the specificity for an antigen to
which the antibody binds.
[0165] The phrase "hybridization is performed under stringent
conditions" as used herein refers to a process in which
hybridization is performed under conditions under which
identification can be achieved by performing hybridization at
68.degree. C. in a commercially available hybridization solution
ExpressHyb.TM. Hybridization Solution (manufactured by Clontech,
Inc.) or by performing hybridization at 68.degree. C. in the
presence of 0.7 to 1.0 M NaCl using a filter having DNA immobilized
thereon, followed by performing washing at 68.degree. C. using 0.1
to 2.times.SSC solution (1.times.SSC solution is composed of 150 mM
NaCl and 15 mM sodium citrate) or under conditions equivalent
thereto.
[0166] 1. B7-H3
[0167] B7-H3 is a member of the B7 family expressed on
antigen-presenting cells as a co-stimulatory molecule, and is
considered to act on a receptor on T cells to enhance or suppress
immune activity.
[0168] B7-H3 is a protein having a single-pass transmembrane
structure, and the N-terminal extracellular domain of B7-H3
contains two variants. The B7-H3 variant 1 (4Ig-B7-H3) contains a
V-like or C-like Ig domain at two sites, respectively, and the
B7-H3 variant 2 (2Ig-B7-H3) contains a V-like or C-like Ig domain
at one site, respectively.
[0169] As for B7-H3 to be used in the invention, B7-H3 can be
directly purified from B7-H3-expressing cells of a human or a
non-human mammal (such as a rat or a mouse) and used, or a cell
membrane fraction of the above-described cells can be prepared and
used. Further, B7-H3 can be obtained by in vitro synthesis thereof
or production thereof in a host cell through genetic engineering.
In the genetic engineering, specifically, after B7-H3 cDNA is
integrated into a vector capable of expressing B7-H3 cDNA, B7-H3
can be obtained by synthesizing it in a solution containing an
enzyme, a substrate and an energy substance required for
transcription and translation, or by expressing B7-H3 in another
prokaryotic or eucaryotic transformed host cell.
[0170] The nucleotide sequence of an open reading frame (ORF) of a
human B7-H3 variant 1 gene is represented by SEQ ID NO:5 in the
Sequence Listing, and the amino acid sequence thereof is
represented by SEQ ID NO:6 in the Sequence Listing. Further, the
sequences of SEQ ID NOS:5 and 6 are shown in FIG. 13.
[0171] The nucleotide sequence of an ORF of a human B7-H3 variant 2
gene is represented by SEQ ID NO:9 in the Sequence Listing, and the
amino acid sequence thereof is represented by SEQ ID NO:10 in the
Sequence Listing. Further, the sequences of SEQ ID NOS:9 and 10 are
shown in FIG. 14.
[0172] Further, a protein which consists of an amino acid sequence
wherein one or several amino acids are substituted, deleted and/or
added in any of the above-described amino acid sequences of B7-H3
and also has a biological activity equivalent to that of the
protein is also included in B7-H3.
[0173] Mature human B7-H3 variant 1 from which the signal sequence
has been removed corresponds to an amino acid sequence consisting
of amino acid residues 27 to 534 of the amino acid sequence
represented by SEQ ID NO:6. Further, mature human B7-H3 variant 2
from which the signal sequence has been removed corresponds to an
amino acid sequence consisting of amino acid residues 27 to 316 of
the amino acid sequence represented by SEQ ID NO:10.
[0174] In the B7-H3 variant 1, the respective domains are present
in the order of IgV1, IgC1, IgV2, and IgC2 from the N terminus, and
in SEQ ID NO:6 in the Sequence Listing, IgV1 corresponds to amino
acid numbers 27 to 139, IgC1 corresponds to amino acid numbers 140
to 244, IgV2 corresponds to amino acid numbers 245 to 357, and IgC2
corresponds to amino acid numbers 358 to 456. Further, in the B7-H3
variant 2, the respective domains are present in the order of IgV1
and IgC2 from the N terminus, and in SEQ ID NO:10 in the Sequence
Listing, IgV1 corresponds to amino acid numbers 27 to 140 and IgC2
corresponds to amino acid numbers 141 to 243.
[0175] B7-H3 cDNA can be obtained by, for example, a so-called PCR
method in which a polymerase chain reaction (hereinafter referred
to as "PCR") is performed using a cDNA library expressing B7-H3
cDNA as a template and primers which specifically amplify B7-H3
cDNA (Saiki, R. K., et al., Science, (1988) 239, pp. 487-491). A
polynucleotide which hybridizes to a polynucleotide consisting of a
nucleotide sequence complementary to the nucleotide sequence
represented by SEQ ID NO:5 or 9 in the Sequence Listing under
stringent conditions and encodes a protein having a biological
activity equivalent to that of B7-H3 is also included in B7-H3
cDNA. Further, a polynucleotide which is a splicing variant
transcribed from the human or mouse B7-H3 locus or a polynucleotide
which hybridizes thereto under stringent conditions and encodes a
protein having a biological activity equivalent to that of B7-H3 is
also included in B7-H3 cDNA.
[0176] Further, a protein which consists of an amino acid sequence
wherein one or several amino acids are substituted, deleted or
added in the amino acid sequence represented by SEQ ID NO:6 or 10
in the Sequence Listing or an amino acid sequence obtained by
removing the signal sequence from either of these sequences and has
a biological activity equivalent to that of B7-H3 is also included
in B7-H3. Further, a protein which consists of an amino acid
sequence encoded by a splicing variant transcribed from the human
or mouse B7-H3 locus or an amino acid sequence wherein one or
several amino acids are substituted, deleted or added in the above
amino acid sequence and has a biological activity equivalent to
that of B7-H3 is also included in B7-H3.
[0177] 2. Production of Anti-B7-H3 Antibody
[0178] The antibody against B7-H3 of the invention can be obtained
by immunizing an animal with B7-H3 or an arbitrary polypeptide
selected from the amino acid sequence of B7-H3, and collecting and
purifying the antibody produced in vivo according to a common
procedure. The biological species of B7-H3 to be used as an antigen
is not limited to being human, and an animal can be immunized with
B7-H3 derived from an animal other than humans such as a mouse or a
rat. In this case, by examining the cross-reactivity between an
antibody binding to the obtained heterologous B7-H3 and human
B7-H3, an antibody applicable to a human disease can be
selected.
[0179] Further, a monoclonal antibody can be obtained from a
hybridoma established by fusing antibody-producing cells which
produce an antibody against B7-H3 with myeloma cells according to a
known method (for example, Kohler and Milstein, Nature, (1975) 256,
pp. 495-497; Kennet, R. ed., Monoclonal Antibodies, pp. 365-367,
Plenum Press, N.Y. (1980)).
[0180] B7-H3 to be used as an antigen can be obtained by expressing
B7-H3 gene in a host cell using genetic engineering.
[0181] Specifically, a vector capable of expressing B7-H3 gene is
produced, and the resulting vector is transfected into a host cell
to express the gene, and then, the expressed B7-H3 is purified.
Hereinafter, a method of obtaining an antibody against B7-H3 will
be specifically described.
[0182] (1) Preparation of Antigen
[0183] Examples of the antigen to be used for producing the
anti-B7-H3 antibody include B7-H3, a polypeptide consisting of a
partial amino acid sequence comprising at least 6 consecutive amino
acids of B7-H3, and a derivative obtained by adding a given amino
acid sequence or carrier thereto.
[0184] B7-H3 can be purified directly from human tumor tissues or
tumor cells and used. Further, B7-H3 can be obtained by
synthesizing it in vitro or by producing it in a host cell by
genetic engineering.
[0185] With respect to the genetic engineering, specifically, after
B7-H3 cDNA is integrated into a vector capable of expressing B7-H3
cDNA, B7-H3 can be obtained by synthesizing it in a solution
containing an enzyme, a substrate and an energy substance required
for transcription and translation, or by expressing B7-H3 in
another prokaryotic or eucaryotic transformed host cell.
[0186] Further, the antigen can also be obtained as a secretory
protein by expressing a fusion protein obtained by ligating the
extracellular domain of B7-H3, which is a membrane protein, to the
constant region of an antibody in an appropriate host-vector
system.
[0187] B7-H3 cDNA can be obtained by, for example, a so-called PCR
method in which a polymerase chain reaction (hereinafter referred
to as "PCR") is performed using a cDNA library expressing B7-H3
cDNA as a template and primers which specifically amplify B7-H3
cDNA (see Saiki, R. K., et al., Science, (1988) 239, pp.
487-491).
[0188] As the in vitro synthesis of the polypeptide, for example,
Rapid Translation System (RTS) manufactured by Roche Diagnostics,
Inc. can be exemplified, but it is not limited thereto.
[0189] Examples of the prokaryotic host cells include Escherichia
coli and Bacillus subtilis. In order to transform the host cells
with a target gene, the host cells are transformed by a plasmid
vector comprising a replicon, i.e., a replication origin derived
from a species compatible with the host, and a regulatory sequence.
Further, the vector preferably has a sequence capable of imposing
phenotypic selectivity on the transformed cell.
[0190] Examples of the eucaryotic host cells include vertebrate
cells, insect cells, and yeast cells. As the vertebrate cells, for
example, simian COS cells (Gluzman, Y., Cell, (1981) 23, pp.
175-182, ATCC CRL-1650), murine fibroblasts NIH3T3 (ATCC No.
CRL-1658), and dihydrofolate reductase-deficient strains (Urlaub,
G. and Chasin, L. A., Proc. Natl. Acad. Sci. USA (1980) 77, pp.
4126-4220) of Chinese hamster ovarian cells (CHO cells; ATCC:
CCL-61); and the like are often used, however, the cells are not
limited thereto.
[0191] The thus obtained transformant can be cultured according to
a common procedure, and by the culturing of the transformant, a
target polypeptide is produced intracellularly or
extracellularly.
[0192] A suitable medium to be used for the culturing can be
selected from various commonly used culture media depending on the
employed host cells. If Escherichia coli is employed, for example,
an LB medium supplemented with an antibiotic such as ampicillin or
IPMG as needed can be used.
[0193] A recombinant protein produced intracellularly or
extracellularly by the transformant through such culturing can be
separated and purified by any of various known separation methods
utilizing the physical or chemical property of the protein.
[0194] Specific examples of the methods include treatment with a
common protein precipitant, ultrafiltration, various types of
liquid chromatography such as molecular sieve chromatography (gel
filtration), adsorption chromatography, ion exchange
chromatography, and affinity chromatography, dialysis, and a
combination thereof.
[0195] Further, by attaching a tag of six histidine residues to a
recombinant protein to be expressed, the protein can be efficiently
purified with a nickel affinity column. Alternatively, by attaching
the IgG Fc region to a recombinant protein to be expressed, the
protein can be efficiently purified with a protein A column.
[0196] By combining the above-described methods, a large amount of
a target polypeptide can be easily produced in high yield and high
purity.
[0197] (2) Production of Anti-B7-H3 Monoclonal Antibody
[0198] Examples of the antibody specific binding to B7-H3 include a
monoclonal antibody specific binding to B7-H3, and a method of
obtaining the antibody is as described below.
[0199] The production of a monoclonal antibody generally requires
the following operational steps of:
[0200] (a) purifying a biopolymer to be used as an antigen;
[0201] (b) preparing antibody-producing cells by immunizing an
animal by injection of the antigen, collecting the blood, assaying
its antibody titer to determine when the spleen is excised;
[0202] (c) preparing myeloma cells (hereinafter referred to as
"myeloma");
[0203] (d) fusing the antibody-producing cells with the
myeloma;
[0204] (e) screening a group of hybridomas producing a desired
antibody;
[0205] (f) dividing the hybridomas into single cell clones
(cloning);
[0206] (g) optionally, culturing the hybridoma or rearing an animal
implanted with the hybridoma for producing a large amount of a
monoclonal antibody;
[0207] (h) examining the thus produced monoclonal antibody for
biological activity and binding specificity, or assaying the same
for properties as a labeled reagent; and the like.
[0208] Hereinafter, the method of producing a monoclonal antibody
will be described in detail following the above steps, however, the
method is not limited thereto, and, for example, antibody-producing
cells other than spleen cells and myeloma can be used.
[0209] (a) Purification of Antigen
[0210] As the antigen, B7-H3 prepared by the method as described
above or a partial peptide thereof can be used.
[0211] Further, a membrane fraction prepared from recombinant cells
expressing B7-H3 or the recombinant cells expressing B7-H3
themselves, and also a partial peptide of the protein of the
invention chemically synthesized by a method known to those skilled
in the art can also be used as the antigen.
[0212] (b) Preparation of Antibody-Producing Cells
[0213] The antigen obtained in the step (a) is mixed with an
adjuvant such as Freund's complete or incomplete adjuvant or
aluminum potassium sulfate and the resulting mixture is used as an
immunogen to immunize an experimental animal. As the experimental
animal, any animal used in a known hybridoma production method can
be used without any trouble. Specifically, for example, a mouse, a
rat, a goat, sheep, cattle, a horse, or the like can be used.
However, from the viewpoint of ease of availability of myeloma
cells to be fused with the extracted antibody-producing cells, a
mouse or a rat is preferably used as the animal to be
immunized.
[0214] Further, the strain of a mouse or a rat to be used is not
particularly limited, and in the case of a mouse, for example,
various strains such as A, AKR, BALB/c, BDP, BA, CE, C3H, 57BL,
C57BL, C57L, DBA, FL, HTH, HT1, LP, NZB, NZW, RF, R III, SJL, SWR,
WB, and 129 and the like can be used, and in the case of a rat, for
example, Wistar, Low, Lewis, Sprague, Dawley, ACI, BN, Fischer and
the like can be used.
[0215] These mice and rats are commercially available from
breeders/distributors of experimental animals, for example, CLEA
Japan, Inc. and Charles River Laboratories Japan, Inc.
[0216] Among these, in consideration of compatibility of fusing
with myeloma cells described below, in the case of a mouse, BALB/c
strain, and in the case of a rat, Wistar and Low strains are
particularly preferred as the animal to be immunized.
[0217] Further, in consideration of antigenic homology between
humans and mice, it is also preferred to use a mouse having
decreased biological function to remove auto-antibodies, that is, a
mouse with an autoimmune disease.
[0218] The age of such mouse or rat at the time of immunization is
preferably 5 to 12 weeks of age, more preferably 6 to 8 weeks of
age.
[0219] In order to immunize an animal with B7-H3 or a recombinant
thereof, for example, a known method described in detail in, for
example, Weir, D. M., Handbook of Experimental Immunology Vol. I.
II. III., Blackwell Scientific Publications, Oxford (1987), Kabat,
E. A. and Mayer, M. M., Experimental Immunochemistry, Charles C
Thomas Publisher Springfield, Ill. (1964) or the like can be
used.
[0220] Among these immunization methods, a preferred specific
method in the invention is, for example, as follows.
[0221] That is, first, a membrane protein fraction serving as the
antigen or cells caused to express the antigen is/are intradermally
or intraperitoneally administrated to an animal.
[0222] However, the combination of both routes of administration is
preferred for increasing the immunization efficiency, and when
intradermal administration is performed in the first half and
intraperitoneal administration is performed in the latter half or
only at the last dosing, the immunization efficiency can be
particularly increased.
[0223] The administration schedule of the antigen varies depending
on the type of animal to be immunized, individual difference or the
like. However, in general, an administration schedule in which the
frequency of administration of the antigen is 3 to 6 times and the
dosing interval is 2 to 6 weeks is preferred, and an administration
schedule in which the frequency of administration of the antigen is
3 to 4 times and the dosing interval is 2 to 4 weeks is more
preferred.
[0224] Further, the dose of the antigen varies depending on the
type of animal, individual differences and the like; however, the
dose is generally set to 0.05 to 5 mg, preferably about 0.1 to 0.5
mg.
[0225] A booster immunization is performed 1 to 6 weeks, preferably
2 to 4 weeks, more preferably 2 to 3 weeks after the administration
of the antigen as described above.
[0226] The dose of the antigen at the time of performing the
booster immunization varies depending on the type or size of animal
or the like, however, in the case of, for example, a mouse, the
dose is generally set to 0.05 to 5 mg, preferably 0.1 to 0.5 mg,
more preferably about 0.1 to 0.2 mg.
[0227] Spleen cells or lymphocytes including antibody-producing
cells are aseptically removed from the immunized animal 1 to 10
days, preferably 2 to 5 days, more preferably 2 to 3 days after the
booster immunization. At this time, the antibody titer is measured,
and if an animal having a sufficiently increased antibody titer is
used as a supply source of the antibody-producing cells, the
subsequent procedure can be carried out more efficiently.
[0228] Examples of the method of measuring the antibody titer to be
used here include an RIA method and an ELISA method, but the method
is not limited thereto.
[0229] For example, if an ELISA method is employed, the measurement
of the antibody titer in the invention can be carried out according
to the procedures as described below.
[0230] First, a purified or partially purified antigen is adsorbed
to the surface of a solid phase such as a 96-well plate for ELISA,
and the surface of the solid phase having no antigen adsorbed
thereto is covered with a protein unrelated to the antigen such as
bovine serum albumin (hereinafter referred to as "BSA"). After
washing the surface, the surface is brought into contact with a
serially-diluted sample (for example, mouse serum) as a primary
antibody to allow the antibody in the sample to bind to the
antigen.
[0231] Further, as a secondary antibody, an antibody labeled with
an enzyme against a mouse antibody is added and is allowed to bind
to the mouse antibody. After washing, a substrate for the enzyme is
added and a change in absorbance which occurs due to color
development induced by degradation of the substrate or the like is
measured and the antibody titer is calculated based on the
measurement.
[0232] The separation of the antibody-producing cells from the
spleen cells or lymphocytes of the immunized animal can be carried
out according to a known method (for example, Kohler et al., Nature
(1975), 256, p. 495; Kohler et al., Eur. J. Immunol. (1977), 6, p.
511; Milstein et al., Nature (1977), 266, p. 550; Walsh, Nature
(1977), 266, p. 495). For example, in the case of spleen cells, a
general method in which the antibody-producing cells are separated
by homogenizing the spleen to obtain the cells through filtration
with a stainless steel mesh and suspending the cells in Eagle's
Minimum Essential Medium (MEM) can be employed.
[0233] (c) Preparation of Myeloma Cells (Hereinafter Referred to as
"Myeloma")
[0234] The myeloma cells to be used for cell fusion are not
particularly limited and suitable cells can be selected from known
cell lines. However, in consideration of convenience when a
hybridoma is selected from fused cells, it is preferred to use an
HGPRT (hypoxanthine-guanine phosphoribosyl transferase) deficient
strain whose selection procedure has been established.
[0235] More specifically, examples of the HGPRT-deficient strain
include X63-Ag8(X63), NS1-ANS/1(NS1), P3X63-Ag8.U1(P3U1),
X63-Ag8.653(X63.653), SP2/0-Ag14(SP2/0), MPC11-45.6TG1.7(45.6TG),
FO, S149/5XXO, and BU.1 derived from mice; 210.RSY3.Ag.1.2.3(Y3)
derived from rats; and U266AR(SKO-007),
GM1500.cndot.GTG-A12(GM1500), UC729-6, LICR-LOW-HMy2(HMy2) and
8226AR/NIP4-1(NP41) derived from humans. These HGPRT-deficient
strains are available from, for example, the American Type Culture
Collection (ATCC) or the like.
[0236] These cell strains are subcultured in an appropriate medium
such as an 8-azaguanine medium (a medium obtained by adding
8-azaguanine to an RPMI 1640 medium supplemented with glutamine,
2-mercaptoethanol, gentamicin, and fetal bovine serum (hereinafter
referred to as "FBS")), Iscove's Modified Dulbecco's Medium
(hereinafter referred to as "IMDM"), or Dulbecco's Modified Eagle
Medium (hereinafter referred to as "DMEM"). In this case, 3 to 4
days before performing cell fusion, the cells are subcultured in a
normal medium (for example, an ASF 104 medium (manufactured by
Ajinomoto Co., Ltd.) containing 10% FBS) to ensure not less than
2.times.10.sup.7 cells on the day of cell fusion.
[0237] (d) Cell Fusion
[0238] Fusion between the antibody-producing cells and the myeloma
cells can be appropriately performed according to a known method
(Weir, D. M. Handbook of Experimental Immunology Vol. I. II. III.,
Blackwell Scientific Publications, Oxford (1987), Kabat, E. A. and
Mayer, M. M., Experimental Immunochemistry, Charles C Thomas
Publisher, Springfield, Ill. (1964), etc.), under conditions such
that the survival rate of cells is not excessively reduced.
[0239] As such a method, for example, a chemical method in which
the antibody-producing cells and the myeloma cells are mixed in a
solution containing a polymer such as polyethylene glycol at a high
concentration, a physical method using electric stimulation, or the
like can be used. Among these methods, a specific example of the
chemical method is as described below.
[0240] That is, in the case where polyethylene glycol is used in
the solution containing a polymer at a high concentration, the
antibody-producing cells and the myeloma cells are mixed in a
solution of polyethylene glycol having a molecular weight of 1500
to 6000, more preferably 2000 to 4000 at a temperature of from 30
to 40.degree. C., preferably from 35 to 38.degree. C. for 1 to 10
minutes, preferably 5 to 8 minutes.
[0241] (e) Selection of a Group of Hybridomas
[0242] The method of selecting hybridomas obtained by the
above-described cell fusion is not particularly limited. Usually,
an HAT (hypoxanthine, aminopterin, thymidine) selection method
(Kohler et al., Nature (1975), 256, p. 495; Milstein et al., Nature
(1977), 266, p. 550) is used.
[0243] This method is effective when hybridomas are obtained using
the myeloma cells of an HGPRT-deficient strain which cannot survive
in the presence of aminopterin.
[0244] That is, by culturing unfused cells and hybridomas in an HAT
medium, only hybridomas resistant to aminopterin are selectively
allowed to survive and proliferate.
[0245] (f) Division into Single Cell Clone (Cloning)
[0246] As a cloning method for hybridomas, a known method such as a
methylcellulose method, a soft agarose method, or a limiting
dilution method can be used (see, for example, Barbara, B. M. and
Stanley, M. S.: Selected Methods in Cellular Immunology, W. H.
Freeman and Company, San Francisco (1980)). Among these methods,
particularly, a three-dimensional culture method such as a
methylcellulose method is preferred. For example, the group of
hybridomas produced by cell fusion are suspended in a
methylcellulose medium such as ClonaCell.TM.-HY Selection Medium D
(manufactured by StemCell Technologies, Inc., #03804) and cultured.
Then, the formed hybridoma colonies are collected, whereby
monoclonal hybridomas can be obtained. The collected respective
hybridoma colonies are cultured, and a hybridoma which has been
confirmed to have a stable antibody titer in an obtained hybridoma
culture supernatant is selected as a B7-H3 monoclonal
antibody-producing hybridoma strain.
[0247] Examples of the thus established hybridoma strain include
B7-H3 hybridoma M30. In this specification, an antibody produced by
the B7-H3 hybridoma M30 is referred to as "M30 antibody" or simply
"M30".
[0248] The heavy chain of the M30 antibody has an amino acid
sequence represented by SEQ ID NO:51 in the Sequence Listing.
Further, the light chain of the M30 antibody has an amino acid
sequence represented by SEQ ID NO:53 in the Sequence Listing. In
the heavy chain amino acid sequence represented by SEQ ID NO:51 in
the Sequence Listing, an amino acid sequence consisting of amino
acid residues 1 to 19 is a signal sequence, an amino acid sequence
consisting of amino acid residues 20 to 141 is a variable region,
and an amino acid sequence consisting of amino acid residues 142 to
471 is a constant region. Further, in the light chain amino acid
sequence represented by SEQ ID NO:53 in the Sequence Listing, an
amino acid sequence consisting of amino acid residues 1 to 22 is a
signal sequence, an amino acid sequence consisting of amino acid
residues 23 to 130 is a variable region, and an amino acid sequence
consisting of amino acid residues 131 to 235 is a constant
region.
[0249] The heavy chain amino acid sequence represented by SEQ ID
NO:51 in the Sequence Listing is encoded by a nucleotide sequence
represented by SEQ ID NO:50 in the Sequence Listing. In the
nucleotide sequence represented by SEQ ID NO:50 in the Sequence
Listing, a nucleotide sequence consisting of nucleotides 1 to 57
encodes the heavy chain signal sequence of the antibody, a
nucleotide sequence consisting of nucleotides 58 to 423 encodes the
heavy chain variable region of the antibody, and a nucleotide
sequence consisting of nucleotides 424 to 1413 encodes the heavy
chain constant region of the antibody.
[0250] The light chain amino acid sequence represented by SEQ ID
NO:53 in the Sequence Listing is encoded by a nucleotide sequence
represented by SEQ ID NO:52 in the Sequence Listing. In the
nucleotide sequence represented by SEQ ID NO:52 in the Sequence
Listing, a nucleotide sequence consisting of nucleotides 1 to 66
encodes the light chain signal sequence of the antibody, a
nucleotide sequence consisting of nucleotides 67 to 390 encodes the
light chain variable region of the antibody, and a nucleotide
sequence consisting of nucleotides 391 to 705 encodes the light
chain constant region of the antibody.
[0251] (g) Preparation of Monoclonal Antibody by Culturing
Hybridoma
[0252] By culturing the thus selected hybridoma, a monoclonal
antibody can be efficiently obtained. However, prior to culturing,
it is preferred to perform screening of a hybridoma which produces
a target monoclonal antibody.
[0253] In such screening, a known method can be employed.
[0254] The measurement of the antibody titer in the invention can
be carried out by, for example, an ELISA method explained in item
(b) described above.
[0255] The hybridoma obtained by the method described above can be
stored in a frozen state in liquid nitrogen or in a freezer at
-80.degree. C. or below.
[0256] After completion of cloning, the medium is changed from an
HT medium to a normal medium, and the hybridoma is cultured.
[0257] Large-scale culture is performed by rotation culture using a
large culture bottle or by spinner culture. From the supernatant
obtained by the large-scale culture, a monoclonal antibody which
specifically binds to the protein of the invention can be obtained
by purification using a method known to those skilled in the art
such as gel filtration.
[0258] Further, the hybridoma is injected into the abdominal cavity
of a mouse of the same strain as the hybridoma (for example, the
above-described BALB/c) or a Nu/Nu mouse to proliferate the
hybridoma, whereby the ascites containing a large amount of the
monoclonal antibody of the invention can be obtained.
[0259] In the case where the hybridoma is administrated in the
abdominal cavity, if a mineral oil such as 2,6,10,14-tetramethyl
pentadecane (pristane) is administrated 3 to 7 days prior thereto,
a larger amount of the ascites can be obtained.
[0260] For example, an immunosuppressant is previously injected
into the abdominal cavity of a mouse of the same strain as the
hybridoma to inactivate T cells. 20 days thereafter, 10.sup.6 to
10.sup.7 hybridoma clone cells are suspended in a serum-free medium
(0.5 ml), and the suspension is administrated in the abdominal
cavity of the mouse. In general, when the abdomen is expanded and
filled with the ascites, the ascites is collected from the mouse.
By this method, the monoclonal antibody can be obtained at a
concentration which is about 100 times or much higher than that in
the culture solution.
[0261] The monoclonal antibody obtained by the above-described
method can be purified by a method described in, for example, Weir,
D. M.: Handbook of Experimental Immunology Vol. I, II, III,
Blackwell Scientific Publications, Oxford (1978).
[0262] The thus obtained monoclonal antibody has high antigen
specificity for B7-H3.
[0263] (h) Assay of Monoclonal Antibody
[0264] The isotype and subclass of the thus obtained monoclonal
antibody can be determined as follows.
[0265] First, examples of the identification method include an
Ouchterlony method, an ELISA method, and an RIA method.
[0266] An Ouchterlony method is simple, but when the concentration
of the monoclonal antibody is low, a condensation operation is
required.
[0267] On the other hand, when an ELISA method or an RIA method is
used, by directly reacting the culture supernatant with an
antigen-adsorbed solid phase and using antibodies corresponding to
various types of immunoglobulin isotypes and subclasses as
secondary antibodies, the isotype and subclass of the monoclonal
antibody can be identified.
[0268] In addition, as a simpler method, a commercially available
identification kit (for example, Mouse Typer.RTM. Kit manufactured
by Bio-Rad Laboratories, Inc.) or the like can also be used.
[0269] Further, the quantitative determination of a protein can be
performed by the Folin Lowry method and a method of calculation
based on the absorbance at 280 nm (1.4 (OD 280)=Immunoglobulin 1
mg/ml).
[0270] Further, even when the monoclonal antibody is separately and
independently obtained by performing again the steps of (a) to (h)
in (2), it is possible to obtain an antibody having a cytotoxic
activity equivalent to that of the M30 antibody. As one example of
such an antibody, an antibody which binds to the same epitope as
the M30 antibody can be exemplified. The M30 recognizes an epitope
in the IgC1 or IgC2 domain, which is a domain in the B7-H3
extracellular domain, and binds to the IgC1 domain or the IgC2
domain or both. Therefore, as the epitope for the M30 antibody,
particularly, an epitope present in the IgC1 or IgC2 domain of
B7-H3 can be exemplified. If a newly produced monoclonal antibody
binds to a partial peptide or a partial tertiary structure to which
the M30 antibody binds, it can be determined that the monoclonal
antibody binds to the same epitope as the M30 antibody. Further, by
confirming that the monoclonal antibody competes with the M30
antibody for the binding to B7-H3 (that is, the monoclonal antibody
inhibits the binding between the M30 antibody and B7-H3), it can be
determined that the monoclonal antibody binds to the same epitope
as the M30 antibody even if the specific epitope sequence or
structure has not been determined. When it is confirmed that the
monoclonal antibody binds to the same epitope as the M30 antibody,
the monoclonal antibody is strongly expected to have a cytotoxic
activity equivalent to that of the M30 antibody.
[0271] (3) Other Antibodies
[0272] The antibody of the invention includes not only the
above-described monoclonal antibody against B7-H3 but also a
recombinant antibody obtained by artificial modification for the
purpose of decreasing heterologous antigenicity to humans such as a
chimeric antibody, a humanized antibody and a human antibody. These
antibodies can be produced using a known method.
[0273] As the chimeric antibody, an antibody in which antibody
variable and constant regions are derived from different species,
for example, a chimeric antibody in which a mouse- or rat-derived
antibody variable region is connected to a human-derived constant
region can be exemplified (see Proc. Natl. Acad. Sci. USA, (1984)
81, pp. 6851-6855). A chimeric antibody derived from a mouse
anti-human B7-H3 antibody M30 is an antibody consisting of a heavy
chain comprising a heavy chain variable region of which an amino
acid sequence consists of amino acid residues 20 to 141 of SEQ ID
NO:51 and a light chain comprising a light chain variable region of
which an amino acid sequence consists of amino acid residues 23 to
130 of SEQ ID NO:53, and may have an arbitrary human-derived
constant region. As one example of such a chimeric antibody, an
antibody consisting of a heavy chain of which an amino acid
sequence consists of amino acid residues 1 to 471 of SEQ ID NO:63
in the Sequence Listing and a light chain of which an amino acid
sequence consists of amino acid residues 1 to 233 of SEQ ID NO:59
in the Sequence Listing can be exemplified. In the heavy chain
sequence represented by SEQ ID NO:63 in the Sequence Listing, an
amino acid sequence consisting of amino acid residues 1 to 19 is a
signal sequence, an amino acid sequence consisting of amino acid
residues 20 to 141 is a variable region, and an amino acid sequence
consisting of amino acid residues 142 to 471 is a constant region.
Further, in the light chain sequence represented by SEQ ID NO:59 in
the Sequence Listing, an amino acid sequence consisting of amino
acid residues 1 to 20 is a signal sequence, an amino acid sequence
consisting of amino acid residues 21 to 128 is a variable region,
and an amino acid sequence consisting of amino acid residues 129 to
233 is a constant region.
[0274] The heavy chain amino acid sequence represented by SEQ ID
NO:63 in the Sequence Listing is encoded by a nucleotide sequence
represented by SEQ ID NO:62 in the Sequence Listing. In the
nucleotide sequence represented by SEQ ID NO:62 in the Sequence
Listing, a nucleotide sequence consisting of nucleotides 1 to 57
encodes the heavy chain signal sequence of the antibody, a
nucleotide sequence consisting of nucleotides 58 to 423 encodes the
heavy chain variable region of the antibody, and a nucleotide
sequence consisting of nucleotides 424 to 1413 encodes the heavy
chain constant region of the antibody.
[0275] The light chain amino acid sequence represented by SEQ ID
NO:59 in the Sequence Listing is encoded by a nucleotide sequence
represented by SEQ ID NO:58 in the Sequence Listing. In the
nucleotide sequence represented by SEQ ID NO:58 in the Sequence
Listing, a nucleotide sequence consisting of nucleotides 1 to 60
encodes the light chain signal sequence of the antibody, a
nucleotide sequence consisting of nucleotides 61 to 384 encodes the
light chain variable region of the antibody, and a nucleotide
sequence consisting of nucleotides 385 to 699 encodes the light
chain constant region of the antibody.
[0276] As the humanized antibody, an antibody obtained by
integrating only a complementarity determining region (CDR) into a
human-derived antibody (see Nature (1986) 321, pp. 522-525), and an
antibody obtained by grafting a part of the amino acid residues of
the framework as well as the CDR sequence to a human antibody by a
CDR-grafting method (WO 90/07861) can be exemplified.
[0277] However, the humanized antibody derived from the M30
antibody is not limited to a specific humanized antibody as long as
the humanized antibody has all 6 types of CDR sequences of the M30
antibody and has an antitumor activity. The heavy chain variable
region of the M30 antibody has CDRH1 (NYVMH) consisting of an amino
acid sequence represented by SEQ ID NO:92 in the Sequence Listing,
CDRH2 (YINPYNDDVKYNEKFKG) consisting of an amino acid sequence
represented by SEQ ID NO:93 in the Sequence Listing, and CDRH3
(WGYYGSPLYYFDY) consisting of an amino acid sequence represented by
SEQ ID NO:94 in the Sequence Listing. Further, the light chain
variable region of the M30 antibody has CDRL1 (RASSRLIYMH)
consisting of an amino acid sequence represented by SEQ ID NO:95 in
the Sequence Listing, CDRL2 (ATSNLAS) consisting of an amino acid
sequence represented by SEQ ID NO:96 in the Sequence Listing, and
CDRL3 (QQWNSNPPT) consisting of an amino acid sequence represented
by SEQ ID NO:97 in the Sequence Listing.
[0278] As an example of the humanized antibody of a mouse antibody
M30, an arbitrary combination of a heavy chain comprising a heavy
chain variable region consisting of any one of (1) an amino acid
sequence consisting of amino acid residues 20 to 141 of SEQ ID
NOS:85, 87, 89, or 91 in the Sequence Listing, (2) an amino acid
sequence having a homology of at least 95% or more with the amino
acid sequence (1) described above, and (3) an amino acid sequence
wherein one or several amino acids in the amino acid sequence (1)
described above are deleted, substituted or added and a light chain
comprising a light chain variable region consisting of any one of
(4) an amino acid sequence consisting of amino acid residues 21 to
128 of SEQ ID NOS:71, 73, 75, 77, 79, 81, or 83 in the Sequence
Listing, (5) an amino acid sequence having a homology of at least
95% or more with the amino acid sequence (4) described above, and
(6) an amino acid sequence wherein one or several amino acids in
the amino acid sequence (4) described above are deleted,
substituted or added can be exemplified.
[0279] The term "several" as used herein refers to 1 to 10, 1 to 9,
1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2.
[0280] As the amino acid substitution in this specification, a
conservative amino acid substitution is preferred. The conservative
amino acid substitution refers to a substitution occurring within a
group of amino acids related to amino acid side chains. Preferred
amino acid groups are as follows: an acidic group (aspartic acid
and glutamic acid); a basic group (lysine, arginine, and
histidine); a non-polar group (alanine, valine, leucine,
isoleucine, proline, phenylalanine, methionine, and tryptophan);
and an uncharged polar family (glycine, asparagine, glutamine,
cysteine, serine, threonine, and tyrosine). More preferred amino
acid groups are as follows: an aliphatic hydroxy group (serine and
threonine); an amide-containing group (asparagine and glutamine);
an aliphatic group (alanine, valine, leucine, and isoleucine); and
an aromatic group (phenylalanine, tryptophan, and tyrosine). Such
an amino acid substitution is preferably performed within a range
which does not impair the properties of a substance having the
original amino acid sequence.
[0281] As an antibody which has a preferred combination of a heavy
chain and a light chain described above, an antibody consisting of
a heavy chain comprising a heavy chain variable region consisting
of an amino acid sequence consisting of amino acid residues 20 to
141 of SEQ ID NO:85 and a light chain comprising a light chain
variable region consisting of an amino acid sequence consisting of
amino acid residues 21 to 128 of SEQ ID NO:71; an antibody
consisting of a heavy chain comprising a heavy chain variable
region consisting of an amino acid sequence consisting of amino
acid residues 20 to 141 of SEQ ID NO:85 and a light chain
comprising a light chain variable region consisting of an amino
acid sequence consisting of amino acid residues 21 to 128 of SEQ ID
NO:73; an antibody consisting of a heavy chain comprising a heavy
chain variable region consisting of an amino acid sequence
consisting of amino acid residues 20 to 141 of SEQ ID NO:85 and a
light chain comprising a light chain variable region consisting of
an amino acid sequence consisting of amino acid residues 21 to 128
of SEQ ID NO:75; an antibody consisting of a heavy chain comprising
a heavy chain variable region consisting of an amino acid sequence
consisting of amino acid residues 20 to 141 of SEQ ID NO:85 and a
light chain comprising a light chain variable region consisting of
an amino acid sequence consisting of amino acid residues 21 to 128
of SEQ ID NO:77; an antibody consisting of a heavy chain comprising
a heavy chain variable region consisting of an amino acid sequence
consisting of amino acid residues 20 to 141 of SEQ ID NO:85 and a
light chain comprising a light chain variable region consisting of
an amino acid sequence consisting of amino acid residues 21 to 128
of SEQ ID NO:79; an antibody consisting of a heavy chain comprising
a heavy chain variable region consisting of an amino acid sequence
consisting of amino acid residues 20 to 141 of SEQ ID NO:85 and a
light chain comprising a light chain variable region consisting of
an amino acid sequence consisting of amino acid residues 21 to 128
of SEQ ID NO:81; an antibody consisting of a heavy chain comprising
a heavy chain variable region consisting of an amino acid sequence
including amino acid residues 20 to 141 of SEQ ID NO:85 and a light
chain comprising a light chain variable region consisting of an
amino acid sequence consisting of amino acid residues 21 to 128 of
SEQ ID NO:83; an antibody consisting of a heavy chain comprising a
heavy chain variable region consisting of an amino acid sequence
consisting of amino acid residues 20 to 141 of SEQ ID NO:91 and a
light chain comprising a light chain variable region consisting of
an amino acid sequence consisting of amino acid residues 21 to 128
of SEQ ID NO: 71; an antibody consisting of a heavy chain
comprising a heavy chain variable region consisting of an amino
acid sequence consisting of amino acid residues 20 to 141 of SEQ ID
NO:91 and a light chain comprising a light chain variable region
consisting of an amino acid sequence consisting of amino acid
residues 21 to 128 of SEQ ID NO:73; an antibody consisting of a
heavy chain comprising a heavy chain variable region consisting of
an amino acid sequence consisting of amino acid residues 20 to 141
of SEQ ID NO:91 and a light chain comprising a light chain variable
region consisting of an amino acid sequence consisting of amino
acid residues 21 to 128 of SEQ ID NO:75; and an antibody consisting
of a heavy chain comprising a heavy chain variable region
consisting of an amino acid sequence consisting of amino acid
residues 20 to 141 of SEQ ID NO:91 and a light chain comprising a
light chain variable region consisting of an amino acid sequence
consisting of amino acid residues 21 to 128 of SEQ ID NO:77 can be
exemplified.
[0282] As an antibody which has a more preferred combination of a
heavy chain and a light chain described above, an antibody
consisting of a heavy chain comprising an amino acid sequence of
SEQ ID NO:85 and a light chain comprising an amino acid sequence of
SEQ ID NO:71; an antibody consisting of a heavy chain comprising an
amino acid sequence of SEQ ID NO:85 and a light chain comprising an
amino acid sequence of SEQ ID NO:73; an antibody consisting of a
heavy chain comprising an amino acid sequence of SEQ ID NO:85 and a
light chain comprising an amino acid sequence of SEQ ID NO:75; an
antibody consisting of a heavy chain comprising an amino acid
sequence of SEQ ID NO:85 and a light chain comprising an amino acid
sequence of SEQ ID NO:77; an antibody consisting of a heavy chain
comprising an amino acid sequence of SEQ ID NO:85 and a light chain
comprising an amino acid sequence of SEQ ID NO:79; an antibody
consisting of a heavy chain comprising an amino acid sequence of
SEQ ID NO:85 and a light chain comprising an amino acid sequence of
SEQ ID NO:81; an antibody consisting of a heavy chain comprising an
amino acid sequence of SEQ ID NO:85 and a light chain comprising an
amino acid sequence of SEQ ID NO:83; an antibody consisting of a
heavy chain comprising an amino acid sequence of SEQ ID NO:91 and a
light chain comprising an amino acid sequence of SEQ ID NO:71; an
antibody consisting of a heavy chain comprising an amino acid
sequence of SEQ ID NO:91 and a light chain comprising an amino acid
sequence of SEQ ID NO:73; an antibody consisting of a heavy chain
comprising an amino acid sequence of SEQ ID NO:91 and a light chain
comprising an amino acid sequence of SEQ ID NO:75; and an antibody
consisting of a heavy chain comprising an amino acid sequence of
SEQ ID NO:91 and a light chain comprising an amino acid sequence of
SEQ ID NO:77 can be exemplified.
[0283] By combining a sequence having a high homology with the
above-described heavy chain amino acid sequence with a sequence
having a high homology with the above-described light chain amino
acid sequence, it is possible to select an antibody having a
cytotoxic activity equivalent to that of each of the
above-described antibodies. Such a homology is generally a homology
of 80% or more, preferably a homology of 90% or more, more
preferably a homology of 95% or more, most preferably a homology of
99% or more. Further, by combining an amino acid sequence wherein
one to several amino acid residues are substituted, deleted or
added in the heavy chain or light chain amino acid sequence, it is
also possible to select an antibody having a cytotoxic activity
equivalent to that of each of the above-described antibodies.
[0284] The homology between two amino acid sequences can be
determined using default parameters of Blast algorithm version
2.2.2 (Altschul, Stephen F., Thomas L. Madden, Alejandro A.
Schiffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J.
Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of
protein database search programs", Nucleic Acids Res. 25, pp.
3389-3402). The Blast algorithm can be used also through the
Internet by accessing the site 1334907992153_0.
[0285] In the heavy chain amino acid sequence represented by SEQ ID
NOS:85, 87, 89 or 91 in the Sequence Listing, an amino acid
sequence consisting of amino acid residues 1 to 19 is a signal
sequence, an amino acid sequence consisting of amino acid residues
20 to 141 is a variable region, and an amino acid sequence
consisting of amino acid residues 142 to 471 is a constant
region.
[0286] Further, in the light chain amino acid sequence represented
by SEQ ID NOS:71, 73, 75, 77, 79, 81 or 83 in the Sequence Listing,
an amino acid sequence consisting of amino acid residues 1 to 20 is
a signal sequence, an amino acid sequence consisting of amino acid
residues 21 to 128 is a variable region, and an amino acid sequence
consisting of amino acid residues 129 to 233 is a constant
region.
[0287] The heavy chain amino acid sequences represented by SEQ ID
NOS:85, 87, 89 or 91 in the Sequence Listing are encoded by
nucleotide sequences represented by SEQ ID NOS:84, 86, 88 or 90,
respectively, in the Sequence Listing. Further, the sequences
represented by SEQ ID NOS:84 and 85 are shown in FIG. 34, the
sequences represented by SEQ ID NOS:86 and 87 are shown in FIG. 35,
the sequences represented by SEQ ID NOS:88 and 89 are shown in FIG.
36, and the sequences represented by SEQ ID NOS:90 and 91 are shown
in FIG. 37. In each of the above nucleotide sequences, a nucleotide
sequence consisting of nucleotides 1 to 57 encodes the heavy chain
signal sequence of the antibody, a nucleotide sequence consisting
of nucleotides 58 to 423 encodes the heavy chain variable region of
the antibody, and a nucleotide sequence consisting of nucleotides
424 to 1413 encodes the heavy chain constant region of the
antibody.
[0288] The light chain amino acid sequences represented by SEQ ID
NOS:71, 73, 75, 77, 79, 81 or 83 in the Sequence Listing are
encoded by nucleotide sequences represented by SEQ ID NOS:70, 72,
74, 76, 78, 80 or 82, respectively, in the Sequence Listing.
Further, the sequences represented by SEQ ID NOS:70 and 71 are
shown in FIG. 27, the sequences represented by SEQ ID NOS:72 and 73
are shown in FIG. 28, the sequences represented by SEQ ID NOS:74
and 75 are shown in FIG. 29, the sequences represented by SEQ ID
NOS:76 and 77 are shown in FIG. 30, the sequences represented by
SEQ ID NOS:78 and 79 are shown in FIG. 31, the sequences
represented by SEQ ID NOS:80 and 81 are shown in FIG. 32, and the
sequences represented by SEQ ID NOS:82 and 83 are shown in FIG. 33.
In each of the above nucleotide sequences, a nucleotide sequence
consisting of nucleotides 1 to 60 encodes the light chain signal
sequence of the antibody, a nucleotide sequence consisting of
nucleotides 61 to 384 encodes the light chain variable region of
the antibody, and a nucleotide sequence consisting of nucleotides
385 to 699 encodes the light chain constant region of the
antibody.
[0289] The homology between any of these nucleotide sequences and a
nucleotide sequence of another antibody can be also determined
using Blast algorithm.
[0290] Further, the antibody of the invention includes a human
antibody which binds to the same epitope as the M30 antibody. An
anti-B7-H3 human antibody refers to a human antibody having only a
gene sequence of an antibody derived from a human chromosome. The
anti-B7-H3 human antibody can be obtained by a method using a human
antibody-producing mouse having a human chromosome fragment
comprising heavy and light chain genes of a human antibody (see
Tomizuka, K. et al., Nature Genetics (1997) 16, pp. 133-143;
Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, pp. 3447-3448;
Yoshida, H. et al., Animal Cell Technology: Basic and Applied
Aspects vol. 10, pp. 69-73 (Kitagawa, Y., Matuda, T. and Iijima, S.
eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et al., Proc.
Natl. Acad. Sci. USA (2000) 97, pp. 722-727, etc.).
[0291] Such a human antibody-producing mouse can be created
specifically as follows. A genetically modified animal in which
endogenous immunoglobulin heavy and light chain gene loci have been
disrupted, and instead, human immunoglobulin heavy and light chain
gene loci have been introduced via a yeast artificial chromosome
(YAC) vector or the like is created by producing a knockout animal
and a transgenic animal and mating these animals.
[0292] Further, according to a recombinant DNA technique, by using
cDNAs encoding each of such a heavy chain and a light chain of a
human antibody, and preferably a vector comprising such cDNAs,
eukaryotic cells are transformed, and a transformant cell which
produces a recombinant human monoclonal antibody is cultured,
whereby the antibody can also be obtained from the culture
supernatant.
[0293] Here, as the host, for example, eukaryotic cells, preferably
mammalian cells such as CHO cells, lymphocytes, or myeloma cells
can be used.
[0294] Further, a method of obtaining a phage display-derived human
antibody selected from a human antibody library (see Wormstone, I.
M. et al., Investigative Ophthalmology & Visual Science. (2002)
43(7), pp. 2301-2308; Carmen, S. et al., Briefings in Functional
Genomics and Proteomics (2002) 1(2), pp. 189-203; Siriwardena, D.
et al., Ophthalmology (2002) 109(3), pp. 427-431, etc.) is also
known.
[0295] For example, a phage display method in which a variable
region of a human antibody is expressed on the surface of a phage
as a single-chain antibody (scFv), and a phage which binds to an
antigen is selected (Nature Biotechnology (2005), 23(9), pp.
1105-1116) can be used.
[0296] By analyzing the gene of the phage selected based on the
binding to an antigen, a DNA sequence encoding the variable region
of a human antibody which binds to an antigen can be
determined.
[0297] If the DNA sequence of scFv which binds to an antigen is
determined, a human antibody can be obtained by preparing an
expression vector comprising the sequence and introducing the
vector into an appropriate host to express it (WO 92/01047, WO
92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO
95/15388, Annu. Rev. Immunol. (1994) 12, pp. 433-455, Nature
Biotechnology (2005) 23(9), pp. 1105-1116).
[0298] If a newly produced human antibody binds to a partial
peptide or a partial tertiary structure to which the M30 antibody
binds, it can be determined that the human antibody binds to the
same epitope as the M30 antibody. Further, by confirming that the
human antibody competes with the M30 antibody for the binding to
B7-H3 (that is, the human antibody inhibits the binding between the
M30 antibody and B7-H3), it can be determined that the human
antibody binds to the same epitope as the M30 antibody even if the
specific epitope sequence or structure has not been determined.
When it is confirmed that the human antibody binds to the same
epitope as the M30 antibody, the human antibody is strongly
expected to have a cytotoxic activity equivalent to that of the M30
antibody.
[0299] The chimeric antibodies, humanized antibodies, or human
antibodies obtained by the above-described method are evaluated for
the binding property to an antigen by a method shown in Example 3
or the like, and a preferred antibody can be selected.
[0300] As one example of another index for use in the comparison of
the properties of antibodies, the stability of antibodies can be
exemplified. The differential scanning calorimetry (DSC) is a
device capable of quickly and accurately measuring a thermal
denaturation midpoint temperature (Tm) to be used as a favorable
index of the relative conformational stability of proteins. By
measuring the Tm values using DSC and comparing the values, a
difference in thermal stability can be compared. It is known that
the storage stability of antibodies shows some correlation with the
thermal stability of antibodies (Lori Burton, et. al.,
Pharmaceutical Development and Technology (2007) 12, pp. 265-273),
and a preferred antibody can be selected by using thermal stability
as an index. Examples of other indices for selecting antibodies
include the following features: the yield in an appropriate host
cell is high; and the aggregability in an aqueous solution is low.
For example, an antibody which shows the highest yield does not
always show the highest thermal stability, and therefore, it is
necessary to select an antibody most suitable for the
administration to humans by making comprehensive evaluation based
on the above-described indices.
[0301] Further, a method in which the full-length heavy and light
chain sequences of an antibody are connected using an appropriate
linker, whereby a single-chain immunoglobulin is obtained is also
known (Lee, H-S, et. al., Molecular Immunology (1999) 36, pp.
61-71; Shirrmann, T. et. al., mAbs (2010), 2(1) pp. 1-4). By
dimerizing such a single-chain immunoglobulin, the resulting dimer
can have a structure and an activity similar to those of an
antibody which is a tetramer itself. Further, the antibody of the
invention may be an antibody which has a single heavy chain
variable region and does not have a light chain sequence. Such an
antibody is called a single domain antibody (sdAb) or a nanobody,
and in fact, such an antibody is observed in a camel or a llama and
has been reported to have an antigen-binding affinity (Muyldemans
S. et. al., Protein Eng. (1994) 7(9), pp. 1129-1135,
Hamers-Casterman C. et al., Nature (1993) 363(6428), pp. 446-448).
The above-described antibodies can also be construed as a type of
functional fragment of the antibody according to the invention.
[0302] In the invention, a modified variant of the antibody or a
functional fragment of the antibody is also included. The modified
variant refers to a variant obtained by subjecting the antibody or
a functional fragment of the antibody of the invention to chemical
or biological modification. Examples of the chemically modified
variant include variants chemically modified by linking a chemical
moiety to an amino acid skeleton, variants chemically modified with
an N-linked or O-linked carbohydrate chain, etc. Examples of the
biologically modified variant include variants obtained by
modification after translation (such as N-linked or O-linked
glycosylation, N- or C-terminal processing, deamidation,
isomerization of aspartic acid, or oxidation of methionine), and
variants in which a methionine residue has been added to the N
terminus by being expressed in a prokaryotic host cell.
[0303] Further, an antibody labeled so as to enable the detection
or isolation of the antibody or an antigen of the invention, for
example, an enzyme-labeled antibody, a fluorescence-labeled
antibody, and an affinity-labeled antibody are also included in the
meaning of the modified variant. Such a modified variant of the
antibody or a functional fragment of the antibody of the invention
is useful for improving the stability and blood retention of the
original antibody or a functional fragment of the antibody of the
invention, reducing the antigenicity thereof, detecting or
isolating such an antibody or an antigen, and so on.
[0304] Further, by regulating the modification of a glycan which is
linked to the antibody of the invention (glycosylation,
defucosylation, etc.), it is possible to enhance an
antibody-dependent cellular cytotoxic activity. As the technique
for regulating the modification of a glycan of antibodies, WO
99/54342, WO 00/61739, WO 02/31140, etc. are known. However, the
technique is not limited thereto. In the antibody and a functional
fragment of the antibody of the invention, an antibody or a
functional fragment of the antibody in which the modification of a
glycan is regulated is also included.
[0305] In the case where an antibody is produced by first isolating
an antibody gene and then introducing the gene into an appropriate
host, a combination of an appropriate host and an appropriate
expression vector can be used. Specific examples of the antibody
gene include a combination of a gene encoding a heavy chain
sequence of an antibody and a gene encoding a light chain sequence
thereof described in this specification. When a host cell is
transformed, it is possible to insert the heavy chain sequence gene
and the light chain sequence gene into the same expression vector,
and also into different expression vectors separately.
[0306] In the case where eukaryotic cells are used as the host,
animal cells, plant cells, and eukaryotic microorganisms can be
used. As the animal cells, mammalian cells, for example, simian COS
cells (Gluzman, Y., Cell, (1981) 23, pp. 175-182, ATCC CRL-1650),
murine fibroblasts NIH3T3 (ATCC No. CRL-1658), and dihydrofolate
reductase-deficient strains (Urlaub, G. and Chasin, L. A., Proc.
Natl. Acad. Sci. USA (1980) 77, pp. 4126-4220) of Chinese hamster
ovarian cells (CHO cells; ATCC: CCL-61) can be exemplified.
[0307] In the case where prokaryotic cells are used, for example,
Escherichia coli and Bacillus subtilis can be exemplified.
[0308] By introducing a gene of a desired antibody or a functional
fragment of the antibody into these cells through transformation,
and culturing the thus transformed cells in vitro, the antibody can
be obtained. In the above-described culture method, the yield may
sometimes vary depending on the sequence of the antibody, and
therefore, it is possible to select an antibody which is easily
produced as a pharmaceutical by using the yield as an index among
the antibodies having an equivalent binding activity. Therefore, in
the antibody and a functional fragment of the antibody of the
invention, an antibody or a functional fragment of the antibody
obtained by a method of producing an antibody or a functional
fragment of the antibody, characterized by including a step of
culturing the transformed host cell and a step of collecting a
desired antibody or a functional fragment of the antibody from a
cultured product obtained in the culturing step is also
included.
[0309] It is known that a lysine residue at the carboxyl terminus
of the heavy chain of an antibody produced in a cultured mammalian
cell is deleted (Journal of Chromatography A, (1995) 705, pp.
129-134), and it is also known that two amino acid residues
(glycine and lysine) at the carboxyl terminus of the heavy chain of
an antibody produced in a cultured mammalian cell are deleted and a
proline residue newly located at the carboxyl terminus is amidated
(Analytical Biochemistry, (2007) 360, pp. 75-83). However, such
deletion and modification of the heavy chain sequence do not affect
the antigen-binding affinity and the effector function (the
activation of a complement, the antibody-dependent cellular
cytotoxicity, etc.) of the antibody. Therefore, in the invention,
an antibody and a functional fragment of the antibody subjected to
such modification are also included, and a deletion variant in
which one or two amino acids have been deleted at the carboxyl
terminus of the heavy chain, a variant obtained by amidation of the
deletion variant (for example, a heavy chain in which the carboxyl
terminal proline residue has been amidated), and the like can be
exemplified. The type of deletion variant having a deletion at the
carboxyl terminus of the heavy chain of the antibody according to
the invention is not limited to the above variants as long as the
antigen-binding affinity and the effector function are conserved.
The two heavy chains constituting the antibody according to the
invention may be of one type selected from the group consisting of
a full-length heavy chain and the above-described deletion variant,
or may be of two types in combination selected therefrom. The ratio
of the amount of each deletion variant can be affected by the type
of cultured mammalian cells which produce the antibody according to
the invention and the culture conditions, however, a case where one
amino acid residue at the carboxyl terminus has been deleted in
both of the two heavy chains contained as main components in the
antibody according to the invention can be exemplified. There is no
limitation on isotype of the antibody of the invention, and
examples thereof include IgG (IgG1, IgG2, IgG3, IgG4), IgM, IgA
(IgA1, IgA2), IgD, and IgE, and preferred examples thereof include
IgG and IgM, and further more preferred examples thereof include
IgG1 and IgG2.
[0310] Further, the antibody of the invention may be a functional
fragment of the antibody having an antigen-binding site of the
antibody or a modified fragment thereof. The fragment of the
antibody can be obtained by treating the antibody with a protease
such as papain or pepsin, or modifying the antibody gene according
to a genetic engineering technique and expressing the modified gene
in suitable cultured cells. Among these antibody fragments, a
fragment having all or part of the functions of the antibody can be
called a functional fragment of the antibody.
[0311] As the functions of the antibody, generally an
antigen-binding activity, an activity of neutralizing the activity
of an antigen, an activity of enhancing the activity of an antigen,
an antibody-dependent cellular cytotoxicity (ADCC) activity and a
complement-dependent cytotoxicity (CDC) activity can be
exemplified. The function of the antibody and a functional fragment
of the antibody according to the invention is a binding activity to
B7-H3, preferably an antibody-dependent cell-mediated phagocytosis
(ADCP) activity, more preferably a cytotoxic activity (antitumor
activity) mediated by an ADCP activity against tumor cells.
Further, the antibody of the invention may have an ADCC activity
and/or a CDC activity in addition to the ADCP activity. In
particular, it has been reported that a pharmaceutical containing a
currently available antitumor antibody directly acts on tumor cells
to block a proliferative signal, directly acts on tumor cells to
induce a cell death signal, suppresses angiogenesis, induces an
ADCC activity mediated by NK cells, and induces a CDC activity
mediated by a complement, thereby suppressing the growth of tumor
cells (J. Clin. Oncol. (2010) 28, pp. 4390-4399; Clin. Cancer Res.
(2010) 16(1), pp. 11-20), however, at least the present inventors
do not know that the ADCP activity of the anti-B7-H3 antibody
according to the invention of this application has been reported as
the activity of a pharmaceutical containing a currently available
antitumor antibody.
[0312] Examples of the fragment of the antibody include Fab,
F(ab').sub.2, Fv, single-chain Fv (scFv) in which Fv molecules of
the heavy chain and the light chain are connected via an
appropriate linker, a diabody (diabodies), a linear antibody, and a
polyspecific antibody composed of the antibody fragment. Further,
Fab' which is a monovalent fragment in a variable region of an
antibody obtained by treating F(ab').sub.2 under reducing
conditions is also included in the fragment of the antibody.
[0313] Further, the antibody of the invention may be a polyspecific
antibody with specificity for at least two different types of
antigens. In general, such an antibody binds to two types of
antigens (that is, bispecific antibody), however, the "polyspecific
antibody" as used herein includes an antibody having specificity
for two or more (for example, three) types of antigens.
[0314] The polyspecific antibody of the invention may be a
full-length antibody or a fragment of such an antibody (for
example, a F(ab').sub.2 bispecific antibody). The bispecific
antibody can be produced by connecting the heavy and light chains
(HL pairs) of two types of antibodies, or can also be produced by
fusing hybridomas which produce different monoclonal antibodies to
prepare bispecific antibody-producing fused cells (Millstein et
al., Nature (1983) 305, pp. 537-539).
[0315] The antibody of the invention may be a single-chain antibody
(also referred to as scFv). The single-chain antibody can be
obtained by connecting the heavy chain variable region and the
light chain variable region of the antibody via a polypeptide
linker (Pluckthun, The Pharmacology of Monoclonal Antibodies, 113
(edited by Rosenberg and Moore), Springer Verlag, New York, pp.
269-315 (1994), Nature Biotechnology (2005), 23, pp. 1126-1136).
Further, a BiscFv fragment produced by connecting two scFv
molecules via a polypeptide linker can also be used as the
bispecific antibody.
[0316] The method of producing a single-chain antibody is known in
this technical field (see, for example, U.S. Pat. Nos. 4,946,778,
5,260,203, 5,091,513, 5,455,030, etc.). In this scFv, the heavy
chain variable region and the light chain variable region are
connected via a linker which does not form a conjugate, preferably
via a polypeptide linker (Huston, J. S. et al., Proc. Natl. Acad.
Sci. USA (1988), 85, pp. 5879-5883). In the scFv, the heavy chain
variable region and the light chain variable region may be derived
from the same antibody or different antibodies.
[0317] As the polypeptide linker to be used for connecting the
variable regions, for example, a given single-chain peptide
consisting of 12 to 19 residues is used.
[0318] A DNA encoding scFv can be obtained by performing
amplification through PCR using a DNA as a template that comprises
all or desired part of a DNA selected from a DNA encoding the heavy
chain or the heavy chain variable region of the above-described
antibody and a DNA encoding the light chain or the light chain
variable region thereof and also using a primer pair that defines
both ends of the template DNA, and further performing amplification
by combining a DNA encoding a polypeptide linker portion and a
primer pair that defines both ends of the polypeptide so as to
connect the both ends thereof to each of the heavy chain and the
light chain.
[0319] Further, once DNA encoding scFv is produced, an expression
vector comprising the same and a host transformed by the expression
vector can be obtained according to a common procedure. Further, by
using the resulting host, scFv can be obtained according to a
common procedure. An antibody fragment thereof can be produced in a
host by obtaining a gene and expressing the gene in the same manner
as described above.
[0320] The antibody of the invention may be multimerized to
increase its affinity for an antigen. The antibody to be
multimerized may be one type of antibody or plural antibodies which
recognize plural epitopes of the same antigen. As a method of
multimerization of the antibody, binding of the IgG CH3 domain to
two scFv molecules, binding to streptavidin, introduction of a
helix-turn-helix motif, and the like can be exemplified.
[0321] The antibody of the invention may be a polyclonal antibody
which is a mixture of plural types of anti-B7-H3 antibodies having
different amino acid sequences. As one example of the polyclonal
antibody, a mixture of plural types of antibodies having different
CDR can be exemplified. As such a polyclonal antibody, antibodies
obtained by culturing a mixture of cells which produce different
antibodies and then purifying the antibodies from the resulting
culture can be used (see WO 2004/061104).
[0322] As a modified antibody, an antibody bound to any of various
types of molecules such as polyethylene glycol (PEG) can also be
used.
[0323] Further, the antibody of the invention may be in the form of
a conjugate formed between any of these antibodies and another
medicinal agent (immunoconjugate). Examples of such an antibody
include a conjugate in which the antibody is conjugated to a
radioactive material or a compound having a pharmacological action
(Nature Biotechnology (2005) 23, pp. 1137-1146). Examples thereof
include indium (.sup.111In)-capromab pendetide, technetium
(.sup.99mTc)-nofetumomab merpentan, indium
(.sup.111In)-ibritumomab, yttrium (.sup.90Y)-ibritumomab, and
iodine (.sup.131I)-tositumomab.
[0324] The obtained antibody can be purified to homogeneity. The
separation and purification of the antibody may be performed
employing a conventional protein separation and purification
method. For example, the antibody can be separated and purified by
appropriately selecting and combining column chromatography, filter
filtration, ultrafiltration, salt precipitation, dialysis,
preparative polyacrylamide gel electrophoresis, isoelectric
focusing electrophoresis, and the like (Strategies for Protein
Purification and Characterization: A Laboratory Course Manual,
Daniel R. Marshak et al. eds., Cold Spring Harbor Laboratory Press
(1996); Antibodies: A Laboratory Manual. Ed Harlow and David Lane,
Cold Spring Harbor Laboratory (1988)), but the method is not
limited thereto.
[0325] Examples of such chromatography include affinity
chromatography, ion exchange chromatography, hydrophobic
chromatography, gel filtration chromatography, reverse phase
chromatography, and adsorption chromatography.
[0326] Such chromatography can be performed employing liquid
chromatography such as HPLC or FPLC.
[0327] As a column to be used in affinity chromatography, a Protein
A column and a Protein G column can be exemplified. For example, as
a column using a Protein A column, HyperD.RTM., POROS.RTM.,
Sepharose FF (Pharmacia) and the like can be exemplified.
[0328] Further, by using a carrier having an antigen immobilized
thereon, the antibody can also be purified utilizing the binding
property of the antibody to the antigen.
[0329] 3. Pharmaceutical Comprising Anti-B7-H3 Antibody
[0330] The antibodies obtained by the method described in the above
item "2. Production of anti-B7-H3 antibody" exhibit a cytotoxic
activity against cancer cells, and therefore can be used as a
pharmaceutical, particularly a therapeutic agent and/or preventive
agent for cancer.
[0331] The cytocidal activity exhibited by an antibody in vitro can
be determined by measuring the inhibitory activity of cell
growth.
[0332] For example, a cancer cell line which overexpresses B7-H3 is
cultured, an antibody is added to the culture system at different
concentrations, and an inhibitory activity against focus formation,
colony formation, and spheroid growth can be measured.
[0333] The in vivo therapeutic effect of an antibody on cancer
using experimental animals can be determined by, for example,
administering the antibody to nude mice implanted with a tumor cell
line which overexpresses B7-H3 and measuring a change of cancer
cells.
[0334] Examples of the type of cancer include lung cancer, kidney
cancer, urothelial carcinoma, colorectal cancer, prostate cancer,
glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast
cancer, a melanoma, liver cancer, bladder cancer, stomach cancer,
and esophageal cancer, however, the type of cancer is not limited
thereto as long as a cancer cell to be treated expresses B7-H3.
[0335] An acceptable substance to be used in a preparation of the
pharmaceutical composition according to the invention is preferably
non-toxic to an individual to whom the pharmaceutical composition
is to be administrated in terms of the dose and concentration.
[0336] The pharmaceutical composition of the invention can comprise
a substance for pharmaceutical use which is capable of changing or
maintaining the pH, osmotic pressure, viscosity, transparency,
color, isotonicity, aseptic condition, stability, solubility,
release rate, absorption rate, and permeability thereof. Examples
of such a substance for pharmaceutical use include, but are not
limited to, amino acids such as glycine, alanine, glutamine,
asparagine, arginine, and lysine; antimicrobial agents;
antioxidants such as ascorbic acid, sodium sulfate, and sodium
hydrogen sulfite; buffers such as phosphate, citrate, borate
buffers, sodium hydrogen carbonate, and Tris-HCl solutions; fillers
such as mannitol and glycine; chelating agents such as
ethylenediamine tetraacetate (EDTA); complexing agents such as
caffeine, polyvinylpyrrolidine, .beta.-cyclodextrin, and
hydroxypropyl-.beta.-cyclodextrin; expanders such as glucose,
mannose, and dextrin; other carbohydrates such as monosaccharides
and disaccharides; coloring agents; flavors; diluents; emulsifying
agents; hydrophilic polymers such as polyvinylpyrrolidine;
preservatives such as low-molecular weight polypeptides,
salt-forming counter ions, benzalkonium chloride, benzoic acid,
salicylic acid, thimerosal, phenethyl alcohol, methylparaben,
propylparaben, chlorhexidine, sorbic acid, and hydrogen peroxide;
solvents such as glycerin, propylene glycol, and polyethylene
glycol; sugar alcohols such as mannitol and sorbitol; suspending
agents; surfactants such as sorbitan ester, polysorbates including
polysorbate 20 and polysorbate 80, Triton, tromethamine, lecithin,
and cholesterol; stability enhancing agents such as sucrose and
sorbitol; elasticity enhancing agents such as sodium chloride,
potassium chloride, and mannitol and sorbitol; transport agents;
excipients; and/or pharmaceutical adjuvants. The amount of these
substances for pharmaceutical use is preferably from 0.001 to 100
times, particularly preferably from 0.1 to 10 times the weight of
the anti-B7-H3 antibody. Those skilled in the art can appropriately
determine a preferred formulation of the pharmaceutical composition
in a preparation depending on the disease to which the composition
is applied, the route of administration to be applied, or the
like.
[0337] The excipient or carrier in the pharmaceutical composition
may be in the form of a liquid or a solid. An appropriate excipient
or carrier may be injectable water, physiological saline, an
artificial cerebrospinal fluid, or other substance commonly used
for parenteral administration. Further, neutral physiological
saline or physiological saline containing serum albumin can also be
used as a carrier. The pharmaceutical composition may contain a
Tris buffer of pH 7.0 to 8.5, an acetate buffer of pH 4.0 to 5.5,
or a citrate buffer of pH 3.0 to 6.2. Further, such a buffer may be
supplemented with sorbitol or another compound.
[0338] Examples of the pharmaceutical composition of the invention
include a pharmaceutical composition comprising the anti-B7-H3
antibody and a pharmaceutical composition comprising the anti-B7-H3
antibody and at least one therapeutic agent for cancer. The
pharmaceutical composition of the invention is prepared in the form
of a lyophilized product or a liquid as a medicinal agent having a
selected composition and a required purity. The pharmaceutical
composition comprising the anti-B7-H3 antibody and the
pharmaceutical composition comprising the anti-B7-H3 antibody and
at least one therapeutic agent for cancer can also be formed into a
lyophilized product using an appropriate excipient such as
sucrose.
[0339] In the above-described pharmaceutical composition, the
therapeutic agent for cancer to be incorporated along with the
anti-B7-H3 antibody may be administrated simultaneously with,
separately from, or sequentially with the anti-B7-H3 antibody, or
the therapeutic agent and the anti-B7-H3 antibody may be
administrated at different dosage intervals. Examples of such a
therapeutic agent for cancer include Abraxane.RTM., carboplatin,
cisplatin, gemcitabine, irinotecan (CPT-11), paclitaxel,
pemetrexed, sorafenib, vinblastin, and medicinal agents described
in WO 2003/038043, and additional examples thereof include LH-RH
analogues (such as leuprorelin and goserelin), estramustine
phosphate, estrogen antagonists (such as tamoxifen and raloxifene),
and aromatase inhibitors (such as anastrozole, letrozole, and
exemestane), however, the agent is not limited thereto as long as
the agent is a medicinal agent having an antitumor activity.
[0340] An individual to whom the pharmaceutical composition is to
be administrated is not particularly limited, however, preferred
are mammals, and more preferred are humans.
[0341] The pharmaceutical composition of the invention can be
prepared for parenteral administration or for gastrointestinal
absorption through oral administration. The composition and
concentration of a preparation can be determined depending on the
administration method. The higher the affinity of the anti-B7-H3
antibody comprised in the pharmaceutical composition of the
invention is for B7-H3, that is, the lower the dissociation
constant (Kd value) thereof is for B7-H3, the more the anti-B7-H3
antibody can exhibit its drug efficacy even when decreasing the
dose for humans. Hence, the dose of the pharmaceutical composition
of the invention for humans can also be determined based on this
result. As for the dose, in the case where a human anti-B7-H3
antibody is administrated to humans, the antibody may be
administrated at a dose of from about 0.001 to 100 mg/kg once or
several times at intervals of 1 to 180 days. Examples of the dosage
form of the pharmaceutical composition of the invention include
injections including infusions, suppositories, transnasal agents,
sublingual agents, and percutaneous absorbents.
[0342] Hereinafter, the invention will be more specifically
described with reference to the Examples, however, the invention is
not limited thereto.
EXAMPLES
[0343] Note that the respective operations regarding gene
manipulation in the following Examples were performed according to
the methods described in "Molecular Cloning" (written by Sambrook,
J., Fritsch, E. F. and Maniatis, T., published by Cold Spring
Harbor Laboratory Press in 1989), or in the case of using
commercially available reagents or kits, they are used according to
the instructions attached thereto unless otherwise stated.
Example 1
Production of Plasmid
[0344] 1)-1 Production of Human B7-H3 Expression Vector
[0345] 1)-1-1 Production of Expression Vector for Full-Length Human
B7-H3 Variant 1
[0346] A PCR reaction was performed using a cDNA synthesized from
the total RNA of LNCaP cells (American Type Culture Collection
(ATCC)) as a template and also using the following primer set,
thereby amplifying a cDNA encoding the human B7-H3 variant 1:
TABLE-US-00001 Primer 1: (SEQ ID NO: 1 in the Sequence Listing)
5'-ctatagggagacccaagctggctagcatgctgcgtcggcggggca g-3'; and Primer
2: (SEQ ID NO: 2 in the Sequence Listing)
5'-aacgggccctctagactcgagcggccgctcaggctatttcttgtc
catcatcttctttgctgtcag-3'.
[0347] Subsequently, the thus obtained PCR product was purified
using MagExtractor.RTM. PCR & Gel cleanup (TOYOBO, Co., Ltd.).
Then, the PCR product was digested with restriction enzymes (NheI
and NotI), followed by purification using MagExtractor PCR &
Gel cleanup (TOYOBO, Co., Ltd.). A pcDNA3.1(+) plasmid DNA was
digested with the same restriction enzymes (NheI and NotI),
followed by purification using MagExtractor PCR & Gel cleanup
(TOYOBO, Co., Ltd.).
[0348] The resulting purified DNA solutions were mixed, and
further, Ligation high (TOYOBO, Co., Ltd.) was added thereto, and
the resulting mixture was incubated at 16.degree. C. for 8 hours to
effect ligation. The resulting reaction mixture was added to E.
coli DH5.alpha. competent cells (Invitrogen Corporation) to effect
transformation.
[0349] Colony direct PCR was performed on the resulting colonies
using the PCR primers and the BGH reverse primer, and a candidate
clone was selected.
[0350] The obtained candidate clone was cultured in a liquid medium
(LB/Amp), and a plasmid DNA was extracted using
MagExtractor-Plasmid--(TOYOBO, Co., Ltd.).
[0351] By using the obtained plasmid DNA as a template, a sequence
between the following Primer 3 and Primer 4 was determined by a
sequence analysis and the sequences were compared between the
obtained clone and the provided CDS sequence:
TABLE-US-00002 Primer 3 (CMV promoter primer): (SEQ ID NO: 3 in the
Sequence Listing) 5'-cgcaaatgggcggtaggcgtg-3'; and Primer 4 (BGH
reverse primer): (SEQ ID NO: 4 in the Sequence Listing)
5'-tagaaggcacagtcgagg-3'.
[0352] After confirming the sequence, the obtained clone was
cultured in 200 ml of LB/Amp medium, and a plasmid DNA was
extracted using Plasmid Midi V-100 kit (VioGene, Inc.).
[0353] The thus obtained vector was named "pcDNA3.1-B7-H3". The
sequence of the ORF region of the B7-H3 variant 1 gene cloned in
this vector is represented by nucleotide numbers 1 to 1602 in SEQ
ID NO:5 in the Sequence Listing. Further, the amino acid sequence
of the B7-H3 variant 1 is represented by SEQ ID NO:6 in the
Sequence Listing.
[0354] 1)-1-2 Production of Expression Vector for Full-Length Human
B7-H3 Variant 2
[0355] PCR was performed using a cDNA synthesized from the total
RNA of LNCaP cells as a template and also using the following
primer set, thereby amplifying a cDNA encoding the human B7-H3
variant 2:
TABLE-US-00003 Primer 5 (SEQ ID NO: 7 in the Sequence Listing)
5'-ggggacaagtttgtacaaaaaagcaggcttcaccatgctgcgtcggc ggggcagccctg-3'
Primer 6 (SEQ ID NO: 8 in the Sequence Listing)
5'-ggggaccactttgtacaagaaagctgggtcggctatttcttgt-3'.
[0356] Purification was performed in the same manner as in Example
1)-1-1, and the PCR product after purification was integrated into
a pDONR221 vector (Invitrogen Corporation) by a Gateway BP
reaction, thereby transforming E. coli TOP10 (Invitrogen
Corporation).
[0357] For the clones obtained after transformation, the size of
the insert was confirmed by colony PCR. For 8 clones in which the
size of the insert was confirmed, the DNA sequence at the 3' end
and the 5' end of the insert was confirmed by performing one
sequencing reaction from the vector side to the insert side for
both ends. A Gateway LR reaction between the entry clone whose
sequence was confirmed and a Gateway destination vector
pcDNA-DEST40 (Invitrogen Corporation) was performed. For the clone
obtained after transformation of E. coli TOP10, the size of the
insert was confirmed by colony PCR. For the clone in which the size
of the insert was confirmed, the DNA sequence at the 3' end and the
5' end of the insert was analyzed to confirm that the insert of
interest was correctly inserted. At least 1 mg of the thus produced
plasmid of the clone was purified using PureLink.TM. HiPure Plasmid
Megaprep Kit (Invitrogen Corporation).
[0358] The thus obtained vector was named "pcDNA-DEST40-B7-H3
variant 2". The sequence of the ORF region of the B7-H3 variant 2
gene cloned in this vector is represented by nucleotide numbers 1
to 948 in SEQ ID NO:9 in the Sequence Listing. Further, the amino
acid sequence of the B7-H3 variant 2 is represented by SEQ ID NO:10
in the Sequence Listing.
[0359] 1)-2 Production of Expression Vector for B7-H3 Partial
Protein
[0360] By using the B7-H3 full-length plasmid related to the B7-H3
variant 1 of Example 1)-1-1 as a template, each of the following
regions was amplified by PCR. The numbers showing each region of
interest correspond to the nucleotide numbers of B7-H3 represented
by SEQ ID NO:5. The primer was designed to contain a stop codon at
the 3' end in addition to the Gateway att sequence.
[0361] Each of the following regions 1), 2), and 3) was prepared by
amplifying two regions and then ligating the regions by PCR to form
one fragment. That is, as for the region 1), amplification was
performed using Primers 7 and 12, and Primers 15 and 11, and the
resulting PCR products were further amplified using Primers 7 and
11. As for the region 2), amplification was performed using Primers
8 and 13, and Primers 15 and 11, and the resulting PCR products
were further amplified using Primers 8 and 11. As for the region
3), amplification was performed using Primers 9 and 14, and Primers
15 and 11, and the resulting PCR products were further amplified
using Primers 9 and 11. As for the region 4), amplification was
performed using Primers 10 and 11. As for the region 5),
amplification was performed using Primers 8 and 11. As for the
region 6), amplification was performed using Primers 9 and 11.
[0362] Regions of Interest [0363] 1) B7-H3 variant 1 ORF: 79-417
and 1369-1602 (573 bp) [0364] 2) B7-H3 variant 1 ORF: 418-732 and
1369-1602 (549 bp) [0365] 3) B7-H3 variant 1 ORF: 733-1071 and
1369-1602 (573 bp) [0366] 4) B7-H3 variant 1 ORF: 1072-1602 (531
bp) [0367] 5) B7-H3 variant 1 ORF: 418-1602 (1185 bp) [0368] 6)
B7-H3 variant 1 ORF: 733-1602 (870 bp)
TABLE-US-00004 [0368] Primer number and base sequence Primer 7 (SEQ
ID NO: 11 in the Sequence Listing)
5'-ggggacaagtttgtacaaaaaagcaggcttcggagccctggaggt ccaggtc-3' Primer
8 (SEQ ID NO: 12 in the Sequence Listing)
5'-ggggacaagtttgtacaaaaaagcaggatcgctccctactcgaagc ccagcatg-3'
Primer 9 (SEQ ID NO: 13 in the Sequence Listing)
5'-ggggacaagtttgtacaaaaaagcaggcttcggagccgtggaggtc caggtc-3' Primer
10 (SEQ ID NO: 14 in the Sequence Listing)
5'-ggggacaagtttgtacaaaaaagcaggatcgctccctactcgaagc ccagcatg-3'
Primer 11 (SEQ ID NO: 15 in the Sequence Listing)
5'-ggggaccactttgtacaagaaagctgggtctcaggctatttcttgt ccatcatc-3'
Primer 12 (SEQ ID NO: 16 in the Sequence Listing)
5'-gggaatgtcataggctgcccggccacctgcaggctgacggcag-3' Primer 13 (SEQ ID
NO: 17 in the Sequence Listing)
5'-gggaatgtcataggctgccctgtggggcttctctggggtgtg-3' Primer 14 (SEQ ID
NO: 18 in the Sequence Listing)
5'-gggaatgtcataggctgcccggccacctgcaggctgacggcag-3' Primer 15 (SEQ ID
NO: 19 in the Sequence Listing)
5'-gggcagcctatgacattccccccagag-3'
[0369] Purification was performed in the same manner as in Example
1)-1-1, and each of the amplified products after purification was
integrated into a pDONR221 vector by a Gateway BP reaction, thereby
transforming E. coli TOP10. For the clones obtained after
transformation, the size of the insert was confirmed by colony
PCR.
[0370] For each of the clones in which the size of the insert was
confirmed, the DNA sequence at the 3' end and the 5' end of the
insert was confirmed by performing one sequencing reaction from the
vector side to the insert side for both ends.
[0371] For the clones which were confirmed to have the insert of
interest, the total DNA sequence of the insert was also confirmed
using the following primers. As a result of sequence analysis, it
was confirmed that all of the sequences were completely identical
to the information of the sequences of interest.
[0372] A Gateway LR reaction between each of the entry clones whose
sequence was confirmed and pFLAG-myc-CMV-19-DEST (Invitrogen
Corporation) was performed. For the clones obtained after
transformation of E. coli DH10B (Invitrogen Corporation), the size
of the insert was confirmed by colony PCR.
[0373] For each of the clones in which the size of the insert was
confirmed, the DNA sequence at the 3' end and the 5' end of the
insert was analyzed to confirm that the insert of interest was
correctly inserted. Hereinafter, the expression vectors obtained by
integrating each of the above regions 1) to 6) were represented by
"B7-H3 IgV1", "B7-H3 IgC1", "B7-H3 IgV2", "B7-H3 IgC2", "B7-H3
IgC1-V2-C2", and "B7-H3 IgV2-C2", respectively.
[0374] The nucleotide sequences of the ORF regions of the B7-H3
IgV1, B7-H3 IgC1, B7-H3 IgV2, B7-H3 IgC2, B7-H3 IgC1-V2-C2, and
B7-H3 IgV2-C2 genes, each of which was cloned in this vector, are
represented by SEQ ID NOS:20, 22, 24, 26, 28, and 30, respectively,
in the Sequence Listing. Further, the amino acid sequences of the
B7-H3 IgV1, B7-H3 IgC1, B7-H3 IgV2, B7-H3 IgC2, B7-H3 IgC1-V2-C2,
and B7-H3 IgV2-C2 are represented by SEQ ID NOS:21, 23, 25, 27, 29,
and 31, respectively, in the Sequence Listing. Further, the
sequences represented by SEQ ID NOS:20 and 21 are shown in FIG. 15,
the sequences represented by SEQ ID NOS:22 and 23 are shown in FIG.
16, the sequences represented by SEQ ID NOS:24 and 25 are shown in
FIG. 17, the sequences represented by SEQ ID NOS:26 and 27 are
shown in FIG. 18, the sequences represented by SEQ ID NOS:28 and 29
are shown in FIG. 19, and the sequences represented by SEQ ID
NOS:30 and 31 are shown in FIG. 20.
[0375] 1)-3 Production of Expression Vectors for B7 Family
Genes
[0376] pCMV6-XL-4-B7RP-1, pCMV6-XL-4-B7-H1, and pCMV6-XL-4-B7-DC
(which are gene expression vectors obtained by integrating each of
B7RP-1, B7-H1, and B7-DC (which are B7 family genes) in an
expression vector pCMV6-XL-4) were all purchased from OriGene,
Inc.
[0377] Vectors expressing each of CD80, CD86, and B7-H4, which are
B7 family genes, were produced as follows.
[0378] pENTR/221-CD80, pENTR/221-CD86, and pENTR/221-B7-H4, which
are clones obtained by integrating each of CD80, CD86, and B7-H4 in
an entry vector pENTR/221, were purchased from Invitrogen
Corporation
[0379] A Gateway LR reaction between each of the entry clones whose
sequence was confirmed and pcDNA3.1-DEST (Invitrogen Corporation)
was performed. For the clones obtained after transformation of E.
coli DH10B, the size of the insert was confirmed by colony PCR. For
each of the clones in which the size of the insert was confirmed,
the DNA sequence at the 3' end and the 5' end of the insert was
analyzed to confirm that the insert of interest was correctly
inserted.
[0380] The nucleotide sequences of the ORF regions of the B7RP-1,
B7-H1, B7-DC, CD80, CD86, and B7-H4 genes, each of which was cloned
in this vector, are represented by SEQ ID NOS:32, 34, 36, 38, 40,
and 42, respectively, in the Sequence Listing. Further, the amino
acid sequences of the B7RP-1, B7-H1, B7-DC, CD80, CD86, and B7-H4
are represented by SEQ ID NOS:33, 35, 37, 39, 41, and 43,
respectively, in the Sequence Listing.
Example 2
Production of Monoclonal Antibody and Screening of Antibody
[0381] 2)-1 Immunization
[0382] BALB/cAnNCrlCrlj mice (Charles River Laboratories Japan,
Inc.), FcgRII KO mice (Taconic, Inc., IBL Co., Ltd.), or GANP mice
(Transgenic, Inc.) at 4 to 6 weeks of age were used. On days 0, 7,
15, and 24, LNCaP cells, MCF7 cells (ATCC) or AsPC1 cells (ATCC)
detached with versene (Invitrogen Corporation) were subcutaneously
administrated in the dorsal region of each mouse at a dose of
5.times.10.sup.6 cells/mouse. On day 31, the same cells were
intravenously administrated to each mouse at a dose of
5.times.10.sup.6 cells. On day 34, the spleen was excised from each
mouse and used for the production of hybridomas.
[0383] 2)-2 Production of Hybridomas
[0384] Spleen cells and mouse myeloma P3X63Ag8U.1 cells (ATCC) were
subjected to cell fusion using PEG 4000 (manufactured by IBL Co.,
Ltd.), thereby producing hybridomas.
[0385] As a result, 9639 clones from the mice immunized with LNCaP
cells, 4043 clones from the mice immunized with MCF7 cells, and
3617 clones from the mice immunized with AsPC1 cells were
established as hybridomas. By using the obtained culture
supernatant of each hybridoma, an antibody-producing hybridoma was
screened by a CDC assay.
[0386] 2)-3 Screening of Antibody by CDC Assay
[0387] On day 0, LNCaP cells or MCF7 cells were diluted to 5000
cells per 80 .mu.L and the resulting solution was added to a
96-well plate at 80 .mu.l/well. Then, the cells were cultured
overnight. The hybridoma culture supernatant was added at 20
.mu.l/well to the plate in which the cells were seeded, and the
plate was left to stand at 4.degree. C. for 1 hour. To a diluted
and lyophilized rabbit complement (Cedarlane Laboratories), 1 mL of
sterile water was added to each vial on ice, and the vial was left
to stand for 1 minute, followed by mixing, and then, the resulting
mixture was mixed with 19 mL of 0.1% BSA/RPMI 1640 medium (BSA,
Sigma Co., Ltd.). A reaction was allowed to proceed at 37.degree.
C. for 1 hour.
[0388] The plate was left at room temperature for 30 minutes to
return to room temperature. 120 .mu.L of CellTiter-Glo.RTM. reagent
(Promega Corporation) was added to each well, and a reaction was
allowed to proceed at room temperature for 10 minutes. The amount
of luminescence was measured using a plate reader (ARVO HTS,
PerkinElmer, Inc.). In a well exhibiting low luminescence, it was
determined that complement-dependent cell death was induced. A
hybridoma which produced a culture supernatant that induced such
complement-dependent cell death was selected.
[0389] As a result, 24 clones from the clones derived from
immunization with LNCaP, 36 clones from the clones derived from
immunization with MCF7, and 3 clones from the clones derived from
immunization with AsPC1 were obtained as positive clones by
screening.
Example 3
Identification of Antigen
[0390] 3)-1 Identification of Immunoprecipitated Substance
[0391] 3)-1-1 Immunoprecipitation
[0392] MCF7 cells were cultured at 5 to 10.times.10.sup.8 cells.
These cells were detached with a cell scraper and the detached
cells were collected and cryopreserved at -80.degree. C. To the
cryopreserved cells, 10 ml of a lysis buffer which contained 1%
NP-40 (Sigma-Aldrich Co., Ltd.) and a protease inhibitor (F.
Hoffmann-La Roche, Ltd.) and was cooled to 4.degree. C. was added
and the cell pellet was lysed on ice with a pipette in such a
manner that the formation of bubbles was avoided. After being
completely lysed, the pellet was left on ice for 30 minutes. The
solubilized sample was centrifuged at 4.degree. C. for 20 minutes
at 10000 to 15000 rpm, and the resulting supernatant was
transferred to a 15 ml falcon tube.
[0393] 500 .mu.l of protein G-Sepharose 4FF beads (Amersham
Pharmacia Biotech Co., Ltd.) were washed three times, and subjected
to buffer exchange with a lysis buffer. 500 .mu.l of the protein
G-Sepharose 4FF beads were added to the solubilized sample
supernatant on ice, and the resulting mixture was subjected to
rotary stirring overnight at 4.degree. C.
[0394] The sample was passed through Poly-Prep.RTM. chromatography
columns (Bio-Rad Laboratories, Inc.), and a passed-through fraction
was used as an immunoprecipitation sample.
[0395] 3 .mu.g of an antibody solution to be used for
immunoprecipitation was added to 50 .mu.l of protein G-Sepharose
4FF beads subjected to buffer exchange with phosphate buffered
saline (PBS) (a 1.5 ml tube), and the resulting mixture was
subjected to rotary stirring at 4.degree. C. for 1 to 16 hours,
whereby the antibody was bound to the beads. To the
immunoprecipitation sample, the beads to which the antibody was
bound were added, and the resulting mixture was subjected to rotary
stirring at 4.degree. C. for 3 hours.
[0396] The column was transferred to an empty 15 ml falcon tube,
and 6.5 ml of a lysis buffer was added thereto. This procedure was
repeated 4 times.
[0397] The outlet of the column was capped, and pipetting was
performed with 500 .mu.l of a lysis buffer, and the beads were
collected in a 1.5 ml tube. This procedure was repeated twice.
[0398] After centrifugation at 4.degree. C. for 1 minute at 5000
rpm, the supernatant was carefully removed. Then, 90 .mu.l of an
elution buffer (10 mM glycine-HCl, pH 2.0) was added thereto,
followed by vortexing and centrifugation. The column of 1.5 ml spin
column was detached, and 10 .mu.l of 1 M Tris-HCl (pH 8.5) was
added thereto, and the column was returned to the original place.
An elution fraction was transferred thereto, and centrifugation was
performed at 10000 rpm for 1 minute, whereby 100 .mu.l of a sample
was obtained.
[0399] The obtained sample was subjected to MS analysis by a liquid
phase digestion technique as shown in the following 3)-1-2.
[0400] 3)-1-2 Identification of Antigen by Mass Spectrometry
Analysis
[0401] According to a common procedure, the fraction obtained by
the immunoprecipitation method was subjected to a digestion
reaction at 37.degree. C. for 16 hours by adding trypsin (modified
trypsin, Promega Corporation) through a liquid phase digestion
technique. The resulting digested peptides were subjected to a
liquid chromatography (LC)/tandem mass spectrometer (MS/MS) (Thermo
Fisher Scientific K.K.). The obtained mass spectral data were
analyzed using a database search software (Mascot, Matrix Science
K.K.). As the database, International Protein Index (IPI) was used.
As a result, 34 types of antigens were identified.
[0402] From the characteristics of the identified antigens,
bibliographic information retrieval was performed in consideration
that B7-H3 is a cell membrane protein, and by focusing on B7-H3
(CD276) antigen (B7-H3 variant 1), experiments described in the
following 3)-2 and 3)-3 were performed.
[0403] 3)-2 Preparation of Antigen Gene-Expressing Cells
[0404] NIH-3T3 cells (ATCC) were seeded at 5.times.10.sup.4
cells/cm.sup.2 in a collagen type I-coated flask (manufactured by
IWAKI Co., Ltd.) and cultured overnight in DMEM medium (Invitrogen
Corporation) containing 10% fetal bovine serum (FBS) under the
conditions of 37.degree. C. and 5% CO.sub.2.
[0405] On the next day, the NIH-3T3 cells were transfected with
each of the pcDNA3.1-B7-H3 produced in Example 1)-1-1,
pcDNA-DEST40-B7-H3 variant 2 produced in 1)-1-2, and pcDNA-DEST40
which is an empty vector using Lipofectamine.RTM. 2000 (Invitrogen
Corporation), and further cultured overnight under the conditions
of 37.degree. C. and 5% CO.sub.2.
[0406] On the next day, the transfected NIH-3T3 cells were treated
with trypsin, and washed with DMEM containing 10% FBS, and
thereafter suspended in PBS containing 5% FBS. The thus obtained
cell suspension was used in a flow cytometric analysis.
[0407] 3)-3 Flow Cytometric Analysis
[0408] The binding specificity, for B7-H3, of the antibody produced
by the hybridoma which immunoprecipitated the B7-H3 variant 1
identified by MS was confirmed by a flow cytometric method. The
cell suspension prepared in Example 3)-2 was centrifuged, and the
supernatant was removed. Then, the hybridoma culture supernatant
was added to the NIH-3T3 cells transfected with each vector to
suspend the cells, and the cells were left to stand at 4.degree. C.
for 1 hour.
[0409] After the cells were washed twice with PBS containing 5%
FBS, fluorescein-conjugated goat IgG fraction to mouse IgG (whole
molecule) (manufactured by ICN Pharmaceuticals, Inc., #55493)
diluted to 1000-fold with PBS containing 5% FBS was added thereto
to suspend the cells, and the cells were left to stand at 4.degree.
C. for 1 hour.
[0410] After the cells were washed twice with PBS containing 5%
FBS, the cells were resuspended in PBS containing 5% FBS
supplemented with 2 .mu.g/ml 7-aminoactinomycin D (manufactured by
Invitrogen Corporation (Molecular Probes)), and the detection was
performed using a flow cytometer (FC500, Beckman Coulter, Inc.).
The data was analyzed using Flowjo (Tree Star, Inc.).
[0411] 7-Aminoactinomycin D-positive dead cells were excluded using
a gate. Then, the FITC fluorescence intensity histograms of viable
cells were created.
[0412] A hybridoma which produced a sample that gave a higher
fluorescence intensity in the fluorescence intensity histograms of
the NIH-3T3 cells expressing the B7-H3 variant 1 and the NIH-3T3
cells expressing the B7-H3 variant 2 than in the fluorescence
intensity histogram of the NIH-3T3 cells transfected with the empty
vector serving as the control was selected as the anti-B7-H3
antibody-producing hybridoma.
[0413] As a result, it was found that the antibodies derived from
the anti-B7-H3 antibody-producing hybridomas of 5 clones (L7, L8,
L11, M30, and M31) have a cross-reactivity with the B7-H3 variant 1
and the B7-H3 variant 2.
[0414] 3)-4 Confirmation of Binding Property of Monoclonal Antibody
to Cancer Cell Line
[0415] It was examined as to whether the monoclonal antibodies
confirmed to bind to the B7-H3 variant 1 and the B7-H3 variant 2 in
Example 3)-3 bind to cancer cells which overexpress the B7-H3
variant 1 and the B7-H3 variant 2 by a flow cytometric method in
the same manner as in Example 3)-3.
[0416] In place of the transfected NIH-3T3 cells, a human breast
cancer cell line (MDA-MB-231) (ATCC) and a human lung cancer cell
line (NCI-H322) (ATCC) were used. As a result, it was confirmed
that the established monoclonal antibodies all bind to these cancer
cell lines.
[0417] 3)-5 Isotype Determination of Monoclonal Antibody
[0418] The isotypes of the monoclonal antibodies were determined
using Mouse monoclonal isotyping kit (manufactured by Serotec Co.,
Ltd.). As a result, the isotypes of the antibodies derived from the
anti-B7-H3 antibody-producing hybridomas (L7, L8, L11, M30, and
M31) were all IgG2a.
[0419] 3)-6 Preparation of Monoclonal Antibody
[0420] The monoclonal antibody was purified from the ascites of a
mouse implanted with a hybridoma or a hybridoma culture supernatant
(hereinafter, referred to as a "starting material for antibody
purification").
[0421] The mouse ascites was prepared as follows. First,
BALB/cAJcl-nu/nu (CLEA Japan, Inc.) mice at 7 to 8 weeks of age
were treated with pristane (manufactured by Sigma Co., Ltd.), and
after about 3 weeks, a hybridoma washed with physiological saline
was implanted into the abdominal cavity at 1.times.10.sup.7 cells
per mouse. After 1 to 2 weeks, the ascites accumulated in the
abdominal cavity was collected and sterilized through a 0.22 .mu.m
filter, and the resulting material was used as a starting material
for antibody purification.
[0422] The hybridoma culture supernatant was prepared using
CELLine.TM. (manufactured by BD Biosciences, Inc.). The culturing
was performed according to the manufacturer's protocol except that
ClonaCellTm-HY Growth Medium E (manufactured by StemCell
Technologies, Inc., #03805) was used as the medium. The collected
culture supernatant was filtered through a 0.45 .mu.m filter, and
the resulting material was used as a starting material for antibody
purification.
[0423] The antibody was purified by an affinity column obtained by
immobilizing Recombinant Protein A rPA50 (manufactured by RepliGen
Corporation) on Formyl-Cellulofine (manufactured by Seikagaku
Corporation) (hereinafter abbreviated as "Formyl-Cellulofine
Protein A") or HiTrap.RTM. MabSelect SuRe.RTM. (manufactured by GE
Healthcare Bio-Sciences Corporation). In the case of the
Formyl-Cellulofine Protein A, the starting material for antibody
purification was diluted to 3-fold with a binding buffer (3 M NaCl,
1.5 M glycine, pH 8.9), and the resulting solution was added to a
column, then, the column was washed with the binding buffer,
followed by elution with 0.1 M citric acid (pH 4.0). On the other
hand, in the case of the HiTrap Mab Select SuRe (GE Healthcare
Corporation), the starting material for antibody purification was
added to a column, and the column was washed with PBS, followed by
elution with 2 M Arginine-HCl (pH 4.0).
[0424] After the eluted antibody solution was neutralized, the
buffer was exchanged with PBS.
[0425] The concentration of the antibody was obtained by eluting
the antibody bound to POROS.RTM. G 20 .mu.m Column PEEK, 4.6
mm.times.100 mm, 1.7 ml (Applied Biosystems, Inc.) and measuring
the absorbance (O.D. 280 nm) of the eluate. Specifically, an
antibody sample diluted with PBS was added to POROS G 20 .mu.m
equilibrated with an equilibrating buffer (30.6 mM sodium
dihydrogen phosphate/12 aq., 19.5 mM monopotassium phosphate, 0.15
M NaCl, pH 7.0). Then, the column was washed with the equilibrating
buffer, and the antibody bound to the column was then eluted with
an eluent (0.1% (v/v) HCl, 0.15 M NaCl). The peak area of the
absorbance (O.D. 280 nm) of the eluate was measured, and the
concentration was calculated according to the following
equation:
Concentration of antibody sample (mg/ml)=(Peak area of antibody
sample)/(Peak area of reference standard (human
IgG1)).times.Concentration of reference standard
(mg/ml).times.Dilution factor of sample.
[0426] Further, the concentration of endotoxin contained in the
obtained antibody was measured using Endospecy ES-50M Set
(Seikagaku Corporation, #020150) and an endotoxin reference
standard CSE-L Set (Seikagaku Corporation, #020055) and was
confirmed to be 1 EU/mg or less. The resulting antibody was used in
the subsequent experiment.
Example 4
Properties of Anti-B7-H3 Antibody
[0427] 4)-1 ADCP Activity
[0428] 1.5 mL of thioglycollate was administrated in the abdominal
cavity of a Balb/c-nu/nu mouse (female, at 6 to 10 weeks of age)
(Charles River Laboratories Japan, Inc.). 5 Days thereafter,
macrophages in the abdominal cavity were collected. The macrophages
were added to a 24-well plate at 500 .mu.L/well (1.times.10.sup.5
cells/well) and cultured overnight at 37.degree. C. The thus
prepared macrophages were used as effector cells.
[0429] The labeling of NCI-H322 cells to be used as target cells
was performed using PKH26 dye labeling kit (Sigma Co., Ltd.) The
target cells were detached with TrypLE (Invitrogen Corporation) and
washed twice with PBS. The cells were suspended in Diluent C at
1.times.10.sup.7 cells/ml. PKH26 dye stock (1 mM) was diluted to 8
.mu.M with Diluent C, and immediately thereafter, the diluted dye
solution was added thereto in an amount equal to that of the cell
suspension. The resulting mixture was left at room temperature for
5 minutes. Then, 1 ml of serum was added thereto, and further, a
medium with serum was added thereto, and washing was performed
twice. The thus prepared cells were used as the target cells.
[0430] The antibody obtained in Example 3)-6 was diluted to 20
.mu.g/ml with a culture solution. Subsequently, the target cells
obtained in Example 4)-1-1 were dispensed at 2.times.10.sup.6
cells/100 .mu.l/tube and mixed. The resulting mixture was left to
stand on ice for 30 minutes. The supernatant was removed, and the
cells were washed twice with a culture solution and suspended in
500 .mu.l of a culture solution. The supernatant was removed from
the effector cells, and the cells having been treated with the
antibody and suspended in the culture solution were added thereto
and mixed therewith. Then, the cells were cultured for 3 hours in a
CO.sub.2 incubator. Thereafter, the cells were detached with
Trypsin-EDTA and collected. To the collected cells, an FITC-labeled
anti-mouse CD11b antibody (Becton, Dickinson and Company, Ltd.) was
added, and the resulting mixture was left to stand on ice for 30
minutes. The supernatant was removed, and the cells were washed
twice with a culture solution. The collected cells were suspended
in 300 .mu.l of a culture solution and analyzed by FACS Calibur.TM.
(Becton Dickinson and Company, Ltd.). In the CD11b-positive
macrophages, a PKH26-positive fraction was evaluated as
phagocytosis-positive cells (n=3).
[0431] As a result, as shown in FIG. 1, the L7, L8, L11, M30, and
M31 induced the phagocytosis of the NCI-H322 cells by macrophages
to give the percentage of phagocytosis of 48.0.+-.0.9%,
52.3.+-.1.1%, 57.1.+-.2.5%, 61.9.+-.2.1%, and 57.7.+-.3.0%,
respectively. Accordingly, it was shown that the L7, L8, L11, M30,
and M31 antibodies have an ADCP activity against the NCI-H322
cells.
[0432] In the same manner, commercially available anti-B7-H3
antibodies were obtained and the ADCP activity thereof was
measured. A rat anti-human B7-H3 antibody MIH35 (eBioscience
Company), a mouse anti-human B7-H3 antibody 185504 (R&D
Systems, Inc.), MIH42 (Serotec Co., Ltd.), and DCN70 (Biolegend
Company) were obtained. It was confirmed that these antibodies bind
to B7-H3 in the same manner as in Example 3)-3. By using these
antibodies, the ADCP activity was measured by the above method.
[0433] As a result, as shown in FIG. 2, when being added at 1
.mu.g/ml, the MIH35, MIH42, and DCN70 induced the phagocytosis of
the NCI-H322 cells by macrophages to 4.2%, 8.2%, and 10.8%,
respectively. Accordingly, it was revealed that the MIH35, MIH42,
and DCN70 exhibited almost no ADCP activity.
[0434] From these results, it was shown that the M30 clones
recognizing B7-H3 obtained by screening this time have a
particularly higher ADCP activity than the commercially available
B7-H3 antibodies.
[0435] 4)-2 ADCC Activity
[0436] 4)-2-1 Preparation of Effector Cells
[0437] The spleen was aseptically excised from a nude mouse
CAnN.Cg-Foxn1.sup.nu/CrlCrlj (Charles River Laboratories Japan,
Inc.). The excised spleen was homogenized with two slide glasses,
and subjected to a hemolysis treatment using BD Pharm Lyse.TM.
(manufactured by BD Biosciences, Ltd. #555899). The thus obtained
spleen cells were suspended in phenol red-free RPMI 1640
(manufactured by Invitrogen Corporation) containing 10% Fetal
Bovine Serum, Ultra-low IgG (manufactured by Invitrogen
Corporation) (hereinafter abbreviated as "ADCC medium"), and the
cell suspension was passed through a cell strainer (pore size: 40
.mu.m, manufactured by BD Biosciences, Ltd.). Then, the viable
cells were counted by a trypan blue dye exclusion assay. After the
spleen cell suspension was centrifuged, the medium was removed, and
the cells were resuspended in the ADCC medium at a viable cell
density of 1.5.times.10.sup.7 cells/ml and used as effector
cells.
[0438] 4)-2-2 Preparation of Target Cells
[0439] B7-H3-expressing 293 cells (ATCC) and empty
vector-transfected 293 cells prepared in the same manner as in
Example 3)-3 were treated with trypsin, and the treated cells of
each type were washed with 10% FBS-containing RPMI 1640 (Invitrogen
Corporation) and then resuspended in 10% FBS-containing RPMI 1640.
The cells (4.times.10.sup.6 cells) of each type were mixed with
chromium-51 (5550 kBq) sterilized through a 0.22 .mu.m filter, and
labeling was performed for 1 hour under the conditions of
37.degree. C. and 5% CO.sub.2. The labeled cells were washed three
times with 10% FBS-containing RPMI 1640 (Invitrogen Corporation),
and the cells were resuspended at 2.times.10.sup.5 cells/ml in the
ADCC medium and used as target cells.
[0440] 4)-2-3 .sup.51Cr Release Assay
[0441] The target cells at a cell density of 2.times.10.sup.5
cells/ml were dispensed at 50 .mu.l/well in a 96-well U-shaped
bottom microplate. Thereto was added 50 .mu.l of M30 or an isotype
control antibody (mIgG2a) (eBioscience Company) diluted with the
ADCC medium so that the final concentration of the antibody after
adding the effector cells was 2.5 .mu.g/ml. Then, the plate was
left to stand at 4.degree. C. for 1 hour. Thereafter, 100 .mu.l of
the effector cells at a cell density of 1.5.times.10.sup.7 cells/ml
were added thereto, and the cells were cultured overnight under the
conditions of 37.degree. C. and 5% CO.sub.2. On the next day, the
supernatant was collected in a LumaPlate.TM. (manufactured by
PerkinElmer, Inc.), and gamma radiation emitted therefrom was
measured using a gamma counter. The percentage of cell lysis caused
by the ADCC activity was calculated according to the following
equation.
Percentage of cell lysis (%)=(A-B)/(C-B).times.100 [0442] A:
Radiation count from the sample well [0443] B: Average spontaneous
radiation emission count (from wells to which the antibody and the
effector cells were not added) (n=3) The same procedure as that for
the sample well was performed except that the ADCC medium was added
in an amount of 50 .mu.l at the time of adding the antibody and in
an amount of 100 .mu.l at the time of adding the effector cells.
[0444] C: Average maximum radiation emission count (from wells in
which the target cells were dissolved with a surfactant) (n=3) The
same procedure as that for the sample well was performed except
that 50 .mu.l of the ADCC medium was added at the time of adding
the antibody and 100 .mu.l of the ADCC medium containing 2% (v/v)
Triton X-100 was added at the time of adding the effector
cells.
[0445] The data shown are an average of triplicate measurements,
and the error bars represent standard deviations. The P value was
calculated using Student's t-test. The measurement results are
shown in FIG. 3.
[0446] As a result, the M30 exhibited a cell lysis activity with a
percentage of cell lysis of 31.6.+-.3.3% against the
B7-H3-expressing 293 cells, and therefore, it was shown that the
M30 antibody has an ADCC activity against the B7-H3-expressing 293
cells.
[0447] 4)-3 CDC Activity
[0448] An experiment was performed in the same manner as in Example
2)-3. As the cells for use in the evaluation, NCI-H322 cells were
used. Each of the anti-B7-H3 antibodies (L7, L8, L11, M30, and M31)
obtained in Example 3)-6 and an isotype control antibody (mIgG2a)
diluted with 10% FBS-containing RPMI 1640 (containing antibiotics:
penicillin and streptomycin) so that the final concentration of the
antibody after adding a complement was 25 .mu.g/ml was added, and
the resulting mixture was left to stand at 4.degree. C. for 1 hour.
Thereto was added a rabbit complement (manufactured by Cedarlane
Laboratories, #CL3051) diluted to 30% with RPMI 1640 so that the
final concentration of the complement was 5%, and the resulting
mixture was incubated for 1 hour under the conditions of 37.degree.
C. and 5% CO.sub.2. Then, the mixture was left to stand at room
temperature for 30 minutes. In order to measure the cell viability,
CellTiter-Glo.RTM. Luminescent Cell Viability Assay (manufactured
by Promega Corporation) was added thereto in an amount equal to
that of the culture solution, and the resulting mixture was stirred
at room temperature for 10 minutes. Thereafter, the amount of
luminescence was measured using a plate reader. The cell viability
was calculated according to the following equation.
Cell viability (%)=(a-b)/(c-b).times.100 [0449] a: Amount of
luminescence from the sample well, [0450] b: Average amount of
luminescence of background (from wells to which the cells and the
antibody were not added) (n=3) The same procedure as that for the
sample well was performed except that an equal amount of 10%
FBS-containing RPMI 1640 (containing antibiotics: penicillin and
streptomycin) was added in place of the cell suspension at the time
of cell seeding and 10% FBS-containing RPMI 1640 (containing
antibiotics: penicillin and streptomycin) was added in an amount
equal to that of the antibody dilution solution at the time of
adding the antibody. [0451] c: Average amount of luminescence from
wells to which the antibody was not added (n=3) The same procedure
as that for the sample well was performed except that 10%
FBS-containing RPMI 1640 (containing antibiotics: penicillin and
streptomycin) was added in an amount equal to that of the antibody
dilution solution at the time of adding the antibody.
[0452] The measurement results are shown in FIG. 4. The data shown
are an average of triplicate measurements, and the error bars
represent standard deviations. As a result, the control antibody,
L7, L8, L11, M30, and M31 induced a decrease in cell viability of
the NCI-H322 cells to 101.5.+-.3.3%, 6.3.+-.4.2%, 13.6.+-.9.1%,
7.2.+-.1.4%, 7.5.+-.1.8%, and 12.8.+-.2.0%, respectively, in the
presence of the complement. Therefore, it was shown that the L7,
L8, L11, M30, and M31 antibodies have a CDC activity against the
NCI-H322 cells.
[0453] 4)-4 Determination of Binding Domain
[0454] It was examined as to which domain of B7-H3 the M30 binds by
a flow cytometric method in the same manner as in Example 3)-3. The
NIH-3T3 cells transfected with each of the expression vectors for
B7-H3 partial proteins prepared in Example 1)-1-3 were used.
[0455] As a result, as shown in FIG. 5, it was confirmed that the
M30 binds to B7-H3 IgC1, B7-H3 IgC2, B7-H3 IgC1-V2-C2, and B7-H3
IgV2-C2. The M30 did not bind to B7-H3 IgV1 and B7-H3 IgV2.
[0456] From these results, it was shown that the M30 binds to the
C1 domain (an amino acid sequence represented by amino acid numbers
140 to 244 in SEQ ID NO:6) and the C2 domain (an amino acid
sequence represented by amino acid numbers 358 to 456 in SEQ ID
NO:6) of B7-H3. In the same manner, it was shown that also the L8,
L11, and M31 bind to the C1 domain and the C2 domain, and the L7
binds to the V1 domain (an amino acid sequence represented by amino
acid numbers 27 to 139 in SEQ ID NO:6) and the V2 domain (an amino
acid sequence represented by amino acid numbers 245 to 357 in SEQ
ID NO:6).
[0457] Accordingly, it was shown that the M30 recognizes an epitope
in the IgC1 domain and/or the IgC2 domain, each of which is a
domain in the B7-H3 extracellular domain, and binds to the IgC1
domain or the IgC2 domain or both.
[0458] 4)-5 Antigen Specificity
[0459] The antigen specificity of the M30 was examined by a flow
cytometric method in the same manner as in Example 3)-3.
[0460] 293T cells transfected with each of the expression vectors
for the CD80, CD86, B7-RP-1, B7-H1, B7-DC, and B7-H4 proteins,
which are B7 family proteins, prepared in Example 1)-1-4 were
used.
[0461] As a result, it was shown that the M30 does not bind to the
CD80, CD86, B7-RP-1, B7-H1, B7-DC, and B7-H4, which are B7 family
molecules.
Example 5
In Vivo Antitumor Effect
[0462] 5)-1 In Vivo Antitumor Effect of Anti-B7-H3 Antibody
[0463] NCI-H322 cells were detached from a culture flask by a
trypsin treatment, and then suspended in 10% FBS-containing RPMI
1640 (Invitrogen Corporation), followed by centrifugation, and the
supernatant was removed. The cells were washed twice with the same
medium, and then suspended in physiological saline (manufactured by
Otsuka Pharmaceutical Co., Ltd.). Then, the cells were implanted
subcutaneously in the axillary region of each BALB/cAJcl-nu/nu
(CLEA Japan, Inc.) mouse at 6 weeks of age at a dose of
1.times.10.sup.7 cells/mouse. The day of implantation was taken as
day 0, and on days 10, 17, 24, 31, and 38, each of the L7, L8, L11,
M30, and M31 antibodies was intraperitoneally administrated at a
dose of 500 .mu.s/mouse (about 25 mg/kg). To the control, PBS was
intraperitoneally administrated in a volume (500 .mu.l) equal to
that of the antibody. The tumor volume was measured on days 10, 17,
24, 31, 38, and 45, and the antitumor effect of the administration
of the antibody was examined.
[0464] As a result, in the M30 and M31 administration groups, the
tumor growth was significantly suppressed as compared with the PBS
administration group (The P values for the M30 and M31 compared
with the PBS administration group in terms of the tumor volume on
day 45 were P<0.05 and P<0.01, respectively. The P values
were calculated using Student's t-test.). Further, the tumor growth
inhibition ratio (=100-(average tumor volume in antibody
administration group)/(average tumor volume in PBS administration
group).times.100) on day 45 in the case of the L7, L8, L11, M30,
and M31 was -16.1%, 0.2%, 25.5%, 47.2%, and 58.2%, respectively.
Accordingly, the M30 and M31 antibodies were observed to have a
very strong antitumor effect in vivo (FIG. 6).
[0465] From the above results, it was revealed that the M30 and M31
antibodies are antibodies which recognize a B7-H3 antigen and
exhibit an antitumor effect.
[0466] 5)-2 In Vivo Antitumor Effect Under Conditions of Depletion
of Macrophages
[0467] In order to deplete macrophages in vivo,
clodronate-encapsulated liposomes were produced. It has been
reported that by administrating clodronate-encapsulated liposomes
in vivo, macrophages in vivo are depleted (Journal of Immunological
Methods (1994) vol. 174, pp. 83-93). According to the method in
this report, clodronate-encapsulated liposomes were produced and
used in the following experiment.
[0468] NCI-H322 cells were detached from a culture flask by a
trypsin treatment, and then suspended in 10% FBS-containing RPMI
1640 (Invitrogen Corporation), followed by centrifugation and the
supernatant was removed. The cells were washed twice with the same
medium, and then suspended in physiological saline (PBS,
manufactured by Otsuka Pharmaceutical Co., Ltd.). Then, the cells
were implanted subcutaneously in the axillary region of each
BALB/cAJcl-nu/nu (CLEA Japan, Inc.) mouse at 6 weeks of age at a
dose of 1.times.10.sup.7 cells/mouse. The day of implantation was
taken as day -14, and grouping was performed on day 0.
[0469] In a group in which the macrophages in vivo in the mice were
depleted, the clodronate-encapsulated liposomes were intravenously
injected at a dose of 0.2 mL/mouse on days 0, 4, 7, 11, 14, 18, 21,
25, 28, and 32. Further, in the negative control group, PBS was
intravenously injected at a dose of 0.2 mL/mouse on the same days
(on days 0, 4, 7, 11, 14, 18, 21, 25, 28, and 32).
[0470] Subsequently, the M30 antibody was intraperitoneally
administrated to both groups at a dose of 500 .mu.s/mouse (about 25
mg/kg) on days 1, 8, 15, 22, and 29. Further, as the negative
control, PBS was intraperitoneally administrated to both groups in
a volume (500 .mu.l) equal to that of the M30 antibody on the same
days (on days 1, 8, 15, 22, and 29).
[0471] The tumor volume was measured on days 0, 8, 15, 22, 29, and
36, and the antitumor effect of the administration of the antibody
was examined (n=8).
[0472] The results are shown in Tables 1 and 2, and FIG. 7.
TABLE-US-00005 TABLE 1 On day 0 On day 8 On day 15 Average Standard
Average Standard Average Standard Tumor volume (mm.sup.3) deviation
(mm.sup.3) deviation (mm.sup.3) deviation PBS + PBS 104.375
6.491581086 149 10.60828517 227.5 18.20027472 administration group
Clod lip + PBS 114.625 4.862162585 159.375 7.676349346 318.625
26.37567704 administration group PBS + M30 103.5 7.221001118
123.625 14.89958952 145 19.58497967 administration group Clod lip +
M30 104.625 5.47049717 143.375 10.46753058 247.75 24.44947414
administration group On day 22 On day 29 On day 36 Average Standard
Average Standard Average Standard Tumor volume (mm.sup.3) deviation
(mm.sup.3) deviation (mm.sup.3) deviation PBS + PBS 394.75
25.77772433 601.25 43.17065389 827 50.82638516 administration group
Clod lip + PBS 443.625 23.52653327 619.75 40.9550058 1002.75
78.18493415 administration group PBS + M30 186.25 25.920035 301.75
47.13610612 415.25 79.84175197 administration group Clod lip + M30
384.25 40.10644319 641.375 80.12176838 837.25 121.349223
administration group
[0473] In the group of PBS intravenous administration+M30 antibody
intraperitoneal administration (PBS+M30 administration group), the
tumor growth was significantly suppressed as compared with the
group of PBS intravenous administration+PBS intraperitoneal
administration (PBS+PBS administration group) serving as the
negative control. To be more specific, the P value for the PBS+M30
administration group compared with the PBS+PBS administration group
in terms of the tumor volume on day 36 was P<0.05 (The P value
was calculated using Student's t-test.). Further, the tumor growth
inhibition ratio (=100-(average tumor volume in PBS+M30
administration group)/(average tumor volume in PBS+PBS
administration group).times.100) on day 36 was 49.8% (Table 2).
[0474] On the other hand, in the group of clodronate-encapsulated
liposome intravenous administration+PBS intraperitoneal
administration (Clod lip+PBS administration group) and the group of
clodronate-encapsulated liposome intravenous administration+M30
antibody intraperitoneal administration (Clod lip+M30
administration group), the suppression of tumor growth was not
observed. To be more specific, the P values for the Clod lip+PBS
administration group and the Clod lip+M30 administration group
compared with the PBS+PBS administration group in terms of the
tumor volume on day 36 were P=0.52 and P=1, respectively (The P
values were calculated using Student's t-test.). Further, the tumor
growth inhibition ratio (=100-(average tumor volume in Clod lip+PBS
administration group or Clod lip+M30 administration group)/(average
tumor volume in PBS+PBS administration group).times.100) on day 36
was -21.2% and -1.4%, respectively (Table 2).
TABLE-US-00006 TABLE 2 Tumor growth inhibition ratio (%) On On On
On On day 8 day 15 day 22 day 29 day 36 Clod lip + PBS -6.6 -39.4
-12.6 -3.5 -21.2 administration group PBS + M30 17.5 36.4 52.8 49.7
49.8 administration group Clod lip + M30 3.2 -8.6 2.6 -6.6 -1.4
administration group
[0475] From the above results, it was shown that the antitumor
effect of the M30 antibody was suppressed by administering the
clodronate-encapsulated liposomes, and therefore, it was revealed
that the antitumor effect of the M30 antibody is mainly an effect
mediated by macrophages.
Example 6
Cloning of Mouse Antibody M30 cDNA and Determination of
Sequence
[0476] 6)-1 Determination of N-Terminal Amino Acid Sequences of
Heavy and Light Chains of Mouse Antibody M30
[0477] In order to determine the N-terminal amino acid sequences of
the heavy and light chains of the mouse antibody M30, the mouse
antibody M30 purified in Example 3)-6 was separated by SDS-PAGE.
The protein in the gel was transferred from the gel after
separation to a PVDF membrane (pore size: 0.45 manufactured by
Invitrogen Corporation). The membrane was washed with a washing
buffer (25 mM NaCl, 10 mM sodium borate buffer pH 8.0), and
thereafter stained by being immersed in a dye solution (50%
methanol, 20% acetic acid, 0.05% Coomassie brilliant blue) for 5
minutes, followed by destaining with 90% methanol. The portions of
the band corresponding to the heavy chain (the band with smaller
mobility) and the band corresponding to the light chain (the band
with larger mobility) visualized on the PVDF membrane were
excised.
[0478] The portion of the band corresponding to the light chain was
incubated at 37.degree. C. for 30 minutes in a small amount of a
0.5% polyvinylpyrrolidone/100 mM acetic acid solution, followed by
washing well with water. Subsequently, modified N-terminal residue
was removed using Pfu Pyroglutamate Aminopeptidase Kit (TaKaRa Bio,
Inc.), followed by washing with water and air drying. Then, an
attempt was made to identify their respective N-terminal amino acid
sequences by an automatic Edman method (see Edman et al., (1967)
Eur. J. Biochem. 1, 80) using Procise (registered trademark) cLC
Protein Sequencer Model 492cLC (Applied Biosystems, Inc.).
[0479] As a result, the N-terminal amino acid sequence of the band
corresponding to the heavy chain of the mouse antibody M30 was
EVQLQQSGPE (SEQ ID NO:44 in the Sequence Listing), and the
N-terminal amino acid sequence of the band corresponding to the
light chain thereof was IVLSQSPTILSASP (SEQ ID NO:45 in the
Sequence Listing).
[0480] 6)-2 Preparation of mRNA from Mouse Antibody M30-Producing
Hybridoma
[0481] In order to clone cDNAs encoding each of the heavy chain and
the light chain of the mouse antibody M30, mRNA was prepared from
the mouse antibody M30-producing hybridoma using Quick Prep.TM.
mRNA Purification Kit (GE Healthcare Corporation).
[0482] 6)-3 Cloning of Mouse Antibody M30 cDNA and Determination of
Sequence
[0483] With reference to the findings that the isotypes of the
heavy and light chains of the mouse antibody M30 are .gamma.2a and
.kappa. found in Example 3)-5, and the N-terminal amino acid
sequences of the heavy and light chains determined in Example 1-1),
and the database of the amino acid sequences of antibodies (see
Kabat, E. A. et al., (1991) in Sequences of Proteins of
Immunological Interest Vol. I and II, U.S. Department of Health and
Human Services), several oligonucleotide primers hybridizing to
each of the 5'-terminal region of an antibody gene coding region
and the 3'-terminal region thereof comprising a stop codon were
synthesized, and a cDNA encoding the heavy chain and a cDNA
encoding the light chain were amplified using the mRNA prepared in
Example 6-2) and TaKaRa One Step RNA PCR Kit (AMV) (TaKaRa Bio,
Inc.). As a result, the cDNA encoding the heavy chain of the
antibody and the cDNA encoding the light chain of the antibody
could be amplified by the following primer sets.
TABLE-US-00007 Primer set for the heavy chain Primer 16 (SEQ ID NO:
46 in the Sequence Listing) 5'-aagaattcatggaatggagttggata-3' Primer
17 (SEQ ID NO: 47 in the Sequence Listing)
5'-aagatatctcatttacccggagtccgggagaa-3' Primer set for the light
chain Primer 18 (SEQ ID NO: 48 in the Sequence Listing)
5'-aagaattcatggattttctggtgcag-3' Primer 19 (SEQ ID NO: 49 in the
Sequence Listing) 5'-aagatatcttaacactcattcctgttgaagct-3'
[0484] Each of the cDNA encoding the heavy chain and the cDNA
encoding the light chain amplified by PCR was cloned using
pEF6/V5-His TOPO TA Expression Kit (Invitrogen Corporation), and
each of the nucleotide sequences of the heavy chain and the light
chain cloned was determined using a gene sequence analyzer ("ABI
PRISM 3700 DNA Analyzer; Applied Biosystems" or "Applied Biosystems
3730xl Analyzer; Applied Biosystems"). In the sequencing reaction,
GeneAmp.RTM. 9700 (Applied Biosystems, Inc.) was used.
[0485] The determined nucleotide sequence of the cDNA encoding the
heavy chain of the mouse antibody M30 is represented by SEQ ID
NO:50 in the Sequence Listing, and the amino acid sequence thereof
is represented by SEQ ID NO:51. Further, the sequences of SEQ ID
NOS:50 and 51 are shown in FIG. 21.
[0486] The determined nucleotide sequence of the cDNA encoding the
light chain of the mouse antibody M30 is represented by SEQ ID
NO:52 in the Sequence Listing, and the amino acid sequence thereof
is represented by SEQ ID NO:53 in the Sequence Listing. The
sequences of SEQ ID NOS:52 and 53 are shown in FIG. 22.
[0487] Further, the amino acid sequences of the heavy chain and the
light chain were analyzed by comparison using KabatMan (see
PROTEINS: Structure, Function and Genetics, 25 (1996), 130-133),
which is the database of the amino acid sequences of antibodies. As
a result, it was found that in the heavy chain of the mouse
antibody M30, an amino acid sequence represented by amino acid
numbers 20 to 141 in SEQ ID NO:51 in the Sequence Listing is a
variable region. It was also found that in the light chain of the
mouse antibody M30, an amino acid sequence represented by amino
acid numbers 23 to 130 in SEQ ID NO:53 in the Sequence Listing is a
variable region.
Example 7
Production of Chimeric Antibody M30 (cM30 Antibody)
[0488] 7)-1 Construction of Chimeric and Humanized Light Chain
Expression Vector pEF6KCL
[0489] By performing PCR using a plasmid pEF6/V5-HisB (Invitrogen
Corporation) as a template and also using the following primers, a
DNA fragment from immediately downstream of BGHpA (Sequence
Position: 2174) to SmaI (Sequence Position: 2958) (a DNA fragment
comprising fl origin of replication and SV40 promoter and origin,
hereinafter referred to as "fragment A") was obtained.
TABLE-US-00008 Primer 20 (SEQ ID NO: 54 in the Sequence Listing)
5'-ccacgcgccctgtagcggcgcattaagc-3' Primer 21 (SEQ ID NO: 55 in the
Sequence Listing) 5'-aaacccgggagctttttgcaaaagcctagg-3'
[0490] The obtained fragment A and a DNA fragment (SEQ ID NO:56,
hereinafter referred to as "fragment B", the sequence of SEQ ID
NO:56 is also shown in FIG. 23) comprising a DNA sequence encoding
a human .kappa. chain secretory signal, a human .kappa. chain
constant region, and a human poly-A additional signal were ligated
to each other by overlap extension PCR. The thus obtained DNA
fragment in which the fragment A and the fragment B were ligated to
each other was digested with the restriction enzymes KpnI and SmaI,
which was ligated to a plasmid pEF6/V5-HisB (Invitrogen
Corporation) which was digested with the restriction enzymes KpnI
and SmaI, whereby a chimeric and humanized light chain expression
vector pEF6KCL having a signal sequence, a cloning site, a human
.kappa. chain constant region, and a human poly-A additional signal
sequence downstream of the EF1 promoter was constructed.
[0491] 7)-2 Construction of pEF1KCL
[0492] A DNA fragment obtained by cleaving the pEF6KCL obtained by
the above-described method with the restriction enzymes KpnI and
SmaI was ligated to pEF1/myc-HisB (Invitrogen Corporation) which
was digested with KpnI and SmaI, whereby a plasmid pEF1KCL was
constructed.
[0493] 7)-3 Construction of Chimeric and Humanized Heavy Chain
Expression Vector pEF1FCCU
[0494] A DNA fragment (SEQ ID NO:57, the sequence of SEQ ID NO:57
is also shown in FIG. 24) comprising a DNA sequence encoding amino
acids of a signal sequence and a constant region of human IgG1 was
digested with the restriction enzymes NheI and PmeI and was ligated
to the plasmid pEF1KCL which was digested with NheI and PmeI,
whereby a chimeric and humanized heavy chain expression vector
pEF1FCCU having a signal sequence, a cloning site, a human heavy
chain constant region, and a human poly-A additional signal
sequence downstream of the EF1 promoter was constructed.
[0495] 7)-4 Construction of M30 Chimera-Type Light Chain Expression
Vector
[0496] By using the cDNA encoding the light chain of the mouse
antibody M30 as a template and also using KOD-Plus--(TOYOBO, Co.,
Ltd.) and the following primer set, a region comprising the cDNA
encoding the light chain variable region was amplified. A DNA
fragment obtained by cleaving the amplified product with the
restriction enzymes NdeI and BsiWI was inserted into the universal
chimeric and humanized antibody light chain expression vector
(pEF6KCL) at the site cleaved with the restriction enzymes NdeI and
BsiWI, whereby an M30 chimera-type light chain expression vector
was constructed. The thus obtained expression vector was named
"pEF6KCL/M30L". The nucleotide sequence of the M30 chimera-type
light chain is represented by SEQ ID NO:58 in the Sequence Listing,
and the amino acid sequence thereof is represented by SEQ ID NO:59.
The sequences of SEQ ID NOS:58 and 59 are shown in FIG. 25. A
threonine residue at position 128 in the amino acid sequence of the
cM30 antibody light chain represented by SEQ ID NO:59 in the
Sequence Listing is located in the carboxyl terminus of the light
chain variable region and corresponds to an alanine residue at
position 130 in the amino acid sequence of the M30 antibody light
chain represented by SEQ ID NO:53 in the Sequence Listing, however,
in the amino acid sequence represented by SEQ ID NO:59, the residue
has already been substituted with a threonine residue derived from
a human antibody light chain.
TABLE-US-00009 Primer set for the light chain Primer 22 (SEQ ID NO:
60 in the Sequence Listing)
5'-aaacatatggccaaattgttctctcccagtctccaacaatcc-3' Primer 23 (SEQ ID
NO: 61 in the Sequence Listing)
5'-aaacgtacgtttcagctccagettggtcccagtaccg-3'
[0497] 7)-5 Construction of M30 Chimera-Type Heavy Chain Expression
Vector
[0498] By using the cDNA encoding the heavy chain of the mouse
antibody M30 as a template, a DNA fragment obtained by performing
PCR using KOD-Plus--(TOYOBO, Co., Ltd.) and the following primer
set A was ligated to a DNA fragment obtained by performing PCR
using the following primer set B through overlap extension PCR
using the following primer set C, whereby the BlpI in the variable
region was removed and also a region comprising the cDNA encoding
the heavy chain variable region was amplified. A DNA fragment
obtained by cleaving the amplified product with the restriction
enzyme BlpI was inserted into the universal chimeric and humanized
antibody heavy chain expression vector (pEF1FCCU) at the site
cleaved with the restriction enzyme BlpI, whereby an M30
chimera-type heavy chain expression vector was constructed. The
thus obtained expression vector was named "pEF1FCCU/M30H".
[0499] The nucleotide sequence of the M30 chimera-type heavy chain
is represented by SEQ ID NO:62 in the Sequence Listing, and the
amino acid sequence thereof is represented by SEQ ID NO:63.
Further, the sequences of SEQ ID NOS:62 and 63 are shown in FIG.
26.
TABLE-US-00010 Primer set A Primer 24 (SEQ ID NO: 64 in the
Sequence Listing) 5'-aaagctgagcgaggtccagctgcagcagtctggacctgag-3'
Primer 25 (SEQ ID NO: 65 in the Sequence Listing)
5'-gaggtcaggctgctgagttccatgtaggctgtgctg-3' Primer set B Primer 26
(SEQ ID NO: 66 in the Sequence Listing)
5'-cagcacagcctacatggaactcagcagcctgacctc-3' Primer 27 (SEQ ID NO: 67
in the Sequence Listing)
5'-aaagctgagctgactgtgagagtggtgccttggccccag-3' Primer set C Primer
28 (SEQ ID NO: 68 in the Sequence Listing)
5'-aaagctgagcgaggtccagctgcagcagtctggacctgag-3' Primer 29 (SEQ ID
NO: 69 in the Sequence Listing)
5'-aaagctgagctgactgtgagagtggtgccttggccccag-3'
[0500] 7)-6 Preparation of Chimeric Antibody M30
[0501] 7)-6-1 Production of Chimeric Antibody M30
[0502] 1.2.times.10.sup.9 cells of FreeStyle 293F cells (Invitrogen
Corporation) in the logarithmic growth phase were seeded into 1.2 L
of fresh FreeStyle.TM. 293 Expression Medium (Invitrogen
Corporation) and cultured for 1 hour by shaking at 90 rpm at
37.degree. C. in an 8% CO.sub.2 incubator. 3.6 mg of
polyethyleneimine (Polyscience #24765) was dissolved in 20 ml of
Opti-Pro.TM. SFM medium (Invitrogen Corporation). Subsequently,
pEF1FCCU/M30H (0.4 mg) and pEF6KCL/M30L (0.8 mg) prepared with
PureLink HiPure Plasmid Kit (Invitrogen Corporation) were suspended
in 20 ml of Opti-Pro SFM medium. Then, 20 ml of the obtained
expression vectors/Opti-Pro SFM mixed liquid was added to 20 ml of
the obtained polyethyleneimine/Opti-Pro SFM mixed liquid, and the
resulting mixture was gently stirred and then left for 5 minutes.
Thereafter, the mixture was added to the FreeStyle 293F cells, and
shaking culture at 90 rpm was performed for 7 days at 37.degree. C.
in an 8% CO.sub.2 incubator. The resulting culture supernatant was
filtered through a disposable capsule filter (Advantec
#CCS-045-E1H).
[0503] A chimeric antibody M30 obtained by a combination of
pEF1FCCU/M30H and pEF6KCL/M30L was named "cM30" or "cM30
antibody".
[0504] 7)-6-2 Purification of cM30
[0505] The culture supernatant obtained in Example 7)-6-1 was
purified by a two-step process including rProtein A affinity
chromatography (at 4 to 6.degree. C.) (GE Healthcare Japan
Corporation) and ceramic hydroxyapatite (at room temperature). A
buffer exchange step after the purification by rProtein A affinity
chromatography and after the purification by ceramic hydroxyapatite
was performed at room temperature. First, 1100 to 1200 ml of the
culture supernatant was applied to MabSelect.TM. SuRe.TM.
(manufactured by GE Healthcare Bio-Sciences Corporation, two
HiTrap.TM. columns (volume: 1 ml) connected in series) equilibrated
with PBS. After all culture solution was poured into the column,
the column was washed with 15 to 30 ml of PBS. Subsequently,
elution was performed with a 2 M arginine hydrochloride solution
(pH 4.0), and a fraction containing the antibody was collected. The
fraction was applied to a desalting column (manufactured by GE
Healthcare Bio-Sciences Corporation, two HiTrap desalting columns
(volume: 5 ml) connected in series), whereby the buffer was
exchanged with a buffer containing 5 mM sodium phosphate, 50 mM
MES, and 20 mM NaCl at pH 6.5.
[0506] Further, the antibody solution subjected to buffer exchange
was applied to a ceramic hydroxyapatite column (Japan Bio-Rad
Laboratories, Inc., Bio-Scale.TM. CHT.TM.2-1 hydroxyapatite column
(volume: 2 ml)) equilibrated with a buffer containing 5 mM NaPi, 50
mM MES, and 20 mM NaCl at pH 6.5. Then, linear concentration
gradient elution with sodium chloride was performed, and a fraction
containing the antibody was collected. The fraction was applied to
a desalting column (manufactured by GE Healthcare Bio-Sciences
Corporation, two HiTrap.RTM. Desalting columns (volume: 5 ml)
connected in series), whereby the liquid was exchanged with CBS
(containing 10 mM citrate buffer and 140 mM sodium chloride, pH
6.0).
[0507] Finally, the resulting solution was concentrated using
Centrifugal UF Filter Device VIVASPIN.RTM. 20 (fractional molecular
weight: 30 K, Sartorius Co., Ltd., at 4.degree. C.), and the
concentration of IgG was adjusted to 1.0 mg/ml or more, and the
thus obtained solution was used as a purified sample.
Example 8
Activity of cM30 Antibody
[0508] 8)-1 Binding Activity of cM30 Antibody to B7-H3
[0509] The affinity between the M30 antibody or the cM30 antibody
and the B7-H3 antigen was measured by a surface plasmon resonance
(SPR) device (GE Healthcare Corporation). According to a common
procedure, an anti-mouse IgG or an anti-human IgG antibody was
immobilized on a sensor chip, and then, the M30 antibody sample or
the cM30 antibody was bound thereto. Thereafter, an extracellular
domain polypeptide of a recombinant B7-H3 variant 2 antigen
(manufactured by R&D Systems, Inc., #2318-B3-050/CF) was added
thereto at different concentrations, and the amount of the antigen
bound to the antibody in a running buffer (phosphate buffer, 0.05%
SP20) was measured over time. The measured amount was analyzed with
a dedicated software (BIAevaluation Version 4.1, GE Healthcare
Corporation) and a dissociation constant was calculated.
[0510] As a result, the M30 antibody and the cM30 antibody bound to
the recombinant B7-H3 antigen with a dissociation constant of 5.89
nM and 3.43 nM, respectively. From these results, it was confirmed
that the M30 antibody and the cM30 antibody bind to the B7-H3
antigen and their binding affinities were substantially equal.
[0511] 8)-2 ADCP Activity of cM30 Antibody
[0512] Peripheral blood mononuclear cells (PBMCs) of a healthy
subject were isolated according to common procedures and suspended
in 10% FBS-containing RPMI 1640 (Invitrogen Corporation) and then
seeded in a flask. The cells were cultured overnight in a CO.sub.2
incubator. The culture supernatant was removed, and to the cells
attached to the flask, 10% FBS-containing RPMI 1640 supplemented
with M-CSF and GM-CSF (PeproTech, Inc.) was added, and the cells
were cultured for 2 weeks. The cells were detached with TrypLE and
collected. Then, the cells were added to a 24-well plate at 500
.mu.l/well (1.times.10.sup.5 cells/well) and cultured overnight at
37.degree. C. The thus prepared cells were used as effector
cells.
[0513] The labeling of NCI-H322 cells to be used as target cells
was performed using PKH26 dye labeling kit (Sigma Co., Ltd.) The
target cells were detached with TrypLE and washed twice with PBS.
The cells were suspended in Diluent C at 1.times.10.sup.7 cells/ml.
PKH26 dye stock (1 mM) was diluted to 8 .mu.M with Diluent C, and
immediately thereafter, the diluted dye solution was added thereto
in an amount equal to that of the cell suspension. The resulting
mixture was left at room temperature for 5 minutes. Then, 1 ml of
serum was added thereto, and further, a medium with serum was added
thereto, and washing was performed twice.
[0514] Each of the M30 antibody and the cM30 antibody was diluted
to 20 .mu.g/ml with a culture solution. Subsequently, the target
cells were dispensed at 2.times.10.sup.6 cells/100 .mu.l/tube and
mixed. The resulting mixture was left to stand on ice for 30
minutes. The supernatant was removed, and the cells were washed
twice with a culture solution and suspended in 500 .mu.l of a
culture solution. The supernatant was removed from the effector
cells, and the cells having been treated with the antibody and
suspended in the culture solution were added thereto and mixed
therewith. Then, the cells were cultured for 3 hours in a CO.sub.2
incubator. Thereafter, the cells were detached with Trypsin-EDTA
and collected. To the collected cells, an FITC-labeled anti-mouse
CD11b antibody (Becton, Dickinson and Company, Ltd.) was added, and
the resulting mixture was left to stand on ice for 30 minutes. The
supernatant was removed, and the cells were washed twice with a
culture solution. The collected cells were suspended in 300 .mu.l
of a culture medium and analyzed by FACS Calibur (Becton, Dickinson
and Company, Ltd.). In the CD11b-positive macrophages, a
PKH26-positive fraction was evaluated as phagocytosis-positive
cells.
[0515] As a result, as shown in FIG. 8, when the M30 antibody and
the cM30 antibody were added at 10 .mu.g/ml, the phagocytosis of
the NCI-H322 cells by macrophages was induced to 33.+-.1% and
35.+-.2%, respectively. Accordingly, it was shown that the cM30
antibody has an ADCP activity against the NCI-H322 cells in the
same manner as the M30 antibody. A similar experimental result was
obtained also for an ADCP activity against MDA-MB-231 cells
(ATCC).
[0516] 8)-3 In Vivo Antitumor Effect of cM30 Antibody
[0517] MDA-MB-231 cells were detached from a culture flask by a
trypsin treatment, and then suspended in 10% FBS-containing RPMI
1640 medium (Invitrogen Corporation), followed by centrifugation
and the supernatant was removed. The cells were washed twice with
the same medium, and then suspended in BD Matrigel.TM. Basement
Membrane Matrix (manufactured by BD Biosciences, Inc.). Then, the
cells were implanted subcutaneously in the axillary region of each
mouse (CB17/Icr-Prkdc[scid]/CrlCrlj, Charles River Laboratories
Japan, Inc.) at 6 weeks of age at a dose of 5.times.10.sup.6
cells/mouse. The day of implantation was taken as day 0, and on
days 14, 21, 28, 35, and 42, the M30 antibody or the cM30 antibody
was intraperitoneally administrated at a dose of 500 .mu.s/mouse
(about 25 mg/kg). The tumor volume was measured on days 14, 18, 21,
25, 28, 32, 35, 39, 42, 46, 49, and 52, and the antitumor effect of
the administration of the antibody was examined.
[0518] As a result, in the M30 and cM30 antibody administration
groups, the tumor growth was significantly suppressed as compared
with the untreated group in which the antibody was not
administrated. The P values for the M30 antibody and the cM30
antibody compared with the untreated group in terms of the tumor
weight on day 52 were both P<0.001. The P values were calculated
using Dunnett's multiple comparison test.
[0519] Further, the tumor growth inhibition ratio (=100-(average
tumor volume in antibody administration group)/(average tumor
volume in untreated group).times.100) on day 52 was 71.3% in the
case of the M30 antibody and 71.7% in the case of the cM30
antibody. Accordingly, the cM30 antibody was observed to have a
very strong antitumor effect in vivo in the same manner as the M30
antibody (FIG. 9).
Example 9
Designing of Humanized Antibody of Mouse Anti-Human B7-H3 Antibody
#M30
[0520] 9)-1 Designing of Humanized M30 Antibody
[0521] 9)-1-1 Molecular Modeling of M30 Variable Regions
[0522] The molecular modeling of the M30 variable regions was
performed according to a method generally known as homology
modeling (Methods in Enzymology, 203, 121-153, (1991)). The primary
sequences (three-dimensional structures derived from the X-ray
crystal structures are available) of the variable regions of human
immunoglobulin registered in Protein Data Bank (Nucl. Acid Res.
(2007) 35, pp. D301-D303) were compared with the M30 variable
regions determined in Example 6-3).
[0523] As a result, 3BKY was selected as a sequence having the
highest sequence homology with the M30 light chain variable region
among the antibodies which similarly have a deletion in the
framework. Further, 3DGG was selected as a sequence having the
highest sequence homology with the M30 heavy chain variable
region.
[0524] The three-dimensional structure of a framework region was
prepared based on a "framework model" by combining the coordinates
of 3BKY corresponding to the M30 light chain with the coordinates
of 3DGG corresponding to the M30 heavy chain. As for the M30 CDRs,
as the coordinates defining the conformations most similar to those
of CDRH1 (SEQ ID NO:92), CDRH2 (SEQ ID NO:93), CDRH3 (SEQ ID
NO:94), CDRL1 (SEQ ID NO:95), CDRL2 (SEQ ID NO:96), and CDRL3 (SEQ
ID NO:97) according to the classification of Thornton et al. (J.
Mol. Biol., 263, 800-815, (1996)) and the H3 rules (FEBS Letters
(1996) 399, pp. 1-8), 2HOJ, 1BBD, 1Q9O, 2FBJ, 1LNK, and 1TET were
selected, respectively, and incorporated in the framework
model.
[0525] Finally, in order to obtain a possible molecular model of
the M30 variable region in terms of energy, an energy calculation
was performed for excluding disadvantageous interatomic contact.
The above procedure was carried out using commercially available
protein tertiary structure prediction program Prime and coordinate
search program MacroModel (Schrodinger, LLC).
[0526] 9)-1-2 Designing of Amino Acid Sequence of Humanized M30
[0527] A humanized M30 antibody was constructed according to a
method generally known as CDR grafting (Proc. Natl. Acad. Sci. USA
(1989) 86, pp. 10029-10033).
[0528] An acceptor antibody was selected based on the amino acid
homology within the framework region. The sequence of the framework
region of M30 was compared with all human framework sequences in
the Kabat Database (Nucl. Acid Res. (2001) 29, pp. 205-206) of
antibody amino acid sequences. As a result, a mAb49'CL antibody
(GenBank in NCBI: D16838.1 and D16837.1) was selected as an
acceptor based on a sequence homology of 70% in the framework
region.
[0529] The amino acid residues in the framework region of mAb49'CL
were aligned with the amino acid residues of M30, and the positions
where different amino acids were used were identified. The
positions of these residues were analyzed using the
three-dimensional model of M30 constructed above. Then, donor
residues to be grafted onto the acceptor were selected according to
the criteria provided by Queen et al. (Proc. Natl. Acad. Sci. USA
(1989) 86, pp. 10029-10033). By transferring some selected donor
residues to the acceptor antibody, humanized M30 antibody sequences
were constructed as described in the following Example.
[0530] 9)-2 Humanization of M30 Heavy Chain
[0531] 9)-2-1 M30-H1-Type Heavy Chain:
[0532] A humanized M30 heavy chain designed by substituting amino
acid numbers 20 (glutamic acid), 24 (glutamine), 28 (proline), 30
(leucine), 31 (valine), 35 (alanine), 39 (methionine), 57 (lysine),
59 (lysine), 67 (isoleucine), 86 (lysine), 87 (alanine), 89
(glutamine), 91 (serine), 93 (lysine), 95 (serine), 106
(threonine), 110 (serine), 136 (threonine), and 137 (leucine) of
the cM30 heavy chain represented by SEQ ID NO:63 in the Sequence
Listing with glutamine, valine, alanine, valine, lysine, serine,
valine, arginine, alanine, methionine, arginine, valine,
isoleucine, alanine, glutamic acid, threonine, arginine, threonine,
leucine, and valine, respectively, was named "M30-H1-type heavy
chain".
[0533] The amino acid sequence of the M30-H1-type heavy chain is
represented by SEQ ID NO:85.
[0534] 9)-2-2 M30-H2-Type Heavy Chain:
[0535] A humanized M30 heavy chain designed by substituting amino
acid numbers 20 (glutamic acid), 24 (glutamine), 28 (proline), 30
(leucine), 31 (valine), 35 (alanine), 39 (methionine), 57 (lysine),
59 (lysine), 86 (lysine), 87 (alanine), 89 (glutamine), 91
(serine), 93 (lysine), 95 (serine), 106 (threonine), 110 (serine),
136 (threonine), and 137 (leucine) of the cM30 heavy chain
represented by SEQ ID NO:63 in the Sequence Listing with glutamine,
valine, alanine, valine, lysine, serine, valine, arginine, alanine,
arginine, valine, isoleucine, alanine, glutamic acid, threonine,
arginine, threonine, leucine, and valine, respectively, was named
"M30-H2-type heavy chain".
[0536] The amino acid sequence of the M30-H2-type heavy chain is
represented by SEQ ID NO:87.
[0537] 9)-2-3 M30-H3-Type Heavy Chain:
[0538] A humanized M30 heavy chain designed by substituting amino
acid numbers 24 (glutamine), 28 (proline), 30 (leucine), 31
(valine), 35 (alanine), 39 (methionine), 59 (lysine), 89
(glutamine), 91 (serine), 93 (lysine), 95 (serine), 106
(threonine), 110 (serine), 136 (threonine), and 137 (leucine) of
the cM30 heavy chain represented by SEQ ID NO:63 in the Sequence
Listing with valine, alanine, valine, lysine, serine, valine,
alanine, isoleucine, alanine, glutamic acid, threonine, arginine,
threonine, leucine, and valine, respectively, was named
"M30-H3-type heavy chain".
[0539] The amino acid sequence of the M30-H3-type heavy chain is
represented by SEQ ID NO:89.
[0540] 9)-2-4 M30-H4-Type Heavy Chain:
[0541] A humanized M30 heavy chain designed by substituting amino
acid numbers 24 (glutamine), 28 (proline), 30 (leucine), 31
(valine), 35 (alanine), 39 (methionine), 59 (lysine), 95 (serine),
106 (threonine), 110 (serine), 136 (threonine), and 137 (leucine)
of the cM30 heavy chain represented by SEQ ID NO:63 in the Sequence
Listing with valine, alanine, valine, lysine, serine, valine,
alanine, threonine, arginine, threonine, leucine, and valine,
respectively, was named "M30-H4-type heavy chain".
[0542] The amino acid sequence of the M30-H4-type heavy chain is
represented by SEQ ID NO:91.
[0543] 9)-3 Humanization of M30 Light Chain
[0544] 9)-3-1 M30-L1-Type Light Chain:
[0545] A humanized M30 light chain designed by substituting amino
acid numbers 21 (glutamine), 25 (serine), 29 (threonine), 30
(isoleucine), 33 (alanine), 38 (lysine), 39 (valine), 41
(methionine), 42 (threonine), 61 (serine), 62 (serine), 64
(lysine), 65 (proline), 66 (tryptophan), 77 (valine), 89 (serine),
90 (tyrosine), 91 (serine), 97 (valine), 99 (alanine), 102
(alanine), 104 (threonine), 119 (threonine), 123 (leucine), and 125
(leucine) of the cM30 light chain represented by SEQ ID NO:59 in
the Sequence Listing with glutamic acid, threonine, alanine,
threonine, leucine, arginine, alanine, leucine, serine, glutamine,
alanine, arginine, leucine, leucine, isoleucine, aspartic acid,
phenylalanine, threonine, leucine, proline, phenylalanine, valine,
glutamine, valine, and isoleucine, respectively, was named
"M30-L1-type light chain".
[0546] The amino acid sequence of the M30-L1-type light chain is
represented by SEQ ID NO:71.
[0547] 9)-3-2 M30-L2-Type Light Chain:
[0548] A humanized M30 light chain designed by substituting amino
acid numbers 21 (glutamine), 25 (serine), 29 (threonine), 30
(isoleucine), 33 (alanine), 38 (lysine), 39 (valine), 41
(methionine), 42 (threonine), 61 (serine), 62 (serine), 64
(lysine), 65 (proline), 77 (valine), 89 (serine), 91 (serine), 97
(valine), 99 (alanine), 102 (alanine), 104 (threonine), 119
(threonine), 123 (leucine), and 125 (leucine) of the cM30 light
chain represented by SEQ ID NO:59 in the Sequence Listing with
glutamic acid, threonine, alanine, threonine, leucine, arginine,
alanine, leucine, serine, glutamine, alanine, arginine, leucine,
isoleucine, aspartic acid, threonine, leucine, proline,
phenylalanine, valine, glutamine, valine, and isoleucine,
respectively, was named "M30-L2-type light chain".
[0549] The amino acid sequence of the M30-L2-type light chain is
represented by SEQ ID NO:73.
[0550] 9)-3-3 M30-L3-Type Light Chain:
[0551] A humanized M30 light chain designed by substituting amino
acid numbers 29 (threonine), 30 (isoleucine), 33 (alanine), 38
(lysine), 39 (valine), 41 (methionine), 62 (serine), 65 (proline),
77 (valine), 91 (serine), 97 (valine), 99 (alanine), 102 (alanine),
104 (threonine), 119 (threonine), 123 (leucine), and 125 (leucine)
of the cM30 light chain represented by SEQ ID NO:59 in the Sequence
Listing with alanine, threonine, leucine, arginine, alanine,
leucine, alanine, leucine, isoleucine, threonine, leucine, proline,
phenylalanine, valine, glutamine, valine, and isoleucine,
respectively, was named "M30-L3-type light chain".
[0552] The amino acid sequence of the M30-L3-type light chain is
represented by SEQ ID NO:75.
[0553] 9)-3-4 M30-L4-Type Light Chain:
[0554] A humanized M30 light chain designed by substituting amino
acid numbers 21 (glutamine), 25 (serine), 29 (threonine), 30
(isoleucine), 33 (alanine), 38 (lysine), 39 (valine), 41
(methionine), 42 (threonine), 61 (serine), 62 (serine), 64
(lysine), 66 (tryptophan), 77 (valine), 89 (serine), 90 (tyrosine),
91 (serine), 96 (arginine), 97 (valine), 99 (alanine), 102
(alanine), 104 (threonine), 119 (threonine), 123 (leucine), and 125
(leucine) of the cM30 light chain represented by SEQ ID NO:59 in
the Sequence Listing with glutamic acid, threonine, alanine,
threonine, leucine, arginine, alanine, leucine, serine, glutamine,
alanine, arginine, leucine, isoleucine, aspartic acid,
phenylalanine, threonine, serine, leucine, proline, phenylalanine,
valine, glutamine, valine, and isoleucine, respectively, was named
"M30-L4-type light chain".
[0555] The amino acid sequence of the M30-L4-type light chain is
represented by SEQ ID NO:77.
[0556] 9)-3-5 M30-L5-Type Light Chain:
[0557] A humanized M30 light chain designed by substituting amino
acid numbers 29 (threonine), 30 (isoleucine), 33 (alanine), 38
(lysine), 39 (valine), 41 (methionine), 62 (serine), 77 (valine),
91 (serine), 97 (valine), 99 (alanine), 102 (alanine), 104
(threonine), 119 (threonine), 123 (leucine), and 125 (leucine) of
the cM30 light chain represented by SEQ ID NO:59 in the Sequence
Listing with alanine, threonine, leucine, arginine, alanine,
leucine, alanine, isoleucine, threonine, leucine, proline,
phenylalanine, valine, glutamine, valine, and isoleucine,
respectively, was named "M30-L5-type light chain".
[0558] The amino acid sequence of the M30-L5-type light chain is
represented by SEQ ID NO:79.
[0559] 9)-3-6 M30-L6-Type Light Chain:
[0560] A humanized M30 light chain designed by substituting amino
acid numbers 21 (glutamine), 25 (serine), 29 (threonine), 30
(isoleucine), 33 (alanine), 38 (lysine), 39 (valine), 41
(methionine), 42 (threonine), 61 (serine), 62 (serine), 64
(lysine), 66 (tryptophan), 77 (valine), 89 (serine), 90 (tyrosine),
91 (serine), 97 (valine), 99 (alanine), 102 (alanine), 104
(threonine), 119 (threonine), 123 (leucine), and 125 (leucine) of
the cM30 light chain represented by SEQ ID NO:59 in the Sequence
Listing with glutamic acid, threonine, alanine, threonine, leucine,
arginine, alanine, leucine, serine, glutamine, alanine, arginine,
leucine, isoleucine, aspartic acid, phenylalanine, threonine,
leucine, proline, phenylalanine, valine, glutamine, valine, and
isoleucine, respectively, was named "M30-L6-type light chain".
[0561] The amino acid sequence of the M30-L6-type light chain is
represented by SEQ ID NO:81.
[0562] 9)-3-7 M30-L7-Type Light Chain:
[0563] A humanized M30 light chain designed by substituting amino
acid numbers 21 (glutamine), 25 (serine), 29 (threonine), 30
(isoleucine), 33 (alanine), 38 (lysine), 39 (valine), 41
(methionine), 42 (threonine), 61 (serine), 62 (serine), 64
(lysine), 66 (tryptophan), 77 (valine), 89 (serine), 91 (serine),
97 (valine), 99 (alanine), 102 (alanine), 104 (threonine), 119
(threonine), 123 (leucine), and 125 (leucine) of the cM30 light
chain represented by SEQ ID NO:59 in the Sequence Listing with
glutamic acid, threonine, alanine, threonine, leucine, arginine,
alanine, leucine, serine, glutamine, alanine, arginine, leucine,
isoleucine, aspartic acid, threonine, leucine, proline,
phenylalanine, valine, glutamine, valine, and isoleucine,
respectively, was named "M30-L7-type light chain".
[0564] The amino acid sequence of the M30-L7-type light chain is
represented by SEQ ID NO:83.
Example 10
Production of Humanized Antibody
[0565] 10)-1 Construction of M30-L1, M30-L2, M30-L3, M30-L4,
M30-L5, M30-L6, and M30-L7-Type Light Chain Expression Vectors
[0566] DNAs comprising a gene encoding an M30-L1, M30-L2, M30-L3,
M30-L4, M30-L5, M30-L6, or M30-L7-type light chain variable region
represented by amino acid numbers 21 to 128 in SEQ ID NO:71, amino
acid numbers 21 to 128 in SEQ ID NO:73, amino acid numbers 21 to
128 in SEQ ID NO:75, amino acid numbers 21 to 128 in SEQ ID NO:77,
amino acid numbers 21 to 128 in SEQ ID NO:79, amino acid numbers 21
to 128 in SEQ ID NO:81, or amino acid numbers 21 to 128 in SEQ ID
NO:83 in the Sequence Listing were synthesized (GENEART, Inc.
Artificial Gene Synthesis Service) based on SEQ ID NOS:70, 72, 74,
76, 78, 80, and 82 according to the nucleotide sequences
corresponding to the above SEQ ID NOS according to the amino acid
sequences. Then, each of the DNA fragments obtained by cleaving the
synthesized DNAs with the restriction enzymes NdeI and BsiWI was
inserted into the universal chimeric and humanized antibody light
chain expression vector (pEF6KCL) at the site cleaved with the
restriction enzymes NdeI and BsiWI, whereby M30-L1, M30-L2, M30-L3,
M30-L4, M30-L5, M30-L6, and M30-L7-type light chain expression
vectors were constructed.
[0567] The thus obtained expression vectors were named
"pEF6KCL/M30-L1", "pEF6KCL/M30-L2", "pEF6KCL/M30-L3",
"pEF6KCL/M30-L4", "pEF6KCL/M30-L5", "pEF6KCL/M30-L6", and
"pEF6KCL/M30-L7", respectively.
[0568] 10)-2 Construction of M30-H1, M30-H2, M30-H3, and
M30-H4-Type Heavy Chain Expression Vectors
[0569] DNAs comprising a gene encoding an M30-H1, M30-H2, M30-H3,
or M30-H4-type heavy chain variable region represented by amino
acid numbers 20 to 141 in SEQ ID NO: 85, amino acid numbers 20 to
141 in SEQ ID NO: 87, amino acid numbers 20 to 141 in SEQ ID NO:
89, or amino acid numbers 20 to 141 in SEQ ID NO: 91 in the
Sequence Listing were synthesized (GENEART, Inc. Artificial Gene
Synthesis Service) based on SEQ ID NO: 84, 86, 88, and 90 according
to the nucleotide sequences corresponding to the above SEQ ID NOS
according to the amino acid sequences. Then, each of the DNA
fragments obtained by cleaving the synthesized DNAs with the
restriction enzyme BlpI was inserted into the universal humanized
antibody heavy chain expression vector (pEF1FCCU) at the site
cleaved with the restriction enzyme BlpI, whereby M30-H1, M30-H2,
M30-H3, and M30-H4-type heavy chain expression vectors were
constructed.
[0570] The thus obtained expression vectors were named
"pEF1FCCU/M30-H1", "pEF1FCCU/M30-H2", "pEF1FCCU/M30-H3", and
"pEF1FCCU/M30-H4", respectively.
[0571] 10)-3 Production of Humanized Antibody
[0572] 1.2.times.10.sup.9 cells of FreeStyle.TM. 293F cells
(Invitrogen Corporation) in the logarithmic growth phase were
seeded into 1.2 L of fresh FreeStyle 293 Expression Medium
(Invitrogen Corporation) and cultured for 1 hour by shaking at 90
rpm at 37.degree. C. in an 8% CO.sub.2 incubator. 3.6 mg of
polyethyleneimine (Polyscience #24765) was dissolved in 20 ml of
Opti-Pro.TM. SFM medium (Invitrogen Corporation). Subsequently, a
heavy chain expression vector (0.4 mg) and a light chain expression
vector (0.8 mg) prepared with PureLink.RTM. HiPure Plasmid Kit
(Invitrogen Corporation) were suspended in 20 ml of Opti-Pro SFM
medium. Then, 20 ml of the obtained expression vectors/Opti-Pro SFM
mixed liquid was added to 20 ml of the obtained
polyethyleneimine/Opti-Pro SFM mixed liquid, and the resulting
mixture was gently stirred and then left for 5 minutes. Thereafter,
the mixture was added to the FreeStyle 293F cells, and shaking
culture at 90 rpm was performed for 7 days at 37.degree. C. in an
8% CO.sub.2 incubator. The resulting culture supernatant was
filtered through a disposable capsule filter (Advantec
#CCS-045-E1H).
[0573] A humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H1 and pEF6KCL/M30-L1 was named "M30-H1-L1", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H1 and pEF6KCL/M30-L2 was named "M30-H1-L2", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H1 and pEF6KCL/M30-L3 was named "M30-H1-L3", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H1 and pEF6KCL/M30-L4 was named "M30-H1-L4", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H4 and pEF6KCL/M30-L1 was named "M30-H4-L1", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H4 and pEF6KCL/M30-L2 was named "M30-H4-L2", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H4 and pEF6KCL/M30-L3 was named "M30-H4-L3", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H4 and pEF6KCL/M30-L4 was named "M30-H4-L4", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H1 and pEF6KCL/M30-L5 was named "M30-H1-L5", a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H1 and pEF6KCL/M30-L6 was named "M30-H1-L6", and a
humanized antibody of M30 obtained by a combination of
pEF1FCCU/M30-H1 and pEF6KCL/M30-L7 was named "M30-H1-L7".
[0574] 10)-4 Purification of Humanized Antibody
[0575] The culture supernatant obtained in Example 10)-3 was
purified by a two-step process including rProtein A affinity
chromatography (at 4 to 6.degree. C.) and ceramic hydroxyapatite
(at room temperature). A buffer exchange step after the
purification by rProtein A affinity chromatography and after the
purification by ceramic hydroxyapatite was performed at room
temperature.
[0576] First, 1100 to 1200 ml of the culture supernatant was
applied to MabSelect.TM. SuRe.TM. (manufactured by GE Healthcare
Bio-Sciences Co., Ltd., two HiTrap.RTM. columns (volume: 1 ml)
connected in series) equilibrated with PBS. After all culture
solution was poured into the column, the column was washed with 15
to 30 ml of PBS. Subsequently, elution was performed with a 2 M
arginine hydrochloride solution (pH 4.0), and a fraction containing
the antibody was collected. The fraction was applied to a desalting
column (manufactured by GE Healthcare Bio-Sciences Co., Ltd., two
HiTrap desalting columns (volume: 5 ml) connected in series),
whereby the buffer was exchanged with a buffer containing 5 mM
sodium phosphate, 50 mM MES, and 20 mM NaCl at pH 6.5.
[0577] Further, the antibody solution subjected to buffer exchange
was applied to a ceramic hydroxyapatite column (Japan Bio-Rad
Laboratories, Inc., Bio-Scale.TM. CHT.TM.2-1 hydroxyapatite column
(volume: 2 ml)) equilibrated with a buffer containing 5 mM NaPi, 50
mM MES, and 20 mM NaCl at pH 6.5. Then, linear concentration
gradient elution with sodium chloride was performed, and a fraction
containing the antibody was collected.
[0578] The fraction was applied to a desalting column (manufactured
by GE Healthcare Bio-Sciences Co., Ltd., two HiTrap desalting
columns (volume: 5 ml) connected in series), whereby the liquid was
exchanged with CBS (containing 10 mM citrate buffer and 140 mM
sodium chloride, pH 6.0).
[0579] Finally, the resulting solution was concentrated using
Centrifugal UF Filter Device VIVASPIN 20 (fractional molecular
weight: 30 K, Sartorius Co., Ltd., at 4.degree. C.), and the
concentration of IgG was adjusted to 1.0 mg/ml or more, and the
thus obtained solution was used as a purified sample.
[0580] 10)-5 Binding Property of Humanized Antibody to B7-H3
Antigen
[0581] The binding property of the humanized M30 antibody to human
B7-H3 which is an antigen was measured by a surface plasmon
resonance (SPR) device (Biacore, Inc.). According to a common
procedure, an anti-human IgG antibody was immobilized on a sensor
chip, and then, each of the purified samples of the humanized M30
antibodies obtained in the above 10)-4 was bound thereto.
Thereafter, an extracellular domain polypeptide of the B7-H3
variant 2 antigen (manufactured by R&D Systems, Inc.,
#2318-B3-050/CF) was added thereto at different concentrations, and
the amount of the antigen bound to the antibody in a running buffer
(phosphate buffer, 0.05% SP20) was measured over time. The measured
amount was analyzed with a dedicated software (BIAevaluation) and a
dissociation constant (Kd [M]) was calculated. The measurement was
performed using the cM30 antibody as a positive control for each
measurement operation. The results are as shown in Table 3. All of
the humanized M30 antibodies had a binding activity against the
B7-H3 antigen.
TABLE-US-00011 TABLE 3 Kd [M] M30-H1-L1 8.7E-08 M30-H1-L2 1.0E-07
M30-H1-L3 1.0E-07 M30-H1-L4 1.6E-08 M30-H4-L1 1.3E-07 M30-H4-L2
1.4E-07 M30-H4-L3 1.6E-07 M30-H4-L4 1.2E-08 M30-H1-L5 1.9E-09
M30-H1-L6 3.4E-09 M30-H1-L7 2.7E-09 cM30 7.3E-10
Example 11
Measurement of Competitive Inhibitory Activities of cM30 Antibody
and Humanized M30 Antibody Against M30 Antibody for the Binding to
B7-H3 Antigen
[0582] The competitive inhibitory activities of the cM30 antibody
and the humanized M30 antibody (M30-H1-L4 antibody) against the M30
antibody for the binding to the B7-H3 variant 1 and variant 2 were
measured by the following method.
[0583] By using EZ-Link.RTM. Sulfo-NHS-LC Biotinylation Kit
(manufactured by Thermo Scientific Corporation, #21435) and
according to the attached protocol, the respective mouse monoclonal
antibodies M30 were biotinylated (hereinafter the respective
biotinylated M30 antibodies were referred to as "bM30"). Further,
as a buffer to be used in the following ELISA method, BD OPTEIA (BD
Biosciences, Inc., #550536) was used in all cases.
[0584] Each of the extracellular domain polypeptide of the B7-H3
variant 1 (manufactured by R&D Systems, Inc., #1949-B3-050/CF)
and the extracellular domain polypeptide of the B7-H3 variant 2
(manufactured by R&D Systems, Inc., #2318-B3-050/CF) was
diluted to 0.5 .mu.g/ml with a coating buffer and the resulting
solution was dispensed at 100 .mu.L/well in an immunoplate
(manufactured by Nunc, Inc., #442404). Then, the plate was left to
stand overnight at 4.degree. C., whereby the protein was adsorbed
to the plate. On the next day, an assay diluent was dispensed at
200 .mu.L/well, and the plate was left to stand at room temperature
for 4 hours.
[0585] After the solution in each well was removed, a mixed
solution of the biotinylated antibody at 5 .mu.g/ml and an
unlabeled antibody at each concentration (0 .mu.g/ml, 1 .mu.g/ml, 5
.mu.g/ml, 25 .mu.g/ml, 50 .mu.g/ml, or 125 .mu.g/ml) was dispensed
at 100 .mu.l/well in an assay diluent, and the plate was left to
stand at room temperature for 1 hour.
[0586] After each well was washed twice with a wash buffer, a
streptavidin-horseradish peroxidase conjugate (manufactured by GE
Healthcare Bio-Sciences Corporation, #RPN1231V) diluted to 500-fold
with an assay diluent was added at 100 .mu.l/well, and the plate
was left to stand at room temperature for 1 hour.
[0587] After the solution in each well was removed and each well
was washed twice with a wash buffer, a substrate solution was added
at 100 .mu.L/well, and a color development reaction was allowed to
proceed while stirring the reaction mixture. After completion of
the color development, a blocking buffer was added thereto at 100
.mu.l/well to stop the color development reaction. Then, an
absorbance at 450 nm was measured using a plate reader.
[0588] As a result, the absorbance of the well to which only bM30
was added was 2.36.+-.0.05 (mean.+-.standard deviation (n=12)) in
the plate to which the polypeptide of the extracellular domain of
the B7-H3 variant 1 was attached, and 1.90.+-.0.20
(mean.+-.standard deviation (n=12)) in the plate to which the
polypeptide of the extracellular domain of the B7-H3 variant 2 was
attached.
[0589] The absorbances in the graphs of FIG. 10 are each expressed
as a mean.+-.standard deviation (n=3). The control IgG did not
inhibit the binding of bM30 to B7-H3.
[0590] On the other hand, it was shown that the binding of bM30 to
B7-H3 is inhibited by the M30 antibody itself, the cM30 antibody,
which is a chimeric antibody of the M30 antibody, and the
M30-H1-L4, which is a humanized antibody, in both of the plate to
which the polypeptide of the extracellular domain of the B7-H3
variant 1 was attached and the plate to which the polypeptide of
the extracellular domain of the B7-H3 variant 2 was attached.
[0591] That is, it was shown that the cM30 antibody and the
humanized antibody (M30-H1-L4 antibody) recognize the same epitope
of the B7-H3 antigen as the M30 antibody.
Example 12
Activity of Humanized M30 Antibody
[0592] 12)-1 ADCP Activity of Humanized M30 Antibody
[0593] PBMCs of a healthy subject were isolated according to a
common procedure and suspended in 10% FBS-containing RPMI 1640 and
then seeded in a flask. The cells were cultured overnight in a
CO.sub.2 incubator. The culture supernatant was removed, and to the
cells attached to the flask, 10% FBS-containing RPMI 1640
supplemented with M-CSF and GM-CSF (PeproTech, Inc.) was added, and
the cells were cultured for 2 weeks. The cells were detached with
TrypLE and collected. Then, the cells were added to a 24-well plate
at 500 .mu.l/well (1.times.10.sup.5 cells/well) and cultured
overnight at 37.degree. C. The thus prepared cells were used as
effector cells.
[0594] The labeling of NCI-H322 cells to be used as target cells
was performed using PKH26 dye labeling kit (Sigma Co., Ltd.) The
target cells were detached with TrypLE and washed twice with PBS.
The cells were suspended in Diluent C at 1.times.10.sup.7 cells/ml.
PKH26 dye stock (1 mM) was diluted to 8 .mu.M with Diluent C, and
immediately thereafter, the diluted dye solution was added thereto
in an amount equal to that of the cell suspension. The resulting
mixture was left at room temperature for 5 minutes. Then, 1 ml of
serum was added thereto, and further, a medium with serum was added
thereto, and washing was performed twice.
[0595] Each of the M30 antibody, the cM30 antibody, and the
humanized M30 antibody (M30-H1-L4 antibody) was diluted to 20
.mu.g/ml with 10% FBS-containing RPMI 1640 (Invitrogen
Corporation). Subsequently, the target cells (NCI-H322 cells) were
dispensed at 2.times.10.sup.6 cells/100 .mu.l/tube and mixed. The
resulting mixture was left to stand on ice for 30 minutes. The
supernatant was removed, and the cells were washed twice with a
culture solution and suspended in 500 .mu.l of a culture
solution.
[0596] The supernatant was removed from the effector cells, and the
cells having been treated with the M30 antibody, the cM30 antibody,
or the humanized M30 antibody (M30-H1-L4 antibody) and suspended in
the culture solution were added thereto and mixed therewith. Then,
the cells were cultured for 3 hours in a CO.sub.2 incubator.
[0597] Thereafter, the cells were detached with Trypsin-EDTA and
collected.
[0598] To the collected cells, an FITC-labeled anti-mouse CD11b
antibody (Becton, Dickinson and Company, Ltd.) was added, and the
resulting mixture was left to stand on ice for 30 minutes.
[0599] The supernatant was removed, and the cells were washed twice
with a culture solution.
[0600] The collected cells were suspended in 300 .mu.l of a culture
medium and analyzed by FACS Calibur (Becton, Dickinson and Company,
Ltd.). In the CD11b-positive macrophages, a PKH26-positive fraction
was evaluated as phagocytosis-positive cells.
[0601] The results are shown in FIG. 11.
[0602] In the group with the addition of the humanized M30 antibody
(M30-H1-L4 antibody), an ADCP activity against the NCI-H322 cells
was observed in the same manner as in the groups with the addition
of the M30 antibody or the cM30 antibody.
[0603] 12)-2 ADCC Activity of Humanized M30 Antibody
[0604] PBMCs of a healthy subject were isolated according to a
common procedure and suspended in 10% FBS-containing RPMI 1640 and
then seeded in a flask. The cells were cultured overnight in a
CO.sub.2 incubator.
[0605] The floating cells were collected, followed by a washing
procedure, and the resulting cells were used as peripheral blood
lymphocytes (PBLs). The obtained PBLs were suspended in phenol
red-free RPMI 1640 (manufactured by Invitrogen Corporation)
containing 10% Fetal Bovine Serum (manufactured by Invitrogen
Corporation) (hereinafter abbreviated as "ADCC medium"), and the
cell suspension was passed through a cell strainer (pore size: 40
.mu.m, manufactured by BD Biosciences, Ltd.). Then, the viable
cells were counted by a trypan blue dye exclusion assay. After the
PBLs suspension was centrifuged, the medium was removed, and the
cells were resuspended in the ADCC medium at a viable cell density
of 2.5.times.10.sup.6 cells/ml and used as effector cells.
[0606] NCI-H322 cells were treated with trypsin, and the treated
cells were washed with 10% FBS-containing RPMI 1640 and then
resuspended in 10% FBS-containing RPMI 1640. The cells
(4.times.10.sup.6 cells) were mixed with chromium-51 (5550 kBq)
sterilized through a 0.22 .mu.m filter, and labeling was performed
for 1 hour under the conditions of 37.degree. C. and 5% CO.sub.2.
The labeled cells were washed three times with the ADCC medium, and
the cells were resuspended at 2.times.10.sup.5 cells/ml in the ADCC
medium and used as target cells.
[0607] The target cells at a cell density of 2.times.10.sup.5
cells/ml were dispensed at 50 .mu.l/well in a 96-well U-shaped
bottom microplate. Thereto was added 50 .mu.l of each of the cM30
antibody and the humanized M30 antibodies (M30-H1-L4, M30-H4-L4,
M30-H1-L5, M30-H1-L6, and M30-H1-L7) diluted with the ADCC medium
so that the final concentration of the antibody after adding the
effector cells was 1, 10, 100, or 1000 ng/ml. Then, 100 .mu.l of
the effector cells at a cell density of 2.5.times.10.sup.6 cells/ml
were added thereto, and the cells were cultured for 4 hours under
the conditions of 37.degree. C. and 5% CO.sub.2. The supernatant
was collected in a LumaPlate (manufactured by PerkinElmer, Inc.),
and gamma radiation emitted therefrom was measured using a gamma
counter. The percentage of cell lysis caused by the ADCC activity
was calculated according to the following equation.
Percentage of cell lysis (%)=(A-B)/(C-B).times.100 [0608] A:
Radiation count from the sample well [0609] B: Average spontaneous
radiation emission count (from wells to which the antibody and the
effector cells were not added) (n=3) The same procedure as that for
the sample well was performed except that the ADCC medium was added
in an amount of 50 at the time of adding the antibody and in an
amount of 100 .mu.l at the time of adding the effector cells.
[0610] C: Average maximum radiation emission count (from wells in
which the target cells were dissolved with a surfactant) (n=3) The
same procedure as that for the sample well was performed except
that 50 .mu.l of the ADCC medium was added at the time of adding
the antibody and 100 .mu.l of the ADCC medium containing 2% (v/v)
Triton X-100 was added at the time of adding the effector
cells.
[0611] The results are shown in Table 4 and FIG. 12.
[0612] The data shown are an average of triplicate measurements,
and the error bars represent standard deviations. The P value was
calculated using Student's t-test.
[0613] In the group with the addition of the M30-H1-L4 antibody, an
ADCC activity was observed in the same manner as in the group with
the addition of the cM30 antibody. Also other humanized M30
antibodies (M30-H4-L4, M30-H1-L5, M30-H1-L6, and M30-H1-L7) were
observed to have an ADCC activity in the same manner.
TABLE-US-00012 TABLE 4 1 ng/mL 10 ng/mL 100 ng/mL 1000 ng/mL
Average Standard Average Standard Average Standard Average Standard
(%) deviation (%) deviation (%) deviation (%) deviation human IgG
3.8 1.6 6.8 1.5 3.9 1.4 6.5 0.5 cM30 11.1 1.2 40.5 2.7 84.3 2.3
88.2 4.0 M30-H1-L4 11.5 1.0 43.1 0.1 83.6 0.7 84.7 1.0 M30-H4-L4
7.6 1.1 26.6 1.6 68.9 2.6 81.7 1.5 M30-H1-L5 9.6 1.1 30.5 2.0 67.8
5.0 78.8 3.0 M30-H1-L6 9.8 1.6 32.0 2.2 74.7 4.0 81.3 2.0 M30-H1-L7
8.3 0.7 29.4 0.7 71.7 2.0 80.7 0.7
[0614] 12)-3 In Vivo Antitumor Effect of Humanized M30 Antibody
[0615] MDA-MB-231 cells were detached from a culture flask by a
trypsin treatment, and then suspended in 10% FBS-containing RPMI
1640 medium (Life Technologies Corporation), followed by
centrifugation and the supernatant was removed. The cells were
washed twice with the same medium, and then suspended in BD
Matrigel Basement Membrane Matrix (manufactured by BD Biosciences,
Inc.). Then, the cells were implanted subcutaneously in the
axillary region of each mouse (FOX CHASE SCID
C.B.17/Icr-scid/scidJcl, CLEA Japan, Inc.) at 6 weeks of age at a
dose of 5.times.10.sup.6 cells/mouse. The day of implantation was
taken as day 0, and on days 14, 21, 28, 35, and 42, the humanized
M30 antibody (M30-H1-L4 antibody) was intraperitoneally
administrated at a dose of 10, 1, 0.1, or 0.01 mg/kg (about 200,
20, 2, or 0.2 .mu.s/mouse, respectively). The tumor volume was
measured on days 14, 18, 21, 25, 28, 31, 35, 39, 42, 45, and 49,
and the antitumor effect of the administration of the antibody was
examined.
[0616] As a result, in the groups of administration of the
humanized M30 antibody (M30-H1-L4 antibody) at 10, 1, and 0.1
mg/kg, the tumor growth was significantly suppressed as compared
with the untreated group in which the antibody was not
administrated. In the groups of administration of the humanized M30
antibody (M30-H1-L4 antibody) at 10, 1, and 0.1 mg/kg, the tumor
growth inhibition ratio (=100-(average tumor weight in antibody
administration group)/(average tumor weight in untreated
group).times.100) compared with the untreated group in terms of the
tumor weight on day 49 was 67, 54, and 51%, respectively, and the P
values were all P<0.0001. The P values were calculated using
Dunnett's multiple comparison test.
[0617] Further, the tumor growth inhibition ratio (%)
(=100-(average tumor volume in antibody administration
group)/(average tumor volume in untreated group).times.100) of the
M30-H1-L4 antibody on day 49 in the 10, 1, 0.1, and 0.01 mg/kg
administration groups was 84, 68, 61, and 30%, respectively.
Accordingly, the humanized M30 antibody (M30-H1-L4 antibody) was
observed to have a very strong antitumor effect in vivo in the same
manner as the M30 antibody and the cM30 antibody, and it was
confirmed that the effect was exhibited in a dose-response manner
(FIG. 38).
INDUSTRIAL APPLICABILITY
[0618] The anti-B7-H3 antibody of the invention has an antitumor
activity, and a pharmaceutical composition comprising the
anti-B7-H3 antibody can become an anticancer agent.
SEQUENCE LISTING FREE TEXT
[0619] SEQ ID NO:1: PCR primer 1
[0620] SEQ ID NO:2: PCR primer 2
[0621] SEQ ID NO:3: CMV promoter primer: primer 3
[0622] SEQ ID NO:4: BGH reverse primer: primer 4
[0623] SEQ ID NO:5: nucleotide sequence of B7-H3 variant 1
[0624] SEQ ID NO:6: amino acid sequence of B7-H3 variant 1
[0625] SEQ ID NO:7: PCR primer 5
[0626] SEQ ID NO:8: PCR primer 6
[0627] SEQ ID NO:9: nucleotide sequence of B7-H3 variant 2
[0628] SEQ ID NO:10: amino acid sequence of B7-H3 variant 2
[0629] SEQ ID NO:11: PCR primer 7
[0630] SEQ ID NO:12: PCR primer 8
[0631] SEQ ID NO:13: PCR primer 9
[0632] SEQ ID NO:14: PCR primer 10
[0633] SEQ ID NO:15: PCR primer 11
[0634] SEQ ID NO:16: PCR primer 12
[0635] SEQ ID NO:17: PCR primer 13
[0636] SEQ ID NO:18: PCR primer 14
[0637] SEQ ID NO:19: PCR primer 15
[0638] SEQ ID NO:20: nucleotide sequence of B7-H3 IgV1
[0639] SEQ ID NO:21: amino acid sequence of B7-H3 IgV1
[0640] SEQ ID NO:22: nucleotide sequence of B7-H3 IgC1
[0641] SEQ ID NO:23: amino acid sequence of B7-H3 IgC1
[0642] SEQ ID NO:24: nucleotide sequence of B7-H3 IgV2
[0643] SEQ ID NO:25: amino acid sequence of B7-H3 IgV2
[0644] SEQ ID NO:26: nucleotide sequence of B7-H3 IgC2
[0645] SEQ ID NO:27: amino acid sequence of B7-H3 IgC2
[0646] SEQ ID NO:28: nucleotide sequence of B7-H3 IgC1-V2-C2
[0647] SEQ ID NO:29: amino acid sequence of B7-H3 IgC1-V2-C2
[0648] SEQ ID NO:30: nucleotide sequence of B7-H3 IgV2-C2
[0649] SEQ ID NO:31: amino acid sequence of B7-H3 IgV2-C2
[0650] SEQ ID NO:32: nucleotide sequence of B7RP-1
[0651] SEQ ID NO:33: amino acid sequence of B7RP-1
[0652] SEQ ID NO:34: nucleotide sequence of B7-H1
[0653] SEQ ID NO:35: amino acid sequence of B7-H1
[0654] SEQ ID NO:36: nucleotide sequence of B7-DC
[0655] SEQ ID NO:37: amino acid sequence of B7-DC
[0656] SEQ ID NO:38: nucleotide sequence of CD80
[0657] SEQ ID NO:39: amino acid sequence of CD80
[0658] SEQ ID NO:40: nucleotide sequence of CD86
[0659] SEQ ID NO:41: amino acid sequence of CD86
[0660] SEQ ID NO:42: nucleotide sequence of B7-H4
[0661] SEQ ID NO:43: amino acid sequence of B7-H4
[0662] SEQ ID NO:44: N-terminal amino acid sequence of mouse
antibody M30 heavy chain
[0663] SEQ ID NO:45: N-terminal amino acid sequence of mouse
antibody M30 light chain
[0664] SEQ ID NO:46: PCR primer 16
[0665] SEQ ID NO:47: PCR primer 17
[0666] SEQ ID NO:48: PCR primer 18
[0667] SEQ ID NO:49: PCR primer 19
[0668] SEQ ID NO:50: nucleotide sequence of cDNA encoding M30
antibody heavy chain
[0669] SEQ ID NO:51: amino acid sequence of M30 antibody heavy
chain
[0670] SEQ ID NO:52: nucleotide sequence of cDNA encoding M30
antibody light chain
[0671] SEQ ID NO:53: amino acid sequence of M30 antibody light
chain
[0672] SEQ ID NO:54: PCR primer 20
[0673] SEQ ID NO:55: PCR primer 21
[0674] SEQ ID NO:56: DNA sequence encoding human .kappa. chain
secretory signal, human .kappa. chain constant region, and human
poly-A additional signal
[0675] SEQ ID NO:57: DNA fragment comprising DNA sequence encoding
amino acids of signal sequence and constant region of human
IgG1
[0676] SEQ ID NO:58: nucleotide sequence of cDNA encoding M30
antibody chimera-type light chain
[0677] SEQ ID NO:59: amino acid sequence of M30 antibody
chimera-type light chain
[0678] SEQ ID NO:60: PCR primer 22
[0679] SEQ ID NO:61: PCR primer 23
[0680] SEQ ID NO:62: nucleotide sequence of cDNA encoding M30
antibody chimera-type heavy chain
[0681] SEQ ID NO:63: amino acid sequence of M30 antibody
chimera-type heavy chain
[0682] SEQ ID NO:64: PCR primer 24
[0683] SEQ ID NO:65: PCR primer 25
[0684] SEQ ID NO:66: PCR primer 26
[0685] SEQ ID NO:67: PCR primer 27
[0686] SEQ ID NO:68: PCR primer 28
[0687] SEQ ID NO:69: PCR primer 29
[0688] SEQ ID NO:70: nucleotide sequence of M30-L1-type light
chain
[0689] SEQ ID NO:71: amino acid sequence of M30-L1-type light
chain
[0690] SEQ ID NO:72: nucleotide sequence of M30-L2-type light
chain
[0691] SEQ ID NO:73: amino acid sequence of M30-L2-type light
chain
[0692] SEQ ID NO:74: nucleotide sequence of M30-L3-type light
chain
[0693] SEQ ID NO:75: amino acid sequence of M30-L3-type light
chain
[0694] SEQ ID NO:76: nucleotide sequence of M30-L4-type light
chain
[0695] SEQ ID NO:77: amino acid sequence of M30-L4-type light
chain
[0696] SEQ ID NO:78: nucleotide sequence of M30-L5-type light
chain
[0697] SEQ ID NO:79: amino acid sequence of M30-L5-type light
chain
[0698] SEQ ID NO:80: nucleotide sequence of M30-L6-type light
chain
[0699] SEQ ID NO:81: amino acid sequence of M30-L6-type light
chain
[0700] SEQ ID NO:82: nucleotide sequence of M30-L7-type light
chain
[0701] SEQ ID NO:83: amino acid sequence of M30-L7-type light
chain
[0702] SEQ ID NO:84: nucleotide sequence of M30-H1-type heavy
chain
[0703] SEQ ID NO:85: amino acid sequence of M30-H1-type heavy
chain
[0704] SEQ ID NO:86: nucleotide sequence of M30-H2-type heavy
chain
[0705] SEQ ID NO:87: amino acid sequence of M30-H2-type heavy
chain
[0706] SEQ ID NO:88: nucleotide sequence of M30-H3-type heavy
chain
[0707] SEQ ID NO:89: amino acid sequence of M30-H3-type heavy
chain
[0708] SEQ ID NO:90: nucleotide sequence of M30-H4-type heavy
chain
[0709] SEQ ID NO:91: amino acid sequence of M30-H4-type heavy
chain
[0710] SEQ ID NO:92: amino acid sequence of M30 antibody CDRH1
[0711] SEQ ID NO:93: amino acid sequence of M30 antibody CDRH2
[0712] SEQ ID NO:94: amino acid sequence of M30 antibody CDRH3
[0713] SEQ ID NO:95: amino acid sequence of M30 antibody CDRL1
[0714] SEQ ID NO:96: amino acid sequence of M30 antibody CDRL2
[0715] SEQ ID NO:97: amino acid sequence of M30 antibody CD
Sequence CWU 1
1
97146DNAArtificial SequencePCR primer 1ctatagggag acccaagctg
gctagcatgc tgcgtcggcg gggcag 46266DNAArtificial SequencePCR primer
2aacgggccct ctagactcga gcggccgctc aggctatttc ttgtccatca tcttctttgc
60tgtcag 66321DNAArtificial SequencePCR primer 3cgcaaatggg
cggtaggcgt g 21418DNAArtificial SequencePCR primer 4tagaaggcac
agtcgagg 1851815DNAHomo sapiens 5atgctgcgtc ggcggggcag ccctggcatg
ggtgtgcatg tgggtgcagc cctgggagca 60ctgtggttct gcctcacagg agccctggag
gtccaggtcc ctgaagaccc agtggtggca 120ctggtgggca ccgatgccac
cctgtgctgc tccttctccc ctgagcctgg cttcagcctg 180gcacagctca
acctcatctg gcagctgaca gataccaaac agctggtgca cagctttgct
240gagggccagg accagggcag cgcctatgcc aaccgcacgg ccctcttccc
ggacctgctg 300gcacagggca acgcatccct gaggctgcag cgcgtgcgtg
tggcggacga gggcagcttc 360acctgcttcg tgagcatccg ggatttcggc
agcgctgccg tcagcctgca ggtggccgct 420ccctactcga agcccagcat
gaccctggag cccaacaagg acctgcggcc aggggacacg 480gtgaccatca
cgtgctccag ctaccagggc taccctgagg ctgaggtgtt ctggcaggat
540gggcagggtg tgcccctgac tggcaacgtg accacgtcgc agatggccaa
cgagcagggc 600ttgtttgatg tgcacagcat cctgcgggtg gtgctgggtg
caaatggcac ctacagctgc 660ctggtgcgca accccgtgct gcagcaggat
gcgcacagct ctgtcaccat cacaccccag 720agaagcccca caggagccgt
ggaggtccag gtccctgagg acccggtggt ggccctagtg 780ggcaccgatg
ccaccctgcg ctgctccttc tcccccgagc ctggcttcag cctggcacag
840ctcaacctca tctggcagct gacagacacc aaacagctgg tgcacagttt
caccgaaggc 900cgggaccagg gcagcgccta tgccaaccgc acggccctct
tcccggacct gctggcacaa 960ggcaatgcat ccctgaggct gcagcgcgtg
cgtgtggcgg acgagggcag cttcacctgc 1020ttcgtgagca tccgggattt
cggcagcgct gccgtcagcc tgcaggtggc cgctccctac 1080tcgaagccca
gcatgaccct ggagcccaac aaggacctgc ggccagggga cacggtgacc
1140atcacgtgct ccagctaccg gggctaccct gaggctgagg tgttctggca
ggatgggcag 1200ggtgtgcccc tgactggcaa cgtgaccacg tcgcagatgg
ccaacgagca gggcttgttt 1260gatgtgcaca gcgtcctgcg ggtggtgctg
ggtgcgaatg gcacctacag ctgcctggtg 1320cgcaaccccg tgctgcagca
ggatgcgcac ggctctgtca ccatcacagg gcagcctatg 1380acattccccc
cagaggccct gtgggtgacc gtggggctgt ctgtctgtct cattgcactg
1440ctggtggccc tggctttcgt gtgctggaga aagatcaaac agagctgtga
ggaggagaat 1500gcaggagctg aggaccagga tggggaggga gaaggctcca
agacagccct gcagcctctg 1560aaacactctg acagcaaaga agatgatgga
caagaaatag cctgagcggc cgccactgtg 1620ctggatatct gcagaattcc
accacactgg actagtggat ccgagctcgg taccaagctt 1680aagtttaaac
cgctgatcag cctcgactgt gccttctagt tgccagccat ctgttgtttg
1740cccctccccc gtgccttcct tgaccctgga aggtgccact cccactgtcc
tttcctaata 1800aaatgaggaa attgc 18156534PRTHomo sapiens 6Met Leu
Arg Arg Arg Gly Ser Pro Gly Met Gly Val His Val Gly Ala 1 5 10 15
Ala Leu Gly Ala Leu Trp Phe Cys Leu Thr Gly Ala Leu Glu Val Gln 20
25 30 Val Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr
Leu 35 40 45 Cys Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu Ala
Gln Leu Asn 50 55 60 Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln Leu
Val His Ser Phe Ala 65 70 75 80 Glu Gly Gln Asp Gln Gly Ser Ala Tyr
Ala Asn Arg Thr Ala Leu Phe 85 90 95 Pro Asp Leu Leu Ala Gln Gly
Asn Ala Ser Leu Arg Leu Gln Arg Val 100 105 110 Arg Val Ala Asp Glu
Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp 115 120 125 Phe Gly Ser
Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys 130 135 140 Pro
Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr 145 150
155 160 Val Thr Ile Thr Cys Ser Ser Tyr Gln Gly Tyr Pro Glu Ala Glu
Val 165 170 175 Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn
Val Thr Thr 180 185 190 Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp
Val His Ser Ile Leu 195 200 205 Arg Val Val Leu Gly Ala Asn Gly Thr
Tyr Ser Cys Leu Val Arg Asn 210 215 220 Pro Val Leu Gln Gln Asp Ala
His Ser Ser Val Thr Ile Thr Pro Gln 225 230 235 240 Arg Ser Pro Thr
Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val 245 250 255 Val Ala
Leu Val Gly Thr Asp Ala Thr Leu Arg Cys Ser Phe Ser Pro 260 265 270
Glu Pro Gly Phe Ser Leu Ala Gln Leu Asn Leu Ile Trp Gln Leu Thr 275
280 285 Asp Thr Lys Gln Leu Val His Ser Phe Thr Glu Gly Arg Asp Gln
Gly 290 295 300 Ser Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro Asp Leu
Leu Ala Gln 305 310 315 320 Gly Asn Ala Ser Leu Arg Leu Gln Arg Val
Arg Val Ala Asp Glu Gly 325 330 335 Ser Phe Thr Cys Phe Val Ser Ile
Arg Asp Phe Gly Ser Ala Ala Val 340 345 350 Ser Leu Gln Val Ala Ala
Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu 355 360 365 Pro Asn Lys Asp
Leu Arg Pro Gly Asp Thr Val Thr Ile Thr Cys Ser 370 375 380 Ser Tyr
Arg Gly Tyr Pro Glu Ala Glu Val Phe Trp Gln Asp Gly Gln 385 390 395
400 Gly Val Pro Leu Thr Gly Asn Val Thr Thr Ser Gln Met Ala Asn Glu
405 410 415 Gln Gly Leu Phe Asp Val His Ser Val Leu Arg Val Val Leu
Gly Ala 420 425 430 Asn Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro Val
Leu Gln Gln Asp 435 440 445 Ala His Gly Ser Val Thr Ile Thr Gly Gln
Pro Met Thr Phe Pro Pro 450 455 460 Glu Ala Leu Trp Val Thr Val Gly
Leu Ser Val Cys Leu Ile Ala Leu 465 470 475 480 Leu Val Ala Leu Ala
Phe Val Cys Trp Arg Lys Ile Lys Gln Ser Cys 485 490 495 Glu Glu Glu
Asn Ala Gly Ala Glu Asp Gln Asp Gly Glu Gly Glu Gly 500 505 510 Ser
Lys Thr Ala Leu Gln Pro Leu Lys His Ser Asp Ser Lys Glu Asp 515 520
525 Asp Gly Gln Glu Ile Ala 530 759DNAArtificial SequencePCR primer
7ggggacaagt ttgtacaaaa aagcaggctt caccatgctg cgtcggcggg gcagccctg
59843DNAArtificial SequencePCR primer 8ggggaccact ttgtacaaga
aagctgggtc ggctatttct tgt 439948DNAHomo sapiens 9atgctgcgtc
ggcggggcag ccctggcatg ggtgtgcatg tgggtgcagc cctgggagca 60ctgtggttct
gcctcacagg agccctggag gtccaggtcc ctgaagaccc agtggtggca
120ctggtgggca ccgatgccac cctgtgctgc tccttctccc ctgagcctgg
cttcagcctg 180gcacagctca acctcatctg gcagctgaca gataccaaac
agctggtgca cagctttgct 240gagggccagg accagggcag cgcctatgcc
aaccgcacgg ccctcttccc ggacctgctg 300gcacagggca acgcatccct
gaggctgcag cgcgtgcgtg tggcggacga gggcagcttc 360acctgcttcg
tgagcatccg ggatttcggc agcgctgccg tcagcctgca ggtggccgct
420ccctactcga agcccagcat gaccctggag cccaacaagg acctgcggcc
aggggacacg 480gtgaccatca cgtgctccag ctaccggggc taccctgagg
ctgaggtgtt ctggcaggat 540gggcagggtg tgcccctgac tggcaacgtg
accacgtcgc agatggccaa cgagcagggc 600ttgtttgatg tgcacagcgt
cctgcgggtg gtgctgggtg cgaatggcac ctacagctgc 660ctggtgcgca
accccgtgct gcagcaggat gcgcacggct ctgtcaccat cacagggcag
720cctatgacat tccccccaga ggccctgtgg gtgaccgtgg ggctgtctgt
ctgtctcatt 780gcactgctgg tggccctggc tttcgtgtgc tggagaaaga
tcaaacagag ctgtgaggag 840gagaatgcag gagctgagga ccaggatggg
gagggagaag gctccaagac agccctgcag 900cctctgaaac actctgacag
caaagaagat gatggacaag aaatagcc 94810316PRTHomo sapiens 10Met Leu
Arg Arg Arg Gly Ser Pro Gly Met Gly Val His Val Gly Ala 1 5 10 15
Ala Leu Gly Ala Leu Trp Phe Cys Leu Thr Gly Ala Leu Glu Val Gln 20
25 30 Val Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala Thr
Leu 35 40 45 Cys Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu Ala
Gln Leu Asn 50 55 60 Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln Leu
Val His Ser Phe Ala 65 70 75 80 Glu Gly Gln Asp Gln Gly Ser Ala Tyr
Ala Asn Arg Thr Ala Leu Phe 85 90 95 Pro Asp Leu Leu Ala Gln Gly
Asn Ala Ser Leu Arg Leu Gln Arg Val 100 105 110 Arg Val Ala Asp Glu
Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp 115 120 125 Phe Gly Ser
Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys 130 135 140 Pro
Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr 145 150
155 160 Val Thr Ile Thr Cys Ser Ser Tyr Arg Gly Tyr Pro Glu Ala Glu
Val 165 170 175 Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr Gly Asn
Val Thr Thr 180 185 190 Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp
Val His Ser Val Leu 195 200 205 Arg Val Val Leu Gly Ala Asn Gly Thr
Tyr Ser Cys Leu Val Arg Asn 210 215 220 Pro Val Leu Gln Gln Asp Ala
His Gly Ser Val Thr Ile Thr Gly Gln 225 230 235 240 Pro Met Thr Phe
Pro Pro Glu Ala Leu Trp Val Thr Val Gly Leu Ser 245 250 255 Val Cys
Leu Ile Ala Leu Leu Val Ala Leu Ala Phe Val Cys Trp Arg 260 265 270
Lys Ile Lys Gln Ser Cys Glu Glu Glu Asn Ala Gly Ala Glu Asp Gln 275
280 285 Asp Gly Glu Gly Glu Gly Ser Lys Thr Ala Leu Gln Pro Leu Lys
His 290 295 300 Ser Asp Ser Lys Glu Asp Asp Gly Gln Glu Ile Ala 305
310 315 1152DNAArtificial SequencePCR primer 11ggggacaagt
ttgtacaaaa aagcaggctt cggagccctg gaggtccagg tc 521255DNAArtificial
SequencePCR primer 12ggggacaagt ttgtacaaaa aagcaggctt cgctccctac
tcgaagccca gcatg 551352DNAArtificial SequencePCR primer
13ggggacaagt ttgtacaaaa aagcaggctt cggagccgtg gaggtccagg tc
521455DNAArtificial SequencePCR primer 14ggggacaagt ttgtacaaaa
aagcaggctt cgctccctac tcgaagccca gcatg 551554DNAArtificial
SequencePCR primer 15ggggaccact ttgtacaaga aagctgggtc tcaggctatt
tcttgtccat catc 541643DNAArtificial SequencePCR primer 16gggaatgtca
taggctgccc ggccacctgc aggctgacgg cag 431742DNAArtificial
SequencePCR primer 17gggaatgtca taggctgccc tgtggggctt ctctggggtg tg
421843DNAArtificial SequencePCR primer 18gggaatgtca taggctgccc
ggccacctgc aggctgacgg cag 431927DNAArtificial SequencePCR primer
19gggcagccta tgacattccc cccagag 2720576DNAHomo sapiens 20ggagccctgg
aggtccaggt ccctgaagac ccagtggtgg cactggtggg caccgatgcc 60accctgtgct
gctccttctc ccctgagcct ggcttcagcc tggcacagct caacctcatc
120tggcagctga cagataccaa acagctggtg cacagctttg ctgagggcca
ggaccagggc 180agcgcctatg ccaaccgcac ggccctcttc ccggacctgc
tggcacaggg caacgcatcc 240ctgaggctgc agcgcgtgcg tgtggcggac
gagggcagct tcacctgctt cgtgagcatc 300cgggatttcg gcagcgctgc
cgtcagcctg caggtggccg ggcagcctat gacattcccc 360ccagaggccc
tgtgggtgac cgtggggctg tctgtctgtc tcattgcact gctggtggcc
420ctggctttcg tgtgctggag aaagatcaaa cagagctgtg aggaggagaa
tgcaggagct 480gaggaccagg atggggaggg agaaggctcc aagacagccc
tgcagcctct gaaacactct 540gacagcaaag aagatgatgg acaagaaata gcctga
57621191PRTHomo sapiens 21Gly Ala Leu Glu Val Gln Val Pro Glu Asp
Pro Val Val Ala Leu Val 1 5 10 15 Gly Thr Asp Ala Thr Leu Cys Cys
Ser Phe Ser Pro Glu Pro Gly Phe 20 25 30 Ser Leu Ala Gln Leu Asn
Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln 35 40 45 Leu Val His Ser
Phe Ala Glu Gly Gln Asp Gln Gly Ser Ala Tyr Ala 50 55 60 Asn Arg
Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser 65 70 75 80
Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly Ser Phe Thr Cys 85
90 95 Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu Gln
Val 100 105 110 Ala Gly Gln Pro Met Thr Phe Pro Pro Glu Ala Leu Trp
Val Thr Val 115 120 125 Gly Leu Ser Val Cys Leu Ile Ala Leu Leu Val
Ala Leu Ala Phe Val 130 135 140 Cys Trp Arg Lys Ile Lys Gln Ser Cys
Glu Glu Glu Asn Ala Gly Ala 145 150 155 160 Glu Asp Gln Asp Gly Glu
Gly Glu Gly Ser Lys Thr Ala Leu Gln Pro 165 170 175 Leu Lys His Ser
Asp Ser Lys Glu Asp Asp Gly Gln Glu Ile Ala 180 185 190
22552DNAHomo sapiens 22gctccctact cgaagcccag catgaccctg gagcccaaca
aggacctgcg gccaggggac 60acggtgacca tcacgtgctc cagctaccag ggctaccctg
aggctgaggt gttctggcag 120gatgggcagg gtgtgcccct gactggcaac
gtgaccacgt cgcagatggc caacgagcag 180ggcttgtttg atgtgcacag
catcctgcgg gtggtgctgg gtgcaaatgg cacctacagc 240tgcctggtgc
gcaaccccgt gctgcagcag gatgcgcaca gctctgtcac catcacaccc
300cagagaagcc ccacagggca gcctatgaca ttccccccag aggccctgtg
ggtgaccgtg 360gggctgtctg tctgtctcat tgcactgctg gtggccctgg
ctttcgtgtg ctggagaaag 420atcaaacaga gctgtgagga ggagaatgca
ggagctgagg accaggatgg ggagggagaa 480ggctccaaga cagccctgca
gcctctgaaa cactctgaca gcaaagaaga tgatggacaa 540gaaatagcct ga
55223183PRTHomo sapiens 23Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu
Glu Pro Asn Lys Asp Leu 1 5 10 15 Arg Pro Gly Asp Thr Val Thr Ile
Thr Cys Ser Ser Tyr Gln Gly Tyr 20 25 30 Pro Glu Ala Glu Val Phe
Trp Gln Asp Gly Gln Gly Val Pro Leu Thr 35 40 45 Gly Asn Val Thr
Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp 50 55 60 Val His
Ser Ile Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser 65 70 75 80
Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp Ala His Ser Ser Val 85
90 95 Thr Ile Thr Pro Gln Arg Ser Pro Thr Gly Gln Pro Met Thr Phe
Pro 100 105 110 Pro Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val Cys
Leu Ile Ala 115 120 125 Leu Leu Val Ala Leu Ala Phe Val Cys Trp Arg
Lys Ile Lys Gln Ser 130 135 140 Cys Glu Glu Glu Asn Ala Gly Ala Glu
Asp Gln Asp Gly Glu Gly Glu 145 150 155 160 Gly Ser Lys Thr Ala Leu
Gln Pro Leu Lys His Ser Asp Ser Lys Glu 165 170 175 Asp Asp Gly Gln
Glu Ile Ala 180 24576DNAHomo sapiens 24ggagccgtgg aggtccaggt
ccctgaggac ccggtggtgg ccctagtggg caccgatgcc 60accctgcgct gctccttctc
ccccgagcct ggcttcagcc tggcacagct caacctcatc 120tggcagctga
cagacaccaa acagctggtg cacagtttca ccgaaggccg ggaccagggc
180agcgcctatg ccaaccgcac ggccctcttc ccggacctgc tggcacaagg
caatgcatcc 240ctgaggctgc agcgcgtgcg tgtggcggac gagggcagct
tcacctgctt cgtgagcatc 300cgggatttcg gcagcgctgc cgtcagcctg
caggtggccg ggcagcctat gacattcccc 360ccagaggccc tgtgggtgac
cgtggggctg tctgtctgtc tcattgcact gctggtggcc 420ctggctttcg
tgtgctggag aaagatcaaa cagagctgtg aggaggagaa tgcaggagct
480gaggaccagg atggggaggg agaaggctcc aagacagccc tgcagcctct
gaaacactct 540gacagcaaag aagatgatgg acaagaaata gcctga
57625191PRTHomo sapiens 25Gly Ala Val Glu Val Gln Val Pro Glu Asp
Pro Val Val Ala Leu Val 1 5 10 15 Gly Thr Asp Ala Thr Leu Arg Cys
Ser Phe Ser Pro Glu Pro Gly Phe 20 25 30 Ser Leu Ala Gln Leu Asn
Leu Ile Trp Gln Leu Thr Asp Thr Lys Gln 35 40 45 Leu Val His Ser
Phe Thr Glu Gly Arg Asp Gln Gly Ser Ala Tyr Ala 50 55 60 Asn Arg
Thr Ala Leu Phe Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser 65 70 75 80
Leu Arg Leu Gln Arg Val Arg Val Ala Asp Glu Gly Ser Phe Thr Cys 85
90 95 Phe Val Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu Gln
Val 100 105 110 Ala Gly
Gln Pro Met Thr Phe Pro Pro Glu Ala Leu Trp Val Thr Val 115 120 125
Gly Leu Ser Val Cys Leu Ile Ala Leu Leu Val Ala Leu Ala Phe Val 130
135 140 Cys Trp Arg Lys Ile Lys Gln Ser Cys Glu Glu Glu Asn Ala Gly
Ala 145 150 155 160 Glu Asp Gln Asp Gly Glu Gly Glu Gly Ser Lys Thr
Ala Leu Gln Pro 165 170 175 Leu Lys His Ser Asp Ser Lys Glu Asp Asp
Gly Gln Glu Ile Ala 180 185 190 26534DNAHomo sapiens 26gctccctact
cgaagcccag catgaccctg gagcccaaca aggacctgcg gccaggggac 60acggtgacca
tcacgtgctc cagctaccgg ggctaccctg aggctgaggt gttctggcag
120gatgggcagg gtgtgcccct gactggcaac gtgaccacgt cgcagatggc
caacgagcag 180ggcttgtttg atgtgcacag cgtcctgcgg gtggtgctgg
gtgcgaatgg cacctacagc 240tgcctggtgc gcaaccccgt gctgcagcag
gatgcgcacg gctctgtcac catcacaggg 300cagcctatga cattcccccc
agaggccctg tgggtgaccg tggggctgtc tgtctgtctc 360attgcactgc
tggtggccct ggctttcgtg tgctggagaa agatcaaaca gagctgtgag
420gaggagaatg caggagctga ggaccaggat ggggagggag aaggctccaa
gacagccctg 480cagcctctga aacactctga cagcaaagaa gatgatggac
aagaaatagc ctga 53427177PRTHomo sapiens 27Ala Pro Tyr Ser Lys Pro
Ser Met Thr Leu Glu Pro Asn Lys Asp Leu 1 5 10 15 Arg Pro Gly Asp
Thr Val Thr Ile Thr Cys Ser Ser Tyr Arg Gly Tyr 20 25 30 Pro Glu
Ala Glu Val Phe Trp Gln Asp Gly Gln Gly Val Pro Leu Thr 35 40 45
Gly Asn Val Thr Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp 50
55 60 Val His Ser Val Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr
Ser 65 70 75 80 Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp Ala His
Gly Ser Val 85 90 95 Thr Ile Thr Gly Gln Pro Met Thr Phe Pro Pro
Glu Ala Leu Trp Val 100 105 110 Thr Val Gly Leu Ser Val Cys Leu Ile
Ala Leu Leu Val Ala Leu Ala 115 120 125 Phe Val Cys Trp Arg Lys Ile
Lys Gln Ser Cys Glu Glu Glu Asn Ala 130 135 140 Gly Ala Glu Asp Gln
Asp Gly Glu Gly Glu Gly Ser Lys Thr Ala Leu 145 150 155 160 Gln Pro
Leu Lys His Ser Asp Ser Lys Glu Asp Asp Gly Gln Glu Ile 165 170 175
Ala 281188DNAHomo sapiens 28gctccctact cgaagcccag catgaccctg
gagcccaaca aggacctgcg gccaggggac 60acggtgacca tcacgtgctc cagctaccag
ggctaccctg aggctgaggt gttctggcag 120gatgggcagg gtgtgcccct
gactggcaac gtgaccacgt cgcagatggc caacgagcag 180ggcttgtttg
atgtgcacag catcctgcgg gtggtgctgg gtgcaaatgg cacctacagc
240tgcctggtgc gcaaccccgt gctgcagcag gatgcgcaca gctctgtcac
catcacaccc 300cagagaagcc ccacaggagc cgtggaggtc caggtccctg
aggacccggt ggtggcccta 360gtgggcaccg atgccaccct gcgctgctcc
ttctcccccg agcctggctt cagcctggca 420cagctcaacc tcatctggca
gctgacagac accaaacagc tggtgcacag tttcaccgaa 480ggccgggacc
agggcagcgc ctatgccaac cgcacggccc tcttcccgga cctgctggca
540caaggcaatg catccctgag gctgcagcgc gtgcgtgtgg cggacgaggg
cagcttcacc 600tgcttcgtga gcatccggga tttcggcagc gctgccgtca
gcctgcaggt ggccgctccc 660tactcgaagc ccagcatgac cctggagccc
aacaaggacc tgcggccagg ggacacggtg 720accatcacgt gctccagcta
ccggggctac cctgaggctg aggtgttctg gcaggatggg 780cagggtgtgc
ccctgactgg caacgtgacc acgtcgcaga tggccaacga gcagggcttg
840tttgatgtgc acagcgtcct gcgggtggtg ctgggtgcga atggcaccta
cagctgcctg 900gtgcgcaacc ccgtgctgca gcaggatgcg cacggctctg
tcaccatcac agggcagcct 960atgacattcc ccccagaggc cctgtgggtg
accgtggggc tgtctgtctg tctcattgca 1020ctgctggtgg ccctggcttt
cgtgtgctgg agaaagatca aacagagctg tgaggaggag 1080aatgcaggag
ctgaggacca ggatggggag ggagaaggct ccaagacagc cctgcagcct
1140ctgaaacact ctgacagcaa agaagatgat ggacaagaaa tagcctga
118829395PRTHomo sapiens 29Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu
Glu Pro Asn Lys Asp Leu 1 5 10 15 Arg Pro Gly Asp Thr Val Thr Ile
Thr Cys Ser Ser Tyr Gln Gly Tyr 20 25 30 Pro Glu Ala Glu Val Phe
Trp Gln Asp Gly Gln Gly Val Pro Leu Thr 35 40 45 Gly Asn Val Thr
Thr Ser Gln Met Ala Asn Glu Gln Gly Leu Phe Asp 50 55 60 Val His
Ser Ile Leu Arg Val Val Leu Gly Ala Asn Gly Thr Tyr Ser 65 70 75 80
Cys Leu Val Arg Asn Pro Val Leu Gln Gln Asp Ala His Ser Ser Val 85
90 95 Thr Ile Thr Pro Gln Arg Ser Pro Thr Gly Ala Val Glu Val Gln
Val 100 105 110 Pro Glu Asp Pro Val Val Ala Leu Val Gly Thr Asp Ala
Thr Leu Arg 115 120 125 Cys Ser Phe Ser Pro Glu Pro Gly Phe Ser Leu
Ala Gln Leu Asn Leu 130 135 140 Ile Trp Gln Leu Thr Asp Thr Lys Gln
Leu Val His Ser Phe Thr Glu 145 150 155 160 Gly Arg Asp Gln Gly Ser
Ala Tyr Ala Asn Arg Thr Ala Leu Phe Pro 165 170 175 Asp Leu Leu Ala
Gln Gly Asn Ala Ser Leu Arg Leu Gln Arg Val Arg 180 185 190 Val Ala
Asp Glu Gly Ser Phe Thr Cys Phe Val Ser Ile Arg Asp Phe 195 200 205
Gly Ser Ala Ala Val Ser Leu Gln Val Ala Ala Pro Tyr Ser Lys Pro 210
215 220 Ser Met Thr Leu Glu Pro Asn Lys Asp Leu Arg Pro Gly Asp Thr
Val 225 230 235 240 Thr Ile Thr Cys Ser Ser Tyr Arg Gly Tyr Pro Glu
Ala Glu Val Phe 245 250 255 Trp Gln Asp Gly Gln Gly Val Pro Leu Thr
Gly Asn Val Thr Thr Ser 260 265 270 Gln Met Ala Asn Glu Gln Gly Leu
Phe Asp Val His Ser Val Leu Arg 275 280 285 Val Val Leu Gly Ala Asn
Gly Thr Tyr Ser Cys Leu Val Arg Asn Pro 290 295 300 Val Leu Gln Gln
Asp Ala His Gly Ser Val Thr Ile Thr Gly Gln Pro 305 310 315 320 Met
Thr Phe Pro Pro Glu Ala Leu Trp Val Thr Val Gly Leu Ser Val 325 330
335 Cys Leu Ile Ala Leu Leu Val Ala Leu Ala Phe Val Cys Trp Arg Lys
340 345 350 Ile Lys Gln Ser Cys Glu Glu Glu Asn Ala Gly Ala Glu Asp
Gln Asp 355 360 365 Gly Glu Gly Glu Gly Ser Lys Thr Ala Leu Gln Pro
Leu Lys His Ser 370 375 380 Asp Ser Lys Glu Asp Asp Gly Gln Glu Ile
Ala 385 390 395 30873DNAHomo sapiens 30ggagccgtgg aggtccaggt
ccctgaggac ccggtggtgg ccctagtggg caccgatgcc 60accctgcgct gctccttctc
ccccgagcct ggcttcagcc tggcacagct caacctcatc 120tggcagctga
cagacaccaa acagctggtg cacagtttca ccgaaggccg ggaccagggc
180agcgcctatg ccaaccgcac ggccctcttc ccggacctgc tggcacaagg
caatgcatcc 240ctgaggctgc agcgcgtgcg tgtggcggac gagggcagct
tcacctgctt cgtgagcatc 300cgggatttcg gcagcgctgc cgtcagcctg
caggtggccg ctccctactc gaagcccagc 360atgaccctgg agcccaacaa
ggacctgcgg ccaggggaca cggtgaccat cacgtgctcc 420agctaccggg
gctaccctga ggctgaggtg ttctggcagg atgggcaggg tgtgcccctg
480actggcaacg tgaccacgtc gcagatggcc aacgagcagg gcttgtttga
tgtgcacagc 540gtcctgcggg tggtgctggg tgcgaatggc acctacagct
gcctggtgcg caaccccgtg 600ctgcagcagg atgcgcacgg ctctgtcacc
atcacagggc agcctatgac attcccccca 660gaggccctgt gggtgaccgt
ggggctgtct gtctgtctca ttgcactgct ggtggccctg 720gctttcgtgt
gctggagaaa gatcaaacag agctgtgagg aggagaatgc aggagctgag
780gaccaggatg gggagggaga aggctccaag acagccctgc agcctctgaa
acactctgac 840agcaaagaag atgatggaca agaaatagcc tga 87331290PRTHomo
sapiens 31Gly Ala Val Glu Val Gln Val Pro Glu Asp Pro Val Val Ala
Leu Val 1 5 10 15 Gly Thr Asp Ala Thr Leu Arg Cys Ser Phe Ser Pro
Glu Pro Gly Phe 20 25 30 Ser Leu Ala Gln Leu Asn Leu Ile Trp Gln
Leu Thr Asp Thr Lys Gln 35 40 45 Leu Val His Ser Phe Thr Glu Gly
Arg Asp Gln Gly Ser Ala Tyr Ala 50 55 60 Asn Arg Thr Ala Leu Phe
Pro Asp Leu Leu Ala Gln Gly Asn Ala Ser 65 70 75 80 Leu Arg Leu Gln
Arg Val Arg Val Ala Asp Glu Gly Ser Phe Thr Cys 85 90 95 Phe Val
Ser Ile Arg Asp Phe Gly Ser Ala Ala Val Ser Leu Gln Val 100 105 110
Ala Ala Pro Tyr Ser Lys Pro Ser Met Thr Leu Glu Pro Asn Lys Asp 115
120 125 Leu Arg Pro Gly Asp Thr Val Thr Ile Thr Cys Ser Ser Tyr Arg
Gly 130 135 140 Tyr Pro Glu Ala Glu Val Phe Trp Gln Asp Gly Gln Gly
Val Pro Leu 145 150 155 160 Thr Gly Asn Val Thr Thr Ser Gln Met Ala
Asn Glu Gln Gly Leu Phe 165 170 175 Asp Val His Ser Val Leu Arg Val
Val Leu Gly Ala Asn Gly Thr Tyr 180 185 190 Ser Cys Leu Val Arg Asn
Pro Val Leu Gln Gln Asp Ala His Gly Ser 195 200 205 Val Thr Ile Thr
Gly Gln Pro Met Thr Phe Pro Pro Glu Ala Leu Trp 210 215 220 Val Thr
Val Gly Leu Ser Val Cys Leu Ile Ala Leu Leu Val Ala Leu 225 230 235
240 Ala Phe Val Cys Trp Arg Lys Ile Lys Gln Ser Cys Glu Glu Glu Asn
245 250 255 Ala Gly Ala Glu Asp Gln Asp Gly Glu Gly Glu Gly Ser Lys
Thr Ala 260 265 270 Leu Gln Pro Leu Lys His Ser Asp Ser Lys Glu Asp
Asp Gly Gln Glu 275 280 285 Ile Ala 290 32909DNAHomo sapiens
32atgcggctgg gcagtcctgg actgctcttc ctgctcttca gcagccttcg agctgatact
60caggagaagg aagtcagagc gatggtaggc agcgacgtgg agctcagctg cgcttgccct
120gaaggaagcc gttttgattt aaatgatgtt tacgtatatt ggcaaaccag
tgagtcgaaa 180accgtggtga cctaccacat cccacagaac agctccttgg
aaaacgtgga cagccgctac 240cggaaccgag ccctgatgtc accggccggc
atgctgcggg gcgacttctc cctgcgcttg 300ttcaacgtca ccccccagga
cgagcagaag tttcactgcc tggtgttgag ccaatccctg 360ggattccagg
aggttttgag cgttgaggtt acactgcatg tggcagcaaa cttcagcgtg
420cccgtcgtca gcgcccccca cagcccctcc caggatgagc tcaccttcac
gtgtacatcc 480ataaacggct accccaggcc caacgtgtac tggatcaata
agacggacaa cagcctgctg 540gaccaggctc tgcagaatga caccgtcttc
ttgaacatgc ggggcttgta tgacgtggtc 600agcgtgctga ggatcgcacg
gacccccagc gtgaacattg gctgctgcat agagaacgtg 660cttctgcagc
agaacctgac tgtcggcagc cagacaggaa atgacatcgg agagagagac
720aagatcacag agaatccagt cagtaccggc gagaaaaacg cggccacgtg
gagcatcctg 780gctgtcctgt gcctgcttgt ggtcgtggcg gtggccatag
gctgggtgtg cagggaccga 840tgcctccaac acagctatgc aggtgcctgg
gctgtgagtc cggagacaga gctcactggc 900cacgtttga 90933302PRTHomo
sapiens 33Met Arg Leu Gly Ser Pro Gly Leu Leu Phe Leu Leu Phe Ser
Ser Leu 1 5 10 15 Arg Ala Asp Thr Gln Glu Lys Glu Val Arg Ala Met
Val Gly Ser Asp 20 25 30 Val Glu Leu Ser Cys Ala Cys Pro Glu Gly
Ser Arg Phe Asp Leu Asn 35 40 45 Asp Val Tyr Val Tyr Trp Gln Thr
Ser Glu Ser Lys Thr Val Val Thr 50 55 60 Tyr His Ile Pro Gln Asn
Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr 65 70 75 80 Arg Asn Arg Ala
Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe 85 90 95 Ser Leu
Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe His 100 105 110
Cys Leu Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val Leu Ser Val 115
120 125 Glu Val Thr Leu His Val Ala Ala Asn Phe Ser Val Pro Val Val
Ser 130 135 140 Ala Pro His Ser Pro Ser Gln Asp Glu Leu Thr Phe Thr
Cys Thr Ser 145 150 155 160 Ile Asn Gly Tyr Pro Arg Pro Asn Val Tyr
Trp Ile Asn Lys Thr Asp 165 170 175 Asn Ser Leu Leu Asp Gln Ala Leu
Gln Asn Asp Thr Val Phe Leu Asn 180 185 190 Met Arg Gly Leu Tyr Asp
Val Val Ser Val Leu Arg Ile Ala Arg Thr 195 200 205 Pro Ser Val Asn
Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln 210 215 220 Asn Leu
Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg Asp 225 230 235
240 Lys Ile Thr Glu Asn Pro Val Ser Thr Gly Glu Lys Asn Ala Ala Thr
245 250 255 Trp Ser Ile Leu Ala Val Leu Cys Leu Leu Val Val Val Ala
Val Ala 260 265 270 Ile Gly Trp Val Cys Arg Asp Arg Cys Leu Gln His
Ser Tyr Ala Gly 275 280 285 Ala Trp Ala Val Ser Pro Glu Thr Glu Leu
Thr Gly His Val 290 295 300 34873DNAHomo sapiens 34atgaggatat
ttgctgtctt tatattcatg acctactggc atttgctgaa cgcatttact 60gtcacggttc
ccaaggacct atatgtggta gagtatggta gcaatatgac aattgaatgc
120aaattcccag tagaaaaaca attagacctg gctgcactaa ttgtctattg
ggaaatggag 180gataagaaca ttattcaatt tgtgcatgga gaggaagacc
tgaaggttca gcatagtagc 240tacagacaga gggcccggct gttgaaggac
cagctctccc tgggaaatgc tgcacttcag 300atcacagatg tgaaattgca
ggatgcaggg gtgtaccgct gcatgatcag ctatggtggt 360gccgactaca
agcgaattac tgtgaaagtc aatgccccat acaacaaaat caaccaaaga
420attttggttg tggatccagt cacctctgaa catgaactga catgtcaggc
tgagggctac 480cccaaggccg aagtcatctg gacaagcagt gaccatcaag
tcctgagtgg taagaccacc 540accaccaatt ccaagagaga ggagaagctt
ttcaatgtga ccagcacact gagaatcaac 600acaacaacta atgagatttt
ctactgcact tttaggagat tagatcctga ggaaaaccat 660acagctgaat
tggtcatccc agaactacct ctggcacatc ctccaaatga aaggactcac
720ttggtaattc tgggagccat cttattatgc cttggtgtag cactgacatt
catcttccgt 780ttaagaaaag ggagaatgat ggatgtgaaa aaatgtggca
tccaagatac aaactcaaag 840aagcaaagtg atacacattt ggaggagacg taa
87335290PRTHomo sapiens 35Met Arg Ile Phe Ala Val Phe Ile Phe Met
Thr Tyr Trp His Leu Leu 1 5 10 15 Asn Ala Phe Thr Val Thr Val Pro
Lys Asp Leu Tyr Val Val Glu Tyr 20 25 30 Gly Ser Asn Met Thr Ile
Glu Cys Lys Phe Pro Val Glu Lys Gln Leu 35 40 45 Asp Leu Ala Ala
Leu Ile Val Tyr Trp Glu Met Glu Asp Lys Asn Ile 50 55 60 Ile Gln
Phe Val His Gly Glu Glu Asp Leu Lys Val Gln His Ser Ser 65 70 75 80
Tyr Arg Gln Arg Ala Arg Leu Leu Lys Asp Gln Leu Ser Leu Gly Asn 85
90 95 Ala Ala Leu Gln Ile Thr Asp Val Lys Leu Gln Asp Ala Gly Val
Tyr 100 105 110 Arg Cys Met Ile Ser Tyr Gly Gly Ala Asp Tyr Lys Arg
Ile Thr Val 115 120 125 Lys Val Asn Ala Pro Tyr Asn Lys Ile Asn Gln
Arg Ile Leu Val Val 130 135 140 Asp Pro Val Thr Ser Glu His Glu Leu
Thr Cys Gln Ala Glu Gly Tyr 145 150 155 160 Pro Lys Ala Glu Val Ile
Trp Thr Ser Ser Asp His Gln Val Leu Ser 165 170 175 Gly Lys Thr Thr
Thr Thr Asn Ser Lys Arg Glu Glu Lys Leu Phe Asn 180 185 190 Val Thr
Ser Thr Leu Arg Ile Asn Thr Thr Thr Asn Glu Ile Phe Tyr 195 200 205
Cys Thr Phe Arg Arg Leu Asp Pro Glu Glu Asn His Thr Ala Glu Leu 210
215 220 Val Ile Pro Glu Leu Pro Leu Ala His Pro Pro Asn Glu Arg Thr
His 225 230 235 240 Leu Val Ile Leu Gly Ala Ile Leu Leu Cys Leu Gly
Val Ala Leu Thr 245 250 255 Phe Ile Phe Arg Leu Arg Lys Gly Arg Met
Met Asp Val Lys Lys Cys 260 265 270 Gly Ile Gln Asp Thr Asn Ser Lys
Lys Gln Ser Asp Thr His Leu Glu 275 280 285 Glu Thr 290
36909DNAHomo sapiens 36atgcggctgg gcagtcctgg actgctcttc ctgctcttca
gcagccttcg agctgatact 60caggagaagg aagtcagagc gatggtaggc agcgacgtgg
agctcagctg cgcttgccct 120gaaggaagcc gttttgattt aaatgatgtt
tacgtatatt ggcaaaccag tgagtcgaaa 180accgtggtga cctaccacat
cccacagaac agctccttgg aaaacgtgga cagccgctac 240cggaaccgag
ccctgatgtc accggccggc atgctgcggg gcgacttctc cctgcgcttg
300ttcaacgtca
ccccccagga cgagcagaag tttcactgcc tggtgttgag ccaatccctg
360ggattccagg aggttttgag cgttgaggtt acactgcatg tggcagcaaa
cttcagcgtg 420cccgtcgtca gcgcccccca cagcccctcc caggatgagc
tcaccttcac gtgtacatcc 480ataaacggct accccaggcc caacgtgtac
tggatcaata agacggacaa cagcctgctg 540gaccaggctc tgcagaatga
caccgtcttc ttgaacatgc ggggcttgta tgacgtggtc 600agcgtgctga
ggatcgcacg gacccccagc gtgaacattg gctgctgcat agagaacgtg
660cttctgcagc agaacctgac tgtcggcagc cagacaggaa atgacatcgg
agagagagac 720aagatcacag agaatccagt cagtaccggc gagaaaaacg
cggccacgtg gagcatcctg 780gctgtcctgt gcctgcttgt ggtcgtggcg
gtggccatag gctgggtgtg cagggaccga 840tgcctccaac acagctatgc
aggtgcctgg gctgtgagtc cggagacaga gctcactggc 900cacgtttga
90937302PRTHomo sapiens 37Met Arg Leu Gly Ser Pro Gly Leu Leu Phe
Leu Leu Phe Ser Ser Leu 1 5 10 15 Arg Ala Asp Thr Gln Glu Lys Glu
Val Arg Ala Met Val Gly Ser Asp 20 25 30 Val Glu Leu Ser Cys Ala
Cys Pro Glu Gly Ser Arg Phe Asp Leu Asn 35 40 45 Asp Val Tyr Val
Tyr Trp Gln Thr Ser Glu Ser Lys Thr Val Val Thr 50 55 60 Tyr His
Ile Pro Gln Asn Ser Ser Leu Glu Asn Val Asp Ser Arg Tyr 65 70 75 80
Arg Asn Arg Ala Leu Met Ser Pro Ala Gly Met Leu Arg Gly Asp Phe 85
90 95 Ser Leu Arg Leu Phe Asn Val Thr Pro Gln Asp Glu Gln Lys Phe
His 100 105 110 Cys Leu Val Leu Ser Gln Ser Leu Gly Phe Gln Glu Val
Leu Ser Val 115 120 125 Glu Val Thr Leu His Val Ala Ala Asn Phe Ser
Val Pro Val Val Ser 130 135 140 Ala Pro His Ser Pro Ser Gln Asp Glu
Leu Thr Phe Thr Cys Thr Ser 145 150 155 160 Ile Asn Gly Tyr Pro Arg
Pro Asn Val Tyr Trp Ile Asn Lys Thr Asp 165 170 175 Asn Ser Leu Leu
Asp Gln Ala Leu Gln Asn Asp Thr Val Phe Leu Asn 180 185 190 Met Arg
Gly Leu Tyr Asp Val Val Ser Val Leu Arg Ile Ala Arg Thr 195 200 205
Pro Ser Val Asn Ile Gly Cys Cys Ile Glu Asn Val Leu Leu Gln Gln 210
215 220 Asn Leu Thr Val Gly Ser Gln Thr Gly Asn Asp Ile Gly Glu Arg
Asp 225 230 235 240 Lys Ile Thr Glu Asn Pro Val Ser Thr Gly Glu Lys
Asn Ala Ala Thr 245 250 255 Trp Ser Ile Leu Ala Val Leu Cys Leu Leu
Val Val Val Ala Val Ala 260 265 270 Ile Gly Trp Val Cys Arg Asp Arg
Cys Leu Gln His Ser Tyr Ala Gly 275 280 285 Ala Trp Ala Val Ser Pro
Glu Thr Glu Leu Thr Gly His Val 290 295 300 38867DNAHomo sapiens
38atgggccaca cacggaggca gggaacatca ccatccaagt gtccatacct caatttcttt
60cagctcttgg tgctggctgg tctttctcac ttctgttcag gtgttatcca cgtgaccaag
120gaagtgaaag aagtggcaac gctgtcctgt ggtcacaatg tttctgttga
agagctggca 180caaactcgca tctactggca aaaggagaag aaaatggtgc
tgactatgat gtctggggac 240atgaatatat ggcccgagta caagaaccgg
accatctttg atatcactaa taacctctcc 300attgtgatcc tggctctgcg
cccatctgac gagggcacat acgagtgtgt tgttctgaag 360tatgaaaaag
acgctttcaa gcgggaacac ctggctgaag tgacgttatc agtcaaagct
420gacttcccta cacctagtat atctgacttt gaaattccaa cttctaatat
tagaaggata 480atttgctcaa cctctggagg ttttccagag cctcacctct
cctggttgga aaatggagaa 540gaattaaatg ccatcaacac aacagtttcc
caagatcctg aaactgagct ctatgctgtt 600agcagcaaac tggatttcaa
tatgacaacc aaccacagct tcatgtgtct catcaagtat 660ggacatttaa
gagtgaatca gaccttcaac tggaatacaa ccaagcaaga gcattttcct
720gataacctgc tcccatcctg ggccattacc ttaatctcag taaatggaat
ttttgtgata 780tgctgcctga cctactgctt tgccccaaga tgcagagaga
gaaggaggaa tgagagattg 840agaagggaaa gtgtacgccc tgtatag
86739288PRTHomo sapiens 39Met Gly His Thr Arg Arg Gln Gly Thr Ser
Pro Ser Lys Cys Pro Tyr 1 5 10 15 Leu Asn Phe Phe Gln Leu Leu Val
Leu Ala Gly Leu Ser His Phe Cys 20 25 30 Ser Gly Val Ile His Val
Thr Lys Glu Val Lys Glu Val Ala Thr Leu 35 40 45 Ser Cys Gly His
Asn Val Ser Val Glu Glu Leu Ala Gln Thr Arg Ile 50 55 60 Tyr Trp
Gln Lys Glu Lys Lys Met Val Leu Thr Met Met Ser Gly Asp 65 70 75 80
Met Asn Ile Trp Pro Glu Tyr Lys Asn Arg Thr Ile Phe Asp Ile Thr 85
90 95 Asn Asn Leu Ser Ile Val Ile Leu Ala Leu Arg Pro Ser Asp Glu
Gly 100 105 110 Thr Tyr Glu Cys Val Val Leu Lys Tyr Glu Lys Asp Ala
Phe Lys Arg 115 120 125 Glu His Leu Ala Glu Val Thr Leu Ser Val Lys
Ala Asp Phe Pro Thr 130 135 140 Pro Ser Ile Ser Asp Phe Glu Ile Pro
Thr Ser Asn Ile Arg Arg Ile 145 150 155 160 Ile Cys Ser Thr Ser Gly
Gly Phe Pro Glu Pro His Leu Ser Trp Leu 165 170 175 Glu Asn Gly Glu
Glu Leu Asn Ala Ile Asn Thr Thr Val Ser Gln Asp 180 185 190 Pro Glu
Thr Glu Leu Tyr Ala Val Ser Ser Lys Leu Asp Phe Asn Met 195 200 205
Thr Thr Asn His Ser Phe Met Cys Leu Ile Lys Tyr Gly His Leu Arg 210
215 220 Val Asn Gln Thr Phe Asn Trp Asn Thr Thr Lys Gln Glu His Phe
Pro 225 230 235 240 Asp Asn Leu Leu Pro Ser Trp Ala Ile Thr Leu Ile
Ser Val Asn Gly 245 250 255 Ile Phe Val Ile Cys Cys Leu Thr Tyr Cys
Phe Ala Pro Arg Cys Arg 260 265 270 Glu Arg Arg Arg Asn Glu Arg Leu
Arg Arg Glu Ser Val Arg Pro Val 275 280 285 40990DNAHomo sapiens
40atggatcccc agtgcactat gggactgagt aacattctct ttgtgatggc cttcctgctc
60tctggtgctg ctcctctgaa gattcaagct tatttcaatg agactgcaga cctgccatgc
120caatttgcaa actctcaaaa ccaaagcctg agtgagctag tagtattttg
gcaggaccag 180gaaaacttgg ttctgaatga ggtatactta ggcaaagaga
aatttgacag tgttcattcc 240aagtatatgg gccgcacaag ttttgattcg
gacagttgga ccctgagact tcacaatctt 300cagatcaagg acaagggctt
gtatcaatgt atcatccatc acaaaaagcc cacaggaatg 360attcgcatcc
accagatgaa ttctgaactg tcagtgcttg ctaacttcag tcaacctgaa
420atagtaccaa tttctaatat aacagaaaat gtgtacataa atttgacctg
ctcatctata 480cacggttacc cagaacctaa gaagatgagt gttttgctaa
gaaccaagaa ttcaactatc 540gagtatgatg gtattatgca gaaatctcaa
gataatgtca cagaactgta cgacgtttcc 600atcagcttgt ctgtttcatt
ccctgatgtt acgagcaata tgaccatctt ctgtattctg 660gaaactgaca
agacgcggct tttatcttca cctttctcta tagagcttga ggaccctcag
720cctcccccag accacattcc ttggattaca gctgtacttc caacagttat
tatatgtgtg 780atggttttct gtctaattct atggaaatgg aagaagaaga
agcggcctcg caactcttat 840aaatgtggaa ccaacacaat ggagagggaa
gagagtgaac agaccaagaa aagagaaaaa 900atccatatac ctgaaagatc
tgatgaagcc cagcgtgttt ttaaaagttc gaagacatct 960tcatgcgaca
aaagtgatac atgtttttag 99041329PRTHomo sapiens 41Met Asp Pro Gln Cys
Thr Met Gly Leu Ser Asn Ile Leu Phe Val Met 1 5 10 15 Ala Phe Leu
Leu Ser Gly Ala Ala Pro Leu Lys Ile Gln Ala Tyr Phe 20 25 30 Asn
Glu Thr Ala Asp Leu Pro Cys Gln Phe Ala Asn Ser Gln Asn Gln 35 40
45 Ser Leu Ser Glu Leu Val Val Phe Trp Gln Asp Gln Glu Asn Leu Val
50 55 60 Leu Asn Glu Val Tyr Leu Gly Lys Glu Lys Phe Asp Ser Val
His Ser 65 70 75 80 Lys Tyr Met Gly Arg Thr Ser Phe Asp Ser Asp Ser
Trp Thr Leu Arg 85 90 95 Leu His Asn Leu Gln Ile Lys Asp Lys Gly
Leu Tyr Gln Cys Ile Ile 100 105 110 His His Lys Lys Pro Thr Gly Met
Ile Arg Ile His Gln Met Asn Ser 115 120 125 Glu Leu Ser Val Leu Ala
Asn Phe Ser Gln Pro Glu Ile Val Pro Ile 130 135 140 Ser Asn Ile Thr
Glu Asn Val Tyr Ile Asn Leu Thr Cys Ser Ser Ile 145 150 155 160 His
Gly Tyr Pro Glu Pro Lys Lys Met Ser Val Leu Leu Arg Thr Lys 165 170
175 Asn Ser Thr Ile Glu Tyr Asp Gly Ile Met Gln Lys Ser Gln Asp Asn
180 185 190 Val Thr Glu Leu Tyr Asp Val Ser Ile Ser Leu Ser Val Ser
Phe Pro 195 200 205 Asp Val Thr Ser Asn Met Thr Ile Phe Cys Ile Leu
Glu Thr Asp Lys 210 215 220 Thr Arg Leu Leu Ser Ser Pro Phe Ser Ile
Glu Leu Glu Asp Pro Gln 225 230 235 240 Pro Pro Pro Asp His Ile Pro
Trp Ile Thr Ala Val Leu Pro Thr Val 245 250 255 Ile Ile Cys Val Met
Val Phe Cys Leu Ile Leu Trp Lys Trp Lys Lys 260 265 270 Lys Lys Arg
Pro Arg Asn Ser Tyr Lys Cys Gly Thr Asn Thr Met Glu 275 280 285 Arg
Glu Glu Ser Glu Gln Thr Lys Lys Arg Glu Lys Ile His Ile Pro 290 295
300 Glu Arg Ser Asp Glu Ala Gln Arg Val Phe Lys Ser Ser Lys Thr Ser
305 310 315 320 Ser Cys Asp Lys Ser Asp Thr Cys Phe 325
42849DNAHomo sapiens 42atggcttccc tggggcagat cctcttctgg agcataatta
gcatcatcat tattctggct 60ggagcaattg cactcatcat tggctttggt atttcaggga
gacactccat cacagtcact 120actgtcgcct cagctgggaa cattggggag
gatggaatcc tgagctgcac ttttgaacct 180gacatcaaac tttctgatat
cgtgatacaa tggctgaagg aaggtgtttt aggcttggtc 240catgagttca
aagaaggcaa agatgagctg tcggagcagg atgaaatgtt cagaggccgg
300acagcagtgt ttgctgatca agtgatagtt ggcaatgcct ctttgcggct
gaaaaacgtg 360caactcacag atgctggcac ctacaaatgt tatatcatca
cttctaaagg caaggggaat 420gctaaccttg agtataaaac tggagccttc
agcatgccgg aagtgaatgt ggactataat 480gccagctcag agaccttgcg
gtgtgaggct ccccgatggt tcccccagcc cacagtggtc 540tgggcatccc
aagttgacca gggagccaac ttctcggaag tctccaatac cagctttgag
600ctgaactctg agaatgtgac catgaaggtt gtgtctgtgc tctacaatgt
tacgatcaac 660aacacatact cctgtatgat tgaaaatgac attgccaaag
caacagggga tatcaaagtg 720acagaatcgg agatcaaaag gcggagtcac
ctacagctgc taaactcaaa ggcttctctg 780tgtgtctctt ctttctttgc
catcagctgg gcacttctgc ctctcagccc ttacctgatg 840ctaaaatag
84943282PRTHomo sapiens 43Met Ala Ser Leu Gly Gln Ile Leu Phe Trp
Ser Ile Ile Ser Ile Ile 1 5 10 15 Ile Ile Leu Ala Gly Ala Ile Ala
Leu Ile Ile Gly Phe Gly Ile Ser 20 25 30 Gly Arg His Ser Ile Thr
Val Thr Thr Val Ala Ser Ala Gly Asn Ile 35 40 45 Gly Glu Asp Gly
Ile Leu Ser Cys Thr Phe Glu Pro Asp Ile Lys Leu 50 55 60 Ser Asp
Ile Val Ile Gln Trp Leu Lys Glu Gly Val Leu Gly Leu Val 65 70 75 80
His Glu Phe Lys Glu Gly Lys Asp Glu Leu Ser Glu Gln Asp Glu Met 85
90 95 Phe Arg Gly Arg Thr Ala Val Phe Ala Asp Gln Val Ile Val Gly
Asn 100 105 110 Ala Ser Leu Arg Leu Lys Asn Val Gln Leu Thr Asp Ala
Gly Thr Tyr 115 120 125 Lys Cys Tyr Ile Ile Thr Ser Lys Gly Lys Gly
Asn Ala Asn Leu Glu 130 135 140 Tyr Lys Thr Gly Ala Phe Ser Met Pro
Glu Val Asn Val Asp Tyr Asn 145 150 155 160 Ala Ser Ser Glu Thr Leu
Arg Cys Glu Ala Pro Arg Trp Phe Pro Gln 165 170 175 Pro Thr Val Val
Trp Ala Ser Gln Val Asp Gln Gly Ala Asn Phe Ser 180 185 190 Glu Val
Ser Asn Thr Ser Phe Glu Leu Asn Ser Glu Asn Val Thr Met 195 200 205
Lys Val Val Ser Val Leu Tyr Asn Val Thr Ile Asn Asn Thr Tyr Ser 210
215 220 Cys Met Ile Glu Asn Asp Ile Ala Lys Ala Thr Gly Asp Ile Lys
Val 225 230 235 240 Thr Glu Ser Glu Ile Lys Arg Arg Ser His Leu Gln
Leu Leu Asn Ser 245 250 255 Lys Ala Ser Leu Cys Val Ser Ser Phe Phe
Ala Ile Ser Trp Ala Leu 260 265 270 Leu Pro Leu Ser Pro Tyr Leu Met
Leu Lys 275 280 4410PRTMus musculus 44Glu Val Gln Leu Gln Gln Ser
Gly Pro Glu 1 5 10 4514PRTMus musculus 45Ile Val Leu Ser Gln Ser
Pro Thr Ile Leu Ser Ala Ser Pro 1 5 10 4626DNAArtificial
SequencePCR primer 46aagaattcat ggaatggagt tggata
264732DNAArtificial SequencePCR primer 47aagatatctc atttacccgg
agtccgggag aa 324826DNAArtificial SequencePCR primer 48aagaattcat
ggattttctg gtgcag 264932DNAArtificial SequencePCR primer
49aagatatctt aacactcatt cctgttgaag ct 32501413DNAMus musculus
50atggaatgga gttggatatt tctctttctc ctgtcaggaa ctgcaggtgt ccactctgag
60gtccagctgc agcagtctgg acctgagctg gtaaagcctg gggcttcagt gaagatgtcc
120tgcaaggctt ctggatacac attcactaac tatgttatgc actgggtgaa
gcagaagcct 180gggcagggcc ttgagtggat tggatatatt aatccttaca
atgatgatgt taagtacaat 240gagaagttca aaggcaaggc cacacagact
tcagacaaat cctccagcac agcctacatg 300gagctcagca gcctgacctc
tgaggactct gcggtctatt actgtgcaag atgggggtac 360tacggtagtc
ccttatacta ctttgactac tggggccaag gcaccactct cacagtctcc
420tcagccaaaa caacagcccc atcggtctat ccactggccc ctgtgtgtgg
agatacaact 480ggctcctcgg tgactctagg atgcctggtc aagggttatt
tccctgagcc agtgaccttg 540acctggaact ctggatccct gtccagtggt
gtgcacacct tcccagctgt cctgcagtct 600gacctctaca ccctcagcag
ctcagtgact gtaacctcga gcacctggcc cagccagtcc 660atcacctgca
atgtggccca cccggcaagc agcaccaagg tggacaagaa aattgagccc
720agagggccca caatcaagcc ctgtcctcca tgcaaatgcc cagcacctaa
cctcttgggt 780ggaccatccg tcttcatctt ccctccaaag atcaaggatg
tactcatgat ctccctgagc 840cccatagtca catgtgtggt ggtggatgtg
agcgaggatg acccagatgt ccagatcagc 900tggtttgtga acaacgtgga
agtacacaca gctcagacac aaacccatag agaggattac 960aacagtactc
tccgggtggt cagtgccctc cccatccagc accaggactg gatgagtggc
1020aaggagttca aatgcaaggt caacaacaaa gacctcccag cgcccatcga
gagaaccatc 1080tcaaaaccca aagggtcagt aagagctcca caggtatatg
tcttgcctcc accagaagaa 1140gagatgacta agaaacaggt cactctgacc
tgcatggtca cagacttcat gcctgaagac 1200atttacgtgg agtggaccaa
caacgggaaa acagagctaa actacaagaa cactgaacca 1260gtcctggact
ctgatggttc ttacttcatg tacagcaagc tgagagtgga aaagaagaac
1320tgggtggaaa gaaatagcta ctcctgttca gtggtccacg agggtctgca
caatcaccac 1380acgactaaga gcttctcccg gactccgggt aaa 141351471PRTMus
musculus 51Met Glu Trp Ser Trp Ile Phe Leu Phe Leu Leu Ser Gly Thr
Ala Gly 1 5 10 15 Val His Ser Glu Val Gln Leu Gln Gln Ser Gly Pro
Glu Leu Val Lys 20 25 30 Pro Gly Ala Ser Val Lys Met Ser Cys Lys
Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Asn Tyr Val Met His Trp Val
Lys Gln Lys Pro Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Tyr Ile
Asn Pro Tyr Asn Asp Asp Val Lys Tyr Asn 65 70 75 80 Glu Lys Phe Lys
Gly Lys Ala Thr Gln Thr Ser Asp Lys Ser Ser Ser 85 90 95 Thr Ala
Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110
Tyr Tyr Cys Ala Arg Trp Gly Tyr Tyr Gly Ser Pro Leu Tyr Tyr Phe 115
120 125 Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys
Thr 130 135 140 Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly
Asp Thr Thr 145 150 155 160 Gly Ser Ser Val Thr Leu Gly Cys Leu Val
Lys Gly Tyr Phe Pro Glu 165 170 175 Pro Val Thr Leu Thr Trp Asn Ser
Gly Ser Leu Ser Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu
Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser 195 200 205 Val Thr Val Thr
Ser Ser Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn 210 215 220 Val Ala
His Pro Ala Ser Ser Thr Lys Val Asp Lys
Lys Ile Glu Pro 225 230 235 240 Arg Gly Pro Thr Ile Lys Pro Cys Pro
Pro Cys Lys Cys Pro Ala Pro 245 250 255 Asn Leu Leu Gly Gly Pro Ser
Val Phe Ile Phe Pro Pro Lys Ile Lys 260 265 270 Asp Val Leu Met Ile
Ser Leu Ser Pro Ile Val Thr Cys Val Val Val 275 280 285 Asp Val Ser
Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val Asn 290 295 300 Asn
Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp Tyr 305 310
315 320 Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln
Asp 325 330 335 Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn
Lys Asp Leu 340 345 350 Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro
Lys Gly Ser Val Arg 355 360 365 Ala Pro Gln Val Tyr Val Leu Pro Pro
Pro Glu Glu Glu Met Thr Lys 370 375 380 Lys Gln Val Thr Leu Thr Cys
Met Val Thr Asp Phe Met Pro Glu Asp 385 390 395 400 Ile Tyr Val Glu
Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr Lys 405 410 415 Asn Thr
Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr Ser 420 425 430
Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr Ser 435
440 445 Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys
Ser 450 455 460 Phe Ser Arg Thr Pro Gly Lys 465 470 52705DNAMus
musculus 52atggattttc tggtgcagat tttcagcttc ctgctaatca gtgcttcagt
cataatgtcc 60agaggacaaa ttgttctctc ccagtctcca acaatcctgt ctgcatctcc
aggggagaag 120gtcacaatga cttgcagggc cagctcaaga ctaatttaca
tgcattggta tcagcagaag 180ccaggatcct cccccaaacc ctggatttat
gccacatcca acctggcttc tggagtccct 240gctcgcttca gtggcagtgg
gtctgggacc tcttactctc tcacaatcag cagagtggag 300gctgaagatg
ctgccactta ttactgccag cagtggaata gtaacccacc cacgttcggt
360actgggacca agctggagct gaaacgggct gatgctgcac caactgtatc
catcttccca 420ccatccagtg agcagttaac atctggaggt gcctcagtcg
tgtgcttctt gaacaacttc 480taccccaaag acatcaatgt caagtggaag
attgatggca gtgaacgaca aaatggcgtc 540ctgaacagtt ggactgatca
ggacagcaaa gacagcacct acagcatgag cagcaccctc 600acgttgacca
aggacgagta tgaacgacat aacagctata cctgtgaggc cactcacaag
660acatcaactt cacccattgt caagagcttc aacaggaatg agtgt 70553235PRTMus
musculus 53Met Asp Phe Leu Val Gln Ile Phe Ser Phe Leu Leu Ile Ser
Ala Ser 1 5 10 15 Val Ile Met Ser Arg Gly Gln Ile Val Leu Ser Gln
Ser Pro Thr Ile 20 25 30 Leu Ser Ala Ser Pro Gly Glu Lys Val Thr
Met Thr Cys Arg Ala Ser 35 40 45 Ser Arg Leu Ile Tyr Met His Trp
Tyr Gln Gln Lys Pro Gly Ser Ser 50 55 60 Pro Lys Pro Trp Ile Tyr
Ala Thr Ser Asn Leu Ala Ser Gly Val Pro 65 70 75 80 Ala Arg Phe Ser
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile 85 90 95 Ser Arg
Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp 100 105 110
Asn Ser Asn Pro Pro Thr Phe Gly Thr Gly Thr Lys Leu Glu Leu Lys 115
120 125 Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser
Glu 130 135 140 Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu
Asn Asn Phe 145 150 155 160 Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys
Ile Asp Gly Ser Glu Arg 165 170 175 Gln Asn Gly Val Leu Asn Ser Trp
Thr Asp Gln Asp Ser Lys Asp Ser 180 185 190 Thr Tyr Ser Met Ser Ser
Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu 195 200 205 Arg His Asn Ser
Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser 210 215 220 Pro Ile
Val Lys Ser Phe Asn Arg Asn Glu Cys 225 230 235 5428DNAArtificial
SequencePCR primer 54ccacgcgccc tgtagcggcg cattaagc
285530DNAArtificial SequencePCR primer 55aaacccggga gctttttgca
aaagcctagg 30561704DNAArtificial Sequencehuman kappa chain
secretion signal, human kappa chain constant region and human poly
A additional signal 56ggtaccaccc aagctggcta ggtaagcttg ctagcgccac
catggtgctg cagacccagg 60tgttcatctc cctgctgctg tggatctccg gcgcatatgg
cgatatcgtg atgattaaac 120gtacggtggc cgccccctcc gtgttcatct
tccccccctc cgacgagcag ctgaagtccg 180gcaccgcctc cgtggtgtgc
ctgctgaata acttctaccc cagagaggcc aaggtgcagt 240ggaaggtgga
caacgccctg cagtccggga actcccagga gagcgtgacc gagcaggaca
300gcaaggacag cacctacagc ctgagcagca ccctgaccct gagcaaagcc
gactacgaga 360agcacaaggt gtacgcctgc gaggtgaccc accagggcct
gagctccccc gtcaccaaga 420gcttcaacag gggggagtgt taggggcccg
tttaaacggg tggcatccct gtgacccctc 480cccagtgcct ctcctggccc
tggaagttgc cactccagtg cccaccagcc ttgtcctaat 540aaaattaagt
tgcatcattt tgtctgacta ggtgtccttc tataatatta tggggtggag
600gggggtggta tggagcaagg ggcaagttgg gaagacaacc tgtagggcct
gcggggtcta 660ttgggaacca agctggagtg cagtggcaca atcttggctc
actgcaatct ccgcctcctg 720ggttcaagcg attctcctgc ctcagcctcc
cgagttgttg ggattccagg catgcatgac 780caggctcacc taatttttgt
ttttttggta gagacggggt ttcaccatat tggccaggct 840ggtctccaac
tcctaatctc aggtgatcta cccaccttgg cctcccaaat tgctgggatt
900acaggcgtga accactgctc cacgcgccct gtagcggcgc attaagcgcg
gcgggtgtgg 960tggttacgcg cagcgtgacc gctacacttg ccagcgccct
agcgcccgct cctttcgctt 1020tcttcccttc ctttctcgcc acgttcgccg
gctttccccg tcaagctcta aatcgggggc 1080tccctttagg gttccgattt
agtgctttac ggcacctcga ccccaaaaaa cttgattagg 1140gtgatggttc
acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg
1200agtccacgtt ctttaatagt ggactcttgt tccaaactgg aacaacactc
aaccctatct 1260cggtctattc ttttgattta taagggattt tgccgatttc
ggcctattgg ttaaaaaatg 1320agctgattta acaaaaattt aacgcgaatt
aattctgtgg aatgtgtgtc agttagggtg 1380tggaaagtcc ccaggctccc
cagcaggcag aagtatgcaa agcatgcatc tcaattagtc 1440agcaaccagg
tgtggaaagt ccccaggctc cccagcaggc agaagtatgc aaagcatgca
1500tctcaattag tcagcaacca tagtcccgcc cctaactccg cccatcccgc
ccctaactcc 1560gcccagttcc gcccattctc cgccccatgg ctgactaatt
ttttttattt atgcagaggc 1620cgaggccgcc tctgcctctg agctattcca
gaagtagtga ggaggctttt ttggaggcct 1680aggcttttgc aaaaagctcc cggg
1704571120DNAArtificial Sequencehuman IgG1 signal sequence and
constant region 57tgctagcgcc accatgaaac acctgtggtt cttcctcctg
ctggtggcag ctcccagatg 60ggtgctgagc caggtgcaat tgtgcaggcg gttagctcag
cctccaccaa gggcccaagc 120gtcttccccc tggcaccctc ctccaagagc
acctctggcg gcacagccgc cctgggctgc 180ctggtcaagg actacttccc
cgaacccgtg accgtgagct ggaactcagg cgccctgacc 240agcggcgtgc
acaccttccc cgctgtcctg cagtcctcag gactctactc cctcagcagc
300gtggtgaccg tgccctccag cagcttgggc acccagacct acatctgcaa
cgtgaatcac 360aagcccagca acaccaaggt ggacaagaga gttgagccca
aatcttgtga caaaactcac 420acatgcccac cctgcccagc acctgaactc
ctggggggac cctcagtctt cctcttcccc 480ccaaaaccca aggacaccct
catgatctcc cggacccctg aggtcacatg cgtggtggtg 540gacgtgagcc
acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg
600cataatgcca agacaaagcc ccgggaggag cagtacaaca gcacgtaccg
ggtggtcagc 660gtcctcaccg tcctgcacca ggactggctg aatggcaagg
agtacaagtg caaggtctcc 720aacaaagccc tcccagcccc catcgagaaa
accatctcca aagccaaagg ccagccccgg 780gaaccacagg tgtacaccct
gcccccatcc cgggaggaga tgaccaagaa ccaggtcagc 840ctgacctgcc
tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat
900ggccagcccg agaacaacta caagaccacc cctcccgtgc tggactccga
cggctccttc 960ttcctctaca gcaagctcac cgtggacaag agcaggtggc
agcagggcaa cgtcttctca 1020tgctccgtga tgcatgaggc tctgcacaac
cactacaccc agaagagcct ctccctgtct 1080cccggcaaat gagatatcgg
gcccgtttaa acgggtggca 112058699DNAArtificial SequenceLight chain of
chimeric M30 58atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60caaattgttc tctcccagtc tccaacaatc ctgtctgcat
ctccagggga gaaggtcaca 120atgacttgca gggccagctc aagactaatt
tacatgcatt ggtatcagca gaagccagga 180tcctccccca aaccctggat
ttatgccaca tccaacctgg cttctggagt ccctgctcgc 240ttcagtggca
gtgggtctgg gacctcttac tctctcacaa tcagcagagt ggaggctgaa
300gatgctgcca cttattactg ccagcagtgg aatagtaacc cacccacgtt
cggtactggg 360accaagctgg agctgaaacg tacggtggcc gccccctccg
tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg caccgcctcc
gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca aggtgcagtg
gaaggtggac aacgccctgc agtccgggaa ctcccaggag 540agcgtgaccg
agcaggacag caaggacagc acctacagcc tgagcagcac cctgaccctg
600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca
ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69959233PRTArtificial SequenceLight chain of chimeric M30 59Met Val
Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10 15
Gly Ala Tyr Gly Gln Ile Val Leu Ser Gln Ser Pro Thr Ile Leu Ser 20
25 30 Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser
Arg 35 40 45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser
Ser Pro Lys 50 55 60 Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala Ser
Gly Val Pro Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr Ser
Tyr Ser Leu Thr Ile Ser Arg 85 90 95 Val Glu Ala Glu Asp Ala Ala
Thr Tyr Tyr Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr Phe
Gly Thr Gly Thr Lys Leu Glu Leu Lys Arg Thr 115 120 125 Val Ala Ala
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140 Lys
Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145 150
155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr His
Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg Gly
Glu Cys 225 230 6042DNAArtificial SequencePCR primer 60aaacatatgg
ccaaattgtt ctctcccagt ctccaacaat cc 426137DNAArtificial SequencePCR
primer 61aaacgtacgt ttcagctcca gcttggtccc agtaccg
37621413DNAArtificial SequenceHeavy chain of chimeric M30
62atgaaacacc tgtggttctt cctcctgctg gtggcagctc ccagatgggt gctgagcgag
60gtccagctgc agcagtctgg acctgagctg gtaaagcctg gggcttcagt gaagatgtcc
120tgcaaggctt ctggatacac attcactaac tatgttatgc actgggtgaa
gcagaagcct 180gggcagggcc ttgagtggat tggatatatt aatccttaca
atgatgatgt taagtacaat 240gagaagttca aaggcaaggc cacacagact
tcagacaaat cctccagcac agcctacatg 300gaactcagca gcctgacctc
tgaggactct gcggtctatt actgtgcaag atgggggtac 360tacggtagtc
ccttatacta ctttgactac tggggccaag gcaccactct cacagtcagc
420tcagcctcca ccaagggccc aagcgtcttc cccctggcac cctcctccaa
gagcacctct 480ggcggcacag ccgccctggg ctgcctggtc aaggactact
tccccgaacc cgtgaccgtg 540agctggaact caggcgccct gaccagcggc
gtgcacacct tccccgctgt cctgcagtcc 600tcaggactct actccctcag
cagcgtggtg accgtgccct ccagcagctt gggcacccag 660acctacatct
gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag
720cccaaatctt gtgacaaaac tcacacatgc ccaccctgcc cagcacctga
actcctgggg 780ggaccctcag tcttcctctt ccccccaaaa cccaaggaca
ccctcatgat ctcccggacc 840cctgaggtca catgcgtggt ggtggacgtg
agccacgaag accctgaggt caagttcaac 900tggtacgtgg acggcgtgga
ggtgcataat gccaagacaa agccccggga ggagcagtac 960aacagcacgt
accgggtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc
1020aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga
gaaaaccatc 1080tccaaagcca aaggccagcc ccgggaacca caggtgtaca
ccctgccccc atcccgggag 1140gagatgacca agaaccaggt cagcctgacc
tgcctggtca aaggcttcta tcccagcgac 1200atcgccgtgg agtgggagag
caatggccag cccgagaaca actacaagac cacccctccc 1260gtgctggact
ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg
1320tggcagcagg gcaacgtctt ctcatgctcc gtgatgcatg aggctctgca
caaccactac 1380acccagaaga gcctctccct gtctcccggc aaa
141363471PRTArtificial SequenceHeavy chain of chimeric M30 63Met
Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp 1 5 10
15 Val Leu Ser Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
20 25 30 Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr
Thr Phe 35 40 45 Thr Asn Tyr Val Met His Trp Val Lys Gln Lys Pro
Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn
Asp Asp Val Lys Tyr Asn 65 70 75 80 Glu Lys Phe Lys Gly Lys Ala Thr
Gln Thr Ser Asp Lys Ser Ser Ser 85 90 95 Thr Ala Tyr Met Glu Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110 Tyr Tyr Cys Ala
Arg Trp Gly Tyr Tyr Gly Ser Pro Leu Tyr Tyr Phe 115 120 125 Asp Tyr
Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Ser Thr 130 135 140
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145
150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Arg Val Glu 225 230 235 240 Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265
270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390
395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys
465 470 6440DNAArtificial SequencePCR primer 64aaagctgagc
gaggtccagc tgcagcagtc tggacctgag 406536DNAArtificial SequencePCR
primer 65gaggtcaggc tgctgagttc catgtaggct gtgctg
366636DNAArtificial SequencePCR primer 66cagcacagcc tacatggaac
tcagcagcct gacctc 366739DNAArtificial SequencePCR primer
67aaagctgagc tgactgtgag agtggtgcct tggccccag 396840DNAArtificial
SequencePCR primer 68aaagctgagc gaggtccagc tgcagcagtc tggacctgag
406939DNAArtificial SequencePCR primer 69aaagctgagc tgactgtgag
agtggtgcct tggccccag 3970699DNAArtificial SequenceHumanized light
chain of M30 70atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60gagatcgtgc tgacccagag ccccgccacc
ctgtctctga gccctggcga gagagccacc 120ctgagctgca gagccagcag
ccgcctgatc tacatgcact ggtatcagca gaagcccggc 180caggccccca
gactgctgat ctacgccacc agcaacctgg ccagcggcat ccccgccaga
240ttttctggca gcggcagcgg caccgacttc accctgacca tctctcggct
ggaacccgag 300gacttcgccg tgtactactg ccagcagtgg aacagcaacc
cccccacctt cggccagggc 360accaaggtcg aaatcaagcg tacggtggcc
gccccctccg tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg
caccgcctcc gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca
aggtgcagtg gaaggtggac aacgccctgc agtccgggaa ctcccaggag
540agcgtgaccg agcaggacag caaggacagc acctacagcc tgagcagcac
cctgaccctg 600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg
aggtgaccca ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69971233PRTArtificial SequenceHumanized light chain of M30 71Met
Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10
15 Gly Ala Tyr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30 Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Ser Arg 35 40 45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg 50 55 60 Leu Leu Ile Tyr Ala Thr Ser Asn Leu Ala
Ser Gly Ile Pro Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg 85 90 95 Leu Glu Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145
150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg
Gly Glu Cys 225 230 72699DNAArtificial SequenceHumanized light
chain of M30 72atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60gagatcgtgc tgacccagag ccccgccacc ctgtctctga
gccctggcga gagagccacc 120ctgagctgca gagccagcag caggctgatc
tacatgcact ggtatcagca gaagcccggc 180caggccccca gactgtggat
ctacgccacc agcaacctgg ccagcggcat ccccgccaga 240ttttctggca
gcggcagcgg caccgactac accctgacca tcagccgcct ggaacccgag
300gacttcgccg tgtactactg ccagcagtgg aacagcaacc cccccacctt
cggccagggc 360accaaggtcg aaatcaagcg tacggtggcc gccccctccg
tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg caccgcctcc
gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca aggtgcagtg
gaaggtggac aacgccctgc agtccgggaa ctcccaggag 540agcgtgaccg
agcaggacag caaggacagc acctacagcc tgagcagcac cctgaccctg
600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca
ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69973233PRTArtificial SequenceHumanized light chain of M30 73Met
Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10
15 Gly Ala Tyr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30 Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Ser Arg 35 40 45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg 50 55 60 Leu Trp Ile Tyr Ala Thr Ser Asn Leu Ala
Ser Gly Ile Pro Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr
Asp Tyr Thr Leu Thr Ile Ser Arg 85 90 95 Leu Glu Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145
150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg
Gly Glu Cys 225 230 74699DNAArtificial SequenceHumanized light
chain of M30 74atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60cagatcgtgc tgtcccagag ccccgccacc ctgtctctga
gccctggcga gagagccacc 120ctgacctgca gagccagcag caggctgatc
tacatgcact ggtatcagca gaagcccggc 180agcgccccca agctgtggat
ctacgccacc agcaacctgg ccagcggcat ccccgccaga 240ttttctggca
gcggcagcgg caccagctac accctgacca tctcccgcct ggaacccgag
300gacttcgccg tgtactactg ccagcagtgg aacagcaacc cccccacctt
cggccagggc 360accaaggtcg aaatcaagcg tacggtggcc gccccctccg
tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg caccgcctcc
gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca aggtgcagtg
gaaggtggac aacgccctgc agtccgggaa ctcccaggag 540agcgtgaccg
agcaggacag caaggacagc acctacagcc tgagcagcac cctgaccctg
600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca
ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69975233PRTArtificial SequenceHumanized light chain of M30 75Met
Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10
15 Gly Ala Tyr Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Thr Leu Ser
20 25 30 Leu Ser Pro Gly Glu Arg Ala Thr Leu Thr Cys Arg Ala Ser
Ser Arg 35 40 45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly
Ser Ala Pro Lys 50 55 60 Leu Trp Ile Tyr Ala Thr Ser Asn Leu Ala
Ser Gly Ile Pro Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Thr Leu Thr Ile Ser Arg 85 90 95 Leu Glu Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145
150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg
Gly Glu Cys 225 230 76699DNAArtificial SequenceHumanized light
chain of M30 76atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60gagatcgtgc tgacccagag ccccgccacc ctgtctctga
gccctggcga gagagccacc 120ctgagctgca gagccagcag ccgcctgatc
tacatgcact ggtatcagca gaagcccggc 180caggccccca gacctctgat
ctacgccacc agcaacctgg ccagcggcat ccccgccaga 240ttttctggca
gcggcagcgg caccgacttc accctgacca tcagcagcct ggaacccgag
300gacttcgccg tgtactactg ccagcagtgg aacagcaacc cccccacctt
cggccagggc 360accaaggtcg aaatcaagcg tacggtggcc gccccctccg
tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg caccgcctcc
gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca aggtgcagtg
gaaggtggac aacgccctgc agtccgggaa ctcccaggag 540agcgtgaccg
agcaggacag caaggacagc acctacagcc tgagcagcac cctgaccctg
600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca
ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69977233PRTArtificial SequenceHumanized light chain of M30 77Met
Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10
15 Gly Ala Tyr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30 Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Ser Arg 35 40 45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg 50 55 60 Pro Leu Ile Tyr Ala Thr Ser Asn Leu Ala
Ser Gly Ile Pro Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser 85 90 95 Leu Glu Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145
150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg
Gly Glu Cys 225 230 78699DNAArtificial SequenceHumanized light
chain of M30 78atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60cagatcgtgc tgtcccagag ccccgccacc ctgtctctga
gccctggcga gagagccacc 120ctgacctgca gagccagcag caggctgatc
tacatgcact ggtatcagca gaagcccggc 180agcgccccca agccttggat
ctacgccacc agcaacctgg ccagcggcat ccccgccaga 240ttttctggca
gcggcagcgg caccagctac accctgacca tctcccgcct ggaacccgag
300gacttcgccg tgtactactg ccagcagtgg aacagcaacc cccccacctt
cggccagggc 360accaaggtcg aaatcaagcg tacggtggcc gccccctccg
tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg caccgcctcc
gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca aggtgcagtg
gaaggtggac aacgccctgc agtccgggaa ctcccaggag 540agcgtgaccg
agcaggacag caaggacagc acctacagcc tgagcagcac cctgaccctg
600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca
ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69979233PRTArtificial SequenceHumanized light chain of M30 79Met
Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10
15 Gly Ala Tyr Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Thr Leu Ser
20 25 30 Leu Ser Pro Gly Glu Arg Ala Thr Leu Thr Cys Arg Ala Ser
Ser Arg 35 40 45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly
Ser Ala Pro Lys 50 55 60 Pro Trp Ile Tyr Ala Thr Ser Asn Leu Ala
Ser Gly Ile Pro Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr
Ser Tyr Thr Leu Thr Ile Ser Arg 85 90 95 Leu Glu Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145
150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg
Gly Glu Cys 225 230 80699DNAArtificial SequenceHumanized light
chain of M30 80atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60gagatcgtgc tgacccagag ccccgccacc ctgtctctga
gccctggcga gagagccacc 120ctgagctgca gagccagcag ccgcctgatc
tacatgcact ggtatcagca gaagcccggc 180caggccccca gacctctgat
ctacgccacc agcaacctgg ccagcggcat ccccgccaga 240ttttctggca
gcggcagcgg caccgacttc accctgacca tcagccgcct ggaacccgag
300gacttcgccg tgtactactg ccagcagtgg aacagcaacc cccccacctt
cggccagggc 360accaaggtcg aaatcaagcg tacggtggcc gccccctccg
tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg caccgcctcc
gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca aggtgcagtg
gaaggtggac aacgccctgc agtccgggaa ctcccaggag 540agcgtgaccg
agcaggacag caaggacagc acctacagcc tgagcagcac cctgaccctg
600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca
ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69981233PRTArtificial SequenceHumanized light chain of M30 81Met
Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10
15 Gly Ala Tyr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30 Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Ser Arg 35 40 45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg 50 55 60 Pro Leu Ile Tyr Ala Thr Ser Asn Leu Ala
Ser Gly Ile Pro Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Arg 85 90 95 Leu Glu Pro Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr
Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145
150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg
Gly Glu Cys 225 230 82699DNAArtificial SequenceHumanized light
chain of M30 82atggtgctgc agacccaggt gttcatctcc ctgctgctgt
ggatctccgg cgcatatggc 60gagatcgtgc tgacccagag ccccgccacc ctgtctctga
gccctggcga gagagccacc 120ctgagctgca gagccagcag ccgcctgatc
tacatgcact ggtatcagca gaagcccggc 180caggccccca gacctctgat
ctacgccacc agcaacctgg ccagcggcat ccccgccaga 240ttttctggca
gcggcagcgg caccgactac accctgacca tcagccgcct ggaacccgag
300gacttcgccg tgtactactg ccagcagtgg aacagcaacc cccccacctt
cggccagggc 360accaaggtcg aaatcaagcg tacggtggcc gccccctccg
tgttcatctt ccccccctcc 420gacgagcagc tgaagtccgg caccgcctcc
gtggtgtgcc tgctgaataa cttctacccc 480agagaggcca aggtgcagtg
gaaggtggac aacgccctgc agtccgggaa ctcccaggag 540agcgtgaccg
agcaggacag caaggacagc acctacagcc tgagcagcac cctgaccctg
600agcaaagccg actacgagaa gcacaaggtg tacgcctgcg aggtgaccca
ccagggcctg 660agctcccccg tcaccaagag cttcaacagg ggggagtgt
69983233PRTArtificial SequenceHumanized light chain of M30 83Met
Val Leu Gln Thr Gln Val Phe Ile Ser Leu Leu Leu Trp Ile Ser 1 5 10
15 Gly Ala Tyr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser
20 25 30 Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Ser Arg 35 40
45 Leu Ile Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg
50 55 60 Pro Leu Ile Tyr Ala Thr Ser Asn Leu Ala Ser Gly Ile Pro
Ala Arg 65 70 75 80 Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu
Thr Ile Ser Arg 85 90 95 Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr
Cys Gln Gln Trp Asn Ser 100 105 110 Asn Pro Pro Thr Phe Gly Gln Gly
Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala Ala Pro Ser Val
Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140 Lys Ser Gly Thr
Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145 150 155 160 Arg
Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 165 170
175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu
Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg Gly Glu Cys 225
230 841413DNAArtificial SequenceHumanized heavy chain of M30
84atgaaacacc tgtggttctt cctcctgctg gtggcagctc ccagatgggt gctgagccag
60gtgcagctgg tgcagtctgg cgccgaagtg aagaaacccg gcagcagcgt gaaggtgtcc
120tgcaaggcca gcggctacac cttcaccaac tacgtgatgc actgggtgcg
ccaggcccct 180gggcagggac tggaatggat gggctacatc aacccctaca
acgacgacgt gaagtacaac 240gagaagttca agggcagagt gaccatcacc
gccgacgaga gcaccagcac cgcctacatg 300gaactgagca gcctgcggag
cgaggacacc gccgtgtact actgcgccag atggggctac 360tacggcagcc
ccctgtacta cttcgactac tggggccagg gcaccctggt gacagtcagc
420tcagcctcca ccaagggccc aagcgtcttc cccctggcac cctcctccaa
gagcacctct 480ggcggcacag ccgccctggg ctgcctggtc aaggactact
tccccgaacc cgtgaccgtg 540agctggaact caggcgccct gaccagcggc
gtgcacacct tccccgctgt cctgcagtcc 600tcaggactct actccctcag
cagcgtggtg accgtgccct ccagcagctt gggcacccag 660acctacatct
gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag
720cccaaatctt gtgacaaaac tcacacatgc ccaccctgcc cagcacctga
actcctgggg 780ggaccctcag tcttcctctt ccccccaaaa cccaaggaca
ccctcatgat ctcccggacc 840cctgaggtca catgcgtggt ggtggacgtg
agccacgaag accctgaggt caagttcaac 900tggtacgtgg acggcgtgga
ggtgcataat gccaagacaa agccccggga ggagcagtac 960aacagcacgt
accgggtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc
1020aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga
gaaaaccatc 1080tccaaagcca aaggccagcc ccgggaacca caggtgtaca
ccctgccccc atcccgggag 1140gagatgacca agaaccaggt cagcctgacc
tgcctggtca aaggcttcta tcccagcgac 1200atcgccgtgg agtgggagag
caatggccag cccgagaaca actacaagac cacccctccc 1260gtgctggact
ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg
1320tggcagcagg gcaacgtctt ctcatgctcc gtgatgcatg aggctctgca
caaccactac 1380acccagaaga gcctctccct gtctcccggc aaa
141385471PRTArtificial SequenceHumanized heavy chain of M30 85Met
Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp 1 5 10
15 Val Leu Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30 Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe 35 40 45 Thr Asn Tyr Val Met His Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu 50 55 60 Glu Trp Met Gly Tyr Ile Asn Pro Tyr Asn
Asp Asp Val Lys Tyr Asn 65 70 75 80 Glu Lys Phe Lys Gly Arg Val Thr
Ile Thr Ala Asp Glu Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Ala
Arg Trp Gly Tyr Tyr Gly Ser Pro Leu Tyr Tyr Phe 115 120 125 Asp Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145
150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Arg Val Glu 225 230 235 240 Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265
270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390
395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys
465 470 861413DNAArtificial SequenceHumanized heavy chain of M30
86atgaaacacc tgtggttctt cctcctgctg gtggcagctc ccagatgggt gctgagccag
60gtgcagctgg tgcagtctgg cgccgaagtg aagaaacccg gcagcagcgt gaaggtgtcc
120tgcaaggcca gcggctacac cttcaccaac tacgtgatgc actgggtgcg
ccaggcccct 180gggcagggac tggaatggat cggctacatc aacccctaca
acgacgacgt gaagtacaac 240gagaagttca agggcagagt gaccatcacc
gccgacgaga gcaccagcac cgcctacatg 300gaactgagca gcctgcggag
cgaggacacc gccgtgtact actgcgccag atggggctac 360tacggcagcc
ccctgtacta cttcgactac tggggccagg gcaccctggt gacagtcagc
420tcagcctcca ccaagggccc aagcgtcttc cccctggcac cctcctccaa
gagcacctct 480ggcggcacag ccgccctggg ctgcctggtc aaggactact
tccccgaacc cgtgaccgtg 540agctggaact caggcgccct gaccagcggc
gtgcacacct tccccgctgt cctgcagtcc 600tcaggactct actccctcag
cagcgtggtg accgtgccct ccagcagctt gggcacccag 660acctacatct
gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag
720cccaaatctt gtgacaaaac tcacacatgc ccaccctgcc cagcacctga
actcctgggg 780ggaccctcag tcttcctctt ccccccaaaa cccaaggaca
ccctcatgat ctcccggacc 840cctgaggtca catgcgtggt ggtggacgtg
agccacgaag accctgaggt caagttcaac 900tggtacgtgg acggcgtgga
ggtgcataat gccaagacaa agccccggga ggagcagtac 960aacagcacgt
accgggtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc
1020aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga
gaaaaccatc 1080tccaaagcca aaggccagcc ccgggaacca caggtgtaca
ccctgccccc atcccgggag 1140gagatgacca agaaccaggt cagcctgacc
tgcctggtca aaggcttcta tcccagcgac 1200atcgccgtgg agtgggagag
caatggccag cccgagaaca actacaagac cacccctccc 1260gtgctggact
ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg
1320tggcagcagg gcaacgtctt ctcatgctcc gtgatgcatg aggctctgca
caaccactac 1380acccagaaga gcctctccct gtctcccggc aaa
141387471PRTArtificial SequenceHumanized heavy chain of M30 87Met
Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp 1 5 10
15 Val Leu Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30 Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe 35 40 45 Thr Asn Tyr Val Met His Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn
Asp Asp Val Lys Tyr Asn 65 70 75 80 Glu Lys Phe Lys Gly Arg Val Thr
Ile Thr Ala Asp Glu Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Ala
Arg Trp Gly Tyr Tyr Gly Ser Pro Leu Tyr Tyr Phe 115 120 125 Asp Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145
150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Arg Val Glu 225 230 235 240 Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265
270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390
395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys
465 470 881413DNAArtificial SequenceHumanized heavy chain of M30
88atgaaacacc tgtggttctt cctcctgctg gtggcagctc ccagatgggt gctgagcgag
60gtgcagctgg tgcagtctgg cgccgaagtg aagaaacccg gcagcagcgt gaaggtgtcc
120tgcaaggcca gcggctacac cttcaccaac tacgtgatgc actgggtgaa
acaggcccct 180gggcagggcc tggaatggat cggctacatc aacccctaca
acgacgacgt gaagtacaac 240gagaagttca agggcaaggc caccatcacc
gccgacgaga gcaccagcac cgcctacatg 300gaactgagca gcctgcggag
cgaggacacc gccgtgtact actgcgccag atggggctac 360tacggcagcc
ccctgtacta cttcgactac tggggccagg gcaccctggt gacagtcagc
420tcagcctcca ccaagggccc aagcgtcttc cccctggcac cctcctccaa
gagcacctct 480ggcggcacag ccgccctggg ctgcctggtc aaggactact
tccccgaacc cgtgaccgtg 540agctggaact caggcgccct gaccagcggc
gtgcacacct tccccgctgt cctgcagtcc 600tcaggactct actccctcag
cagcgtggtg accgtgccct ccagcagctt gggcacccag 660acctacatct
gcaacgtgaa tcacaagccc agcaacacca aggtggacaa gagagttgag
720cccaaatctt gtgacaaaac tcacacatgc ccaccctgcc cagcacctga
actcctgggg 780ggaccctcag tcttcctctt ccccccaaaa cccaaggaca
ccctcatgat ctcccggacc 840cctgaggtca catgcgtggt ggtggacgtg
agccacgaag accctgaggt caagttcaac 900tggtacgtgg acggcgtgga
ggtgcataat gccaagacaa agccccggga ggagcagtac 960aacagcacgt
accgggtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc
1020aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga
gaaaaccatc 1080tccaaagcca aaggccagcc ccgggaacca caggtgtaca
ccctgccccc atcccgggag 1140gagatgacca agaaccaggt cagcctgacc
tgcctggtca aaggcttcta tcccagcgac 1200atcgccgtgg agtgggagag
caatggccag cccgagaaca actacaagac cacccctccc 1260gtgctggact
ccgacggctc cttcttcctc tacagcaagc tcaccgtgga caagagcagg
1320tggcagcagg gcaacgtctt ctcatgctcc gtgatgcatg aggctctgca
caaccactac 1380acccagaaga gcctctccct gtctcccggc aaa
141389471PRTArtificial SequenceHumanized heavy chain of M30 89Met
Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp 1 5 10
15 Val Leu Ser Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30 Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe 35 40 45 Thr Asn Tyr Val Met His Trp Val Lys Gln Ala Pro
Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn
Asp Asp Val Lys Tyr Asn 65 70 75 80 Glu Lys Phe Lys Gly Lys Ala Thr
Ile Thr Ala Asp Glu Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu
Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Ala
Arg Trp Gly Tyr Tyr Gly Ser Pro Leu Tyr Tyr Phe 115 120 125 Asp Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 130 135 140
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145
150 155 160 Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
Pro Glu 165 170 175 Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
Ser Gly Val His 180 185 190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser Leu Ser Ser 195 200 205 Val Val Thr Val Pro Ser Ser Ser
Leu Gly Thr Gln Thr Tyr Ile Cys 210 215 220 Asn Val Asn His Lys Pro
Ser Asn Thr Lys Val Asp Lys Arg Val Glu 225 230 235 240 Pro Lys Ser
Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu
Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265
270 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
275 280 285 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
Val Asp 290 295 300 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg
Glu Glu Gln Tyr 305 310 315 320 Asn Ser Thr Tyr Arg Val Val Ser Val
Leu Thr Val Leu His Gln Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr
Lys Cys Lys Val Ser Asn Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln
Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390
395 400 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
Lys 405 410 415 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
Leu Tyr Ser 420 425 430 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
Gly Asn Val Phe Ser 435 440 445 Cys Ser Val Met His Glu Ala Leu His
Asn His Tyr Thr Gln Lys Ser 450
455 460 Leu Ser Leu Ser Pro Gly Lys 465 470 901413DNAArtificial
SequenceHumanized heavy chain of M30 90atgaaacacc tgtggttctt
cctcctgctg gtggcagctc ccagatgggt gctgagcgag 60gtgcagctgg tgcagtctgg
cgccgaagtg aagaaacccg gcagcagcgt gaaggtgtcc 120tgcaaggcca
gcggctacac cttcaccaac tacgtgatgc actgggtcaa gcaggcccct
180gggcagggcc tggaatggat cggctacatc aacccctaca acgacgacgt
gaagtacaac 240gagaagttca agggcaaggc cacccagacc agcgacaaga
gcaccagcac cgcctacatg 300gaactgagca gcctgcggag cgaggacacc
gccgtgtact actgcgccag atggggctac 360tacggcagcc ccctgtacta
cttcgactac tggggccagg gcaccctggt caccgtcagc 420tcagcctcca
ccaagggccc aagcgtcttc cccctggcac cctcctccaa gagcacctct
480ggcggcacag ccgccctggg ctgcctggtc aaggactact tccccgaacc
cgtgaccgtg 540agctggaact caggcgccct gaccagcggc gtgcacacct
tccccgctgt cctgcagtcc 600tcaggactct actccctcag cagcgtggtg
accgtgccct ccagcagctt gggcacccag 660acctacatct gcaacgtgaa
tcacaagccc agcaacacca aggtggacaa gagagttgag 720cccaaatctt
gtgacaaaac tcacacatgc ccaccctgcc cagcacctga actcctgggg
780ggaccctcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat
ctcccggacc 840cctgaggtca catgcgtggt ggtggacgtg agccacgaag
accctgaggt caagttcaac 900tggtacgtgg acggcgtgga ggtgcataat
gccaagacaa agccccggga ggagcagtac 960aacagcacgt accgggtggt
cagcgtcctc accgtcctgc accaggactg gctgaatggc 1020aaggagtaca
agtgcaaggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc
1080tccaaagcca aaggccagcc ccgggaacca caggtgtaca ccctgccccc
atcccgggag 1140gagatgacca agaaccaggt cagcctgacc tgcctggtca
aaggcttcta tcccagcgac 1200atcgccgtgg agtgggagag caatggccag
cccgagaaca actacaagac cacccctccc 1260gtgctggact ccgacggctc
cttcttcctc tacagcaagc tcaccgtgga caagagcagg 1320tggcagcagg
gcaacgtctt ctcatgctcc gtgatgcatg aggctctgca caaccactac
1380acccagaaga gcctctccct gtctcccggc aaa 141391471PRTArtificial
SequenceHumanized heavy chain of M30 91Met Lys His Leu Trp Phe Phe
Leu Leu Leu Val Ala Ala Pro Arg Trp 1 5 10 15 Val Leu Ser Glu Val
Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ser
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Thr
Asn Tyr Val Met His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu 50 55
60 Glu Trp Ile Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Val Lys Tyr Asn
65 70 75 80 Glu Lys Phe Lys Gly Lys Ala Thr Gln Thr Ser Asp Lys Ser
Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Ala Arg Trp Gly Tyr Tyr Gly
Ser Pro Leu Tyr Tyr Phe 115 120 125 Asp Tyr Trp Gly Gln Gly Thr Leu
Val Thr Val Ser Ser Ala Ser Thr 130 135 140 Lys Gly Pro Ser Val Phe
Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 145 150 155 160 Gly Gly Thr
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 165 170 175 Pro
Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 180 185
190 Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
195 200 205 Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
Ile Cys 210 215 220 Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
Lys Arg Val Glu 225 230 235 240 Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys Pro Ala Pro 245 250 255 Glu Leu Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys 260 265 270 Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 275 280 285 Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 290 295 300 Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 305 310
315 320 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
Asp 325 330 335 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
Lys Ala Leu 340 345 350 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala
Lys Gly Gln Pro Arg 355 360 365 Glu Pro Gln Val Tyr Thr Leu Pro Pro
Ser Arg Glu Glu Met Thr Lys 370 375 380 Asn Gln Val Ser Leu Thr Cys
Leu Val Lys Gly Phe Tyr Pro Ser Asp 385 390 395 400 Ile Ala Val Glu
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 405 410 415 Thr Thr
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 420 425 430
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 435
440 445 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
Ser 450 455 460 Leu Ser Leu Ser Pro Gly Lys 465 470 925PRTMus
musculus 92Asn Tyr Val Met His 1 5 9317PRTMus musculus 93Tyr Ile
Asn Pro Tyr Asn Asp Asp Val Lys Tyr Asn Glu Lys Phe Lys 1 5 10 15
Gly 9413PRTMus musculus 94Trp Gly Tyr Tyr Gly Ser Pro Leu Tyr Tyr
Phe Asp Tyr 1 5 10 9510PRTMus musculus 95Arg Ala Ser Ser Arg Leu
Ile Tyr Met His 1 5 10 967PRTMus musculus 96Ala Thr Ser Asn Leu Ala
Ser 1 5 979PRTMus musculus 97Gln Gln Trp Asn Ser Asn Pro Pro Thr 1
5
* * * * *